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Abstract 
Humans come into contact and interact with potential infective agents. The innate 
immune system is the first line of response to ward off infection. Innate immunity is, 
in part, under genetic control. This genetic control may help us understand the 
differences between individuals in preventing infection or limiting infectious and 
inflammatory illness. 
Systemic inflammation is a complex disorder that is difficult to define. Current 
definitions are derived from consensus meetings. A need has been expressed for a 
more useful definition of systemic inflammation. 
The work presented here identifies some of the underlying hereditability in limiting or 
being more vulnerable to severe infectious and injurious insults. Individual differences 
in complement activation potential and endotoxin recognition underlie part of the 
observed differences in a systemic inflammatory response to severe infection and 
injury. 
An exploratory study using heart rate variability as a non-invasive method to 
distinguish infectious systemic inflammation from sterile systemic inflammation was 
inconclusive. 
Chapter 1 gives the background to this study and an introduction to the approaches 
taken in this thesis. 
Chapter 2 describes in detail the methods used in the genetic association study and 
physiological systems analysis. 
Chapter 3 goes into some detail about the potential pitfalls in genotyping association 
studies and how these were addressed in the current study. The areas of genotyping 
quality, linkage disequilibrium, ethnicity, sample size and validation of previously 
done work are discussed using MBL-2 and ACE as examples. 
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Chapter 4 is a description of the work done on genetic variability in the endotoxin 
receptor complex and how in may result in the host response to severe infection and 
physical insults. TLR4 polymorphisms were associated with lower platelet counts in 
severe inflammation. The reasons for this are unclear but may point to a direct effect 
of the TLR4 pathways on platelets or indicate that platelet counts are a more sensitive 
marker of systemic inflammation than SIRS criteria.  These data support the view that 
variation in TLR4 function influences the early inflammatory response. This 
phenomenon may be one aspect of reduced fitness in the capacity to respond 
appropriately to an insult.  
Chapter 5 reports the central role of complement in the acute phase response. 
Polymorphisms in two out of the three complement activation pathways were shown 
to have potential modifying effects in paediatric systemic inflammation. This chapter 
reports that polymorphisms in the CFH gene may modulate the acute inflammatory 
response and corroborates the previously reported finding that MBL-2 variant 
genotypes are a risk factor for the early occurrence of SIRS/sepsis in a large cohort of 
paediatric critical care patients, independent of other potentially important functional 
polymorphisms in the complement and innate immunity system. A better 
understanding of how these polymorphisms operate at the pathophysiological level is 
needed before these findings can be translated to clinically useful therapeutic 
modalities. This study demonstrates that genetic polymorphisms associated with 
reduced complement activation may be associated with early SIRS/sepsis. This is 
consistent with a view that appropriate complement activation occurring early 
following an infectious or inflammatory insult protects children from early 
SIRS/sepsis. 
Chapter 6 assesses the usefulness of full MBL-2 genotyping and compares the MBL-2 
genotype and MBL serum levels between a cohort of healthy children and a cohort of 
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critically ill paediatric patients. MBL2 genotyping did not render more information 
with regards to MBL serum level when all promoter and structural polymorphisms 
were identified over and above structural polymorphisms and the XY promoter 
polymorphism. The children admitted with infection did not have a surplus of MBL 
deficient genotypes as compared with healthy children. This suggests that MBL 
deficient genotypes do not predispose to severe infection. 
MBL serum levels in SIRS or sepsis were lower compared with critically ill children 
without systemic inflammation. MBL levels were most reduced in the acute phase 
response in those genotypes with intermediate serum levels, which may reflect a 
consumption of MBL in critical illness and an inability to maintain pre-insult MBL 
serum levels. 
Chapter 7 explores a novel way to discriminate SIRS from sepsis by means of heart 
rate variability analysis. In this small paired sample study no differences were seen in 
LF metrics to differentiate sterile SIRS from sepsis. Neither was there a difference in 
LF metrics between those children who went on to develop a nosocomial infection and 
those who did not. Normalised HF was significantly higher in sterile SIRS vs. sepsis. 
These preliminary finding require further validation and a longitudinal approach in a 
larger cohort. 
Finally, Chapter 8 discusses the findings of this thesis in the context of interpretation 
and of the findings and potential future approaches. 
This thesis supports the view that better metrics are required to discriminate systemic 
inflammation as well as the concept that in children control of an inflammatory threat 
is aided by a vigorous capacity to respond. 
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Chapter 1 Introduction 
1.1 Paediatric intensive care 
Paediatric intensive care is the medical subspecialty that cares for the sickest acutely 
ill children in the population. The severity of illness is such that vital organ functions 
require external support. Supportive measures include intubation and ventilation, vaso-
active medication, renal replacement therapy and mechanical cardiovascular support. 
Invasive and non-invasive devices are routinely used to monitor heart rate, blood 
pressure, cardiac output, oxygen saturation and intracranial pressure. Monitoring and 
interventions assess and support vital organ functions, ultimately aiming to promote 
healing and recovery. In the UK, paediatric intensive care units admit approximately 
17000 children per year.(PICANet 2010) 
Early in the course of illness the critically ill child will have mounted an acute phase 
response. This physiological state is an activation of many regulatory systems, 
including the autonomic nervous system, innate immune system and the neuro-
endocrine axis. The goal of this host response is to contain and eliminate the threat 
induced by infection or injury. The acute phase response may lead to systemic 
inflammation and organ dysfunction. 
 
1.2 The Acute Phase Response 
The initial response to an invading pathogen or to severe injury is an immediate 
activation of the host’s innate immunity, autonomic nervous system and neuro-
endocrine axes (Cavaillon and Annane 2006). 
The ultimate goals of this complex response are to prevent the host from being 
overwhelmed by infection and allow for resolution and repair. For this to succeed, 
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extensive cross-talk is necessary between the activated systems, attempting a 
concerted effort to contain and neutralise the threat. Examples of failure to control the 
initial threat are bacterial septic shock and more locally, uncontrolled intracranial 
hypertension after traumatic brain injury. 
In the minutes to hours after injury or microbial invasion the immune system is 
triggered; acute phase proteins are synthesized, neutrophils and platelets are activated, 
monocytes produce cytokines. The autonomic nervous system responds with 
activation of both the sympathetic and parasympathetic components. Last, a neuro-
endocrine response is triggered to maintain vital organ function (Vanhorebeek, 
Langouche et al. 2006) 
These responses are ubiquitous in critically ill patients. Patients differ, however, in 
their capacity to mount an effective response. The key question is how to explain these 
differences. Answers to this question will help guide interventions, ultimately 
improving outcome. To define and understand better the clinical course of critically ill 
patients one needs to address the insult (severity, type etc), the patient (predisposition, 
response) and the outcome (organ dysfunction). (Angus, Burgner et al. 2003, Gerlach, 
Dhainaut et al. 2003, Vincent, Opal et al. 2003, Vincent, Wendon et al. 2003) 
 
1.3 Systemic inflammation and multiple organ dysfunction syndrome 
The Systemic Inflammatory Response Syndrome (SIRS) is a generalised response to 
an insult. SIRS is a clinical description of a complex entity that underlies much of 
PICU related morbidity. Multi organ dysfunction syndrome (MODS) secondary to 
systemic inflammation remains the leading cause of death in infants and children 
admitted to paediatric intensive care units (PICUs).(Leteurtre, Martinot et al. 2003, 
Tantalean, Leon et al. 2003) (Proulx, Joyal et al. 2009) In an attempt to delineate SIRS 
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as a measurable entity a group of researchers in intensive care came to a consensus 
definition. (1992) In essence, SIRS in all its complexity was scaled back to four 
domains (heart rate, respiratory rate, temperature and white cell count). Systemic 
inflammation secondary to infection was called sepsis. Although sterile SIRS and 
infectious SIRS (or sepsis) only differ in the etiology from a definition point of view, 
there are preliminary data that support a different mechanism underlying the 
seemingly similar host response. Using micro-array technology Allantaz and 
colleagues differentiated systemic juvenile arthritis, i.e. sterile SIRS, from systemic 
inflammation secondary to several infectious agents, i.e. sepsis. (Allantaz, Chaussabel 
et al. 2007) The natural history of sterile SIRS following trauma is different from that 
following infection: many children admitted to PICU after trauma develop SIRS, but 
very few progress to MODS.(Calkins, Bensard et al. 2002, Wood, Partrick et al. 2010) 
Paediatric MODS invariably occurs early (within 48 hrs) in the PICU course of 
admission, usually in an overwhelming fashion (Tantalean, Leon et al. 2003). This 
pattern is different from that seen in adults, in which a later, more sequential onset is 
the norm (Moore and Moore 1995). Extrapolating data and studies from adults to the 
paediatric population may not serve our patients well. Specific paediatric data are 
required to understand better the etiology and course of our sickest children. 
It is appreciated that the innate immune system plays a central role in inciting SIRS 
and MODS after infectious (Medzhitov 2007) and injurious (Hietbrink, Koenderman 
et al. 2006, Stahel, Smith et al. 2007) insults. 
 
1.3.1 Epidemiology of paediatric sepsis 
Sepsis is defined as systemic inflammation with proven or suspected infection (Levy, 
Fink et al. 2003).  
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Globally, the burden of paediatric sepsis is high: annually millions of children die with 
severe infections. This includes severe malaria, severe pneumonia, severe diarrhoea 
and severe measles. (Mangia, Kissoon et al. 2009) 
In the United States paediatric intensive care units admit an estimated 42000 children 
with severe sepsis/year.(Watson, Carcillo et al. 2003) Each year the United Kingdom 
sees approximately 1000 children with severe sepsis admitted to PICUs.(PICANet 
2010) Although mortality has reduced in the past decade in paediatric sepsis, it 
remains  high, with an associated mortality of about 20%. This does not include the 
unknown number of children with sepsis who die before they reach a PICU. A recent 
UK study showed that children with sepsis accepted to PICU are young (median age 
13.6 months) and predominantly male (58%). In 70% of cases sepsis was microbe 
positive, with 54% bacterial and 16% viral diagnosis. Meningococccal disease was 
diagnosed in over a third (36%), followed by pneumococcal disease (14%) and RSV 
(9%). Most children showed organ dysfunction on meeting the critical care team: 92% 
were ventilated, 69% received inotropic support, 12% got renal replacement therapy 
and 8% received ECMO.(Inwald, Tasker et al. 2009). Some of this organ dysfunction 
and mortality may be a result of suboptimal care.(Ninis, Phillips et al. 2005, Launay, 
Gras-Le Guen et al. 2010)Nonetheless, after many interventional studies in large 
patient cohorts failed, including paediatric studies (Levin, Quint et al. 2000, Nadel, 
Goldstein et al. 2007), there is an understanding that individuals differ widely in both 
their predisposition and response to insults (Levy, Fink et al. 2003). Given its 
primordial role in the initial host response the innate immune system may be one 
important source of this variability. 
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1.4 The innate immune system 
1.4.1 Outline and function 
The innate immune system is the first line of defence to pathogens after physical 
barriers have been breached. Innate immunity can be viewed as a system for 
recognising exogenous ‘danger signals’ on potential pathogens (Oppenheim and Yang 
2005). This process of ‘pathogen-associated molecular pattern’ (PAMP) recognition 
triggers a range of host responses. This is a well-appreciated role of the innate immune 
system. More recently, the innate immune system is recognized also to trigger an 
inflammatory response after injury. This occurs by recognizing endogenous danger 
signals. These ‘danger associated molecular patterns’ (DAMPS) are intracellular 
components that are released into the extracellular environment after sterile insults 
such as trauma.(Matzinger 2002) Innate immunity is thus central to infectious as well 
as injurious insults.(Miyake 2007) 
Figure 1-1 gives a condensed view of key actors in the first response to pathogen and 
danger recognition. 
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Figure 1-1 Innate pattern recognition overview  
Both microbes and endogenous cells can trigger recognition. This process occurs at 
cell surface, intra-cellularly and in the circulation. Cell surface recognition receptors 
include Toll Like Receptors (TLR). Intracellular pattern recognition receptors include 
TLRs and Nucleotide-binding oligomerization domain-containing proteins (NODs). 
Examples of circulating proteins are Complement and natural antibodies such as 
Endotoxin core antibodies (EndoCAb). 
Abbreviations: C1q complement component 1 q subcomponent. MBL Mannose 
Binding Lectin; C3b Complement component 3 b. 
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Innate immunity is evolutionary ancient and found in nearly all multicellular 
organisms. In humans the innate immune system is largely present at birth. This 
contrasts with the adaptive immune system that is found in vertebrates only and which 
takes years to build its repertoire. Given that the adaptive immune system evolved in 
the presence of innate immunity, these systems do not operate in isolation from each 
other; rather the innate immune system presents to and instructs the adaptive part of 
immunity.(Medzhitov 2007) 
An ideal first-line response to invading microbes would readily recognise and 
promptly neutralise infectious agents without widespread collateral tissue injury. The 
innate immune system achieves these objectives to some degree by a combination of 
circulating molecules that either cause direct pathogen lysis or prime pathogens for 
phagocytosis and by phagocytic cells themselves.  
Innate immunity encompasses immune cells, such as tissue macrophages, neutrophils 
and monocytes and also cells that are primarily known for other functions: platelets 
and endothelial cells. Complex networks of circulating mediators including cytokines, 
chemokines, the complement cascade, collectins, defensins and coagulation factors are 
integral parts of innate immunity. Recent work has highlighted apparent contributions 
from neuro-humoral and autonomic nervous systems via the 7 nicotinic 
acetylcholinergic receptor (NACHR7).(Borovikova, Ivanova et al. 2000, Wang, Yu et 
al. 2003) 
The afferent, or ‘sensing’, limb of the innate immune system consists of pattern 
recognition molecules (PRMs) that recognise typical molecular structures on 
pathogenic micro-organisms or endogenous substances. For example, TLR4 
recognizes the Gram-negative bacterial cell wall component lipopolysaccharide 
(Poltorak, He et al. 1998) and endogenous fibrinogen (Smiley, King et al. 2001); 
TLR2 recognizes the Gram-positive cell wall component lipoteichoic acid 
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(Yoshimura, Lien et al. 1999) and endogenous human heat shock protein 60 (HSP 60) 
(Asea, Rehli et al. 2002). Mannose binding lectin (MBL) binds to non-human patterns 
of sugars such as mannose on yeast(Turner 2003)but also endogenous ligands 
(Takahashi, Ip et al. 2006). 
The importance of these danger signals is illustrated by the number of names  
competing in the literature to describe them: pathogen-associated molecular patterns 
(PAMPs), danger associated molecular patterns (DAMPs), and most recently 
‘alarmins’ (Oppenheim and Yang 2005, Bianchi 2007).  Whatever name is used, the 
importance is that when such patterns encounter pattern recognition molecules of the 
innate immune system, they initiate and/or potentiate a cascade of events, which is 
aimed at rapid killing of invading pathogens or re-establishing immune homeostasis. 
Pre-existing cell surface components (e.g. CD14 and TLR4) and humoral (e.g. 
Mannose Binding Lectin) elements recognize danger signals. After ligation these 
sentinel modalities then induce an inflammatory response that includes cell signalling, 
cytokine production, opsonization and phagocytosis. This means that no critically ill 
child is admitted to intensive care without activation of its innate immune system. 
Infection, trauma, ischemia-reperfusion and cardiopulmonary bypass sequelae are all 
mediated largely by the innate immune system. (Wood, Partrick et al. 2010) 
Our understanding of the immune system has thus evolved from a modality to 
distinguish tissues that are “infectious non-self” from “non-infectious-self” (Janeway 
1992) to an even more complex tool that recognizes ‘dangerous’ and ‘non-dangerous’ 
matter (Matzinger 2002). 
The different types of pattern recognition molecules have the capacity to recognize 
specific motifs that signify danger or infection. They do not operate individually, but 
cooperate in between themselves, not only intra recognition group, such as the 
endotoxin recognition complex, but also across different types of recognition 
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molecules and cell types. For example: TLR2 co-locates with TLR6 or TLR1 in 
recognizing different bacterial lipopeptides (Gay and Gangloff 2007), TLR4 on 
platelets and polymorphonuclear leukocytes form neutrophil extracellular traps 
(NETS) (Clark, Ma et al. 2007) and CD14 interacts with complement receptor 3 (CR3) 
in the recognition and response to yeast (Brandhorst, Wuthrich et al. 2004). 
The following paragraphs outline pertinent components of the innate immune system 
which play an integral part in paediatric SIRS. 
 
1.4.2 The Complement pathway 
Complement is a group of proteins that is central in infection and inflammation. Its 
major tasks are killing micro-organisms directly via the membrane attack complex and 
indirectly via opsonization and readying for phagocytosis; plus activation of the 
coagulation cascade and inflammation via anaphylatoxins. This component of innate 
immune system is a cascade of events, in which early components are activated and 
subsequently cleave other components. 
Three pathways activate previously inactive proteins. (Figure 1-2) The classical, 
alternative and lectin pathways converge in the activation of C3, from where a 
common pathway leads to further Complement activation. The lectin-complement 
pathway facilitates pathogen removal via carbohydrate recognition mediated 
phagocytosis. The alternative complement pathway is a continuously activated 
bactericidal humoral mechanism. (Holers 2008) The classical pathway activates when 
antibody-antigen complexes bind to C1, which in turn leads to generation of C1q. 
(Walport 2001) 
  
 30 
 
Figure 1-2 Complement activation 
The three pathways that activate the complement cascade are initiated and/or 
modulated by C1qA, MBL, CFH and CFB. These pathways converge at C3, from 
where the downstream complement proteins lead to chemotaxis, opsonization and cell 
wall lysis. 
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The role of complement in combating invasive bacterial disease is well established. 
(Figueroa and Densen 1991) Children with complement deficiencies are at higher risk 
of contracting meningococcal disease. This is illustrated by the relationship between 
the incidence of meningococcal disease and the prevalence of complement deficiency 
in an international comparison. When the incidence of meningococcal disease is low, 
such as in Japan, the prevalence of complement deficiency in meningococcal disease is 
high. Conversely, when there is a high incidence of meningococcal disease, such as in 
Denmark, the prevalence of complement deficiency in meningococcal disease is low 
(Figueroa and Densen 1991). This suggests that in areas with low exposure to the 
micro-organism, those that do exhibit the disease have predisposing factors such as 
complement deficiency. Figure 1-3. 
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Figure 1-3 Relationship of prevalence of meningococcal disease and complement 
deficiency 
Amended from (Figueroa and Densen 1991). 
  
 33 
 
Complement activation occurs not only in infectious insults, but also in sterile 
inflammation such as trauma. (Ganter, Brohi et al. 2007) 
Part of the complement activation cascade are sugar-recognizing collectins, molecules 
which contain collagenous structures and C-type carbohydrate recognizing domains 
(CRD) such as mannose binding lectin (MBL). These collectins also include surfactant 
proteins A and D (SP-A and SP-D), but these do not take part in complement 
activation.  MBL is a liver derived acute phase reactant whereas SP-A and SP-D are 
synthesized in the lung. The main determinant of MBL levels is genotype, whereas 
SP-A and SP-D increase significantly with inflammatory stress. Collectins bind to 
many microbes: viruses, bacteria, fungi and protozoa and prepare organisms for 
phagocytosis (opsonization) and activate complement pathways. The ficolins, L-
ficolin, M-ficolin, H-ficolin are similar but they have different structures with a 
fibrinogen-like domain. Both MBL and the ficolins initiate the lectin pathway of 
complement activation via mannose binding lectin associated serine proteases 
(MASPs).(Holmskov, Thiel et al. 2003) 
 
1.4.3 Cellular Pattern Recognition Receptors: Toll Like Receptors  (TLR) and 
Nod Like Receptors (NLR) 
1.4.3.1 Toll Like Receptors 
Toll like receptors (TLRs) are evolutionary preserved from the worm Caenorhabditis 
elegans and strikingly homologous to Toll, a gene product essential to Drosophila 
immunity. The TLRs are trans-membrane glycoproteins that are characterized by an 
extracellular binding domain with varying numbers of leucine-rich-repeat (LRR) 
motifs and an intracellular cytoplasmic signalling domain homologous to that of the 
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interleukin 1 receptor (IL-1R). This Toll/IL-1R homology (TIR) domain sits beneath 
the plasma membrane and interfaces primarily with the key signalling adaptor myeloid 
differentiation primary response gene 88 (MyD88).(O'Neill and Bowie 2007) There 
are at least 10 related receptors in humans (Table 1-1). 
Toll-like receptor-2 recognizes the cell wall components lipoteichoic acid (LTA) and 
peptidoglycan of Gram positive bacteria, whereas TLR5 recognizes flagellin on 
Salmonella enterica. Viral matter is recognized by TLR3, TLR7 and TLR8. Toll-like 
receptors also combine in heterodimers and thus generate wider ligand specificity, for 
instance TLR6/TLR2 recognizes the fungal cell wall component zymosan. 
Intracellular Toll-like receptor-9 recognizes bacterial DNA, which is distinct from 
mammal DNA by way of the presence of unmethylated CpG dinucleotides. 
Mitochondrial DNA is one alarmin that signals through TLR9. This pathway may 
explain some of the systemic inflammation after tissue injury. (Zhang, Raoof et al. 
2010) 
One TLR may also recognise different pathogen components; TLR4 not only binds 
LPS, but also the structurally unrelated fusion protein of respiratory syncytial virus 
(RSV) (Kurt-Jones, Popova et al. 2000) and Plasmodium falciparum 
glycosylphosphatidylinositol (GPI) (Krishnegowda, Hajjar et al. 2005). Fibrinogen, 
heat shock proteins, reactive oxygen species, hyaluronic acid and haeme are all ligands 
for TLR4 in the absence of endotoxin (Takeda, Kaisho et al. 2003, Taylor, Trowbridge 
et al. 2004, Zhang, Shan et al. 2005, Figueiredo, Fernandez et al. 2007). These 
interesting observations suggest that these pathways contribute to the on-going 
immune response from other insults such as trauma rather than being specific to 
individual pathogens. This fits with a danger model of immunity, rather than a strict 
pathogen non-self and non-pathogen self model. 
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Toll-like receptors are expressed on many immune and non-immune cells, including 
macrophages, platelets and cardiac myocytes. This expression is modulated rapidly in 
response to pathogens and cytokines. Many of these TLRs, e.g. TLR1, 2, 4 and 5, are 
expressed on the cell wall, others are found intracellularly, e.g. TLR3, 7 and 9. (Gay 
and Gangloff 2007) 
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PRR PAMP Organism Endogenous 
ligand 
Location 
TLR1-
TLR2 
Triacyl 
lipopolypeptide 
Gram pos 
bacteria 
 Cell surface 
TLR2-
TLR6 
Diacyl lipopeptide 
LTA 
Zymosan 
Mycoplasma 
Gram pos 
bacteria 
Fungus 
 Cell surface 
TLR2 Porins 
Peptidoglycan 
Haemagglutinin 
protein 
Neisseria 
Gram pos 
bacteria 
Measles 
Hyaluronic 
acid 
HSP 
HMGB1 
Cell surface 
TLR3 dsDNA Virus  Intracellular 
vesicles 
TLR4 LPS 
Envelope proteins 
Gram neg 
bacteria 
RSV 
Fibrinogen 
HSP 
ROS 
Hyaluronic 
acid 
Haeme 
HMGB1 
Cell surface 
TLR5 Flagellin Bacteria 
Salmonella 
 Cell surface 
TLR6    Cell surface 
TLR7 ssRNA RNA virus  Intracellular 
vesicles 
TLR8 ssRNA RNA virus  Intracellular 
vesicles 
TLR9 CpG DNA 
DNA 
Malaria hemozoin 
Bacteria 
DNA virus 
Parasites 
 Lysosomes 
TLR10 Unknown Unknown  B lymphocytes 
Table 1-1 TLR Classification 
PRR Pattern recognition Receptor; PAMP Pathogen Associated Molecular pattern; 
LTA Lipoteichoic Acid; HSP Heat Shock protein; HMGB1 High-mobility group 
protein B1; ds DNA double stranded deoxyribonucleic acid; RSV Human respiratory 
syncytial virus; ROS reactive oxygen species; ssRNA single stranded Ribonucleic 
acid; CpG DNA Cytosine phosphate Guanine deoxyribonucleic acid. Reviewed in 
(Pandey and Agrawal 2006) 
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1.4.3.1.1 Toll Like Receptor 4 
The archetypal pathogen-associated molecular pattern (PAMP) is the Gram-negative 
bacterial cell wall component lipopolysaccharide (LPS), to which humans are 
exquisitely sensitive. (Sauter and Wolfensberger 1980) Endotoxin or LPS is 
recognised by the humoral factor lipopolysaccharide binding protein (LBP) 
(Schumann, Leong et al. 1990) and the cell membrane receptor toll-like receptor 4 
(TLR4) (Poltorak, Smirnova et al. 1998). Lipopolysaccharide binding protein (LBP), a 
liver-derived glycoprotein, binds to LPS and shuttles it to an immune cell surface, 
such as a monocyte. The monocyte receives the LBP/LPS compound on a complex 
consisting of TLR4 (Medzhitov, Preston-Hurlburt et al. 1997, Poltorak, Smirnova et 
al. 1998), CD14 (Wright, Ramos et al. 1990) and MD2 (Shimazu, Akashi et al. 1999) 
(Figure 1-4). 
TLR4 signalling depends on the ligand being recognized. Microbial ligands include 
the lipid A component of LPS, which is present on the gram negative cell wall (Raetz 
and Whitfield 2002), RSV fusion protein (Kurt-Jones, Popova et al. 2000), and 
endogenous ligands including heat shock proteins (Ohashi, Burkart et al. 2000)and 
fibrinogen (Smiley, King et al. 2001). 
On binding, the trans-membrane receptor TLR4 signals to intracellular components, 
which, in turn, leads to NFB mediated downstream gene expression and cytokine 
activation. (Figure 1-5). Thus, a Gram-negative infection such as meningococcemia 
gives rise to a rapid non-specific response which aims to kill the inoculum and contain 
the infection. 
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Figure 1-4 TLR4 complex 
Lipopolysaccharide (LPS) is shuttled to the endotoxin receptor complex by 
lipopolysacharide binding protein (LPB). CD14 independent signalling via TLR4 is 
possible for endogenous danger signals such as heat shock protein 70. LPS induced 
signalling on monocytes is optimal when all the components, i.e. MD-2, CD14, and 
TLR4 are available. TLR4 transduces signals via intracellular components to activate 
the transcription factor nuclear factor B (NFB), MAP kinases p38, and C-Jun N-
terminal kinases (JNK). These then activate the inflammatory cascade via gene 
transcription. (Guha and Mackman 2001) 
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Figure 1-5 TLR signalling process 
 (taken from(Agbeko and Peters 2011)) 
LBP shepherds LPS to the TLR4 complex. On ligation, TLR4 dimerizes and activates 
the two distinct MyD88- and MyD88-independent TRIF-dependent pathways.  The 
early inflammatory phase is characterized by the MyD88-dependent pathway. This 
pathway activates MAPKinase and NFB mediated pro-inflammatory gene induction. 
The TRIF-dependent pathway will activate late phase NFB and IRF3 mediated gene 
expression resulting in a more endotoxin tolerant response. (Kawai and Akira 2006, 
Biswas, Bist et al. 2007, Mogensen 2009) 
LBP, Lipopolysaccharide binding protein; LPS, Lipopolysaccharide (endotoxin); 
CD14, Cluster of Differentiation 14; MD2, Myeloid differentiation protein 2; TLR4, 
Toll-like Receptor 4; MyD88, Myeloid differentiation primary-response protein 88; 
MAL/TIRAP, MyD88 adaptor like/Toll-interleukin 1 receptor (TIR) domain 
containing adaptor protein; IRAK4, Interleukin 1 receptor associated kinase 4; IRAK1, 
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Interleukin 1 receptor associated kinase 1; TAK1, transforming growth factor -
associated kinase 1; TRIF, TIR domain-containing adaptor protein inducing Interferon 
; TRAM, TRIF related adaptor molecule; TRAF6, Tumour necrosis factor receptor 
associated factor 6; TRAF3, Tumour necrosis factor receptor associated factor 3; 
TANK, TRAF family member associated NFB activator; TBK1, TANK binding 
kinase 1; IKK, inhibitor of nuclear factor B kinase ; ; IKK, inhibitor of nuclear 
factor B kinase ; IKK, inhibitor of nuclear factor B kinase ; p38, p38 kinase; 
JNK, c-Jun N-terminal kinase; MAPKs, mitogen activated protein kinases; NEMO, 
nuclear factor B essential modulator; IRF3, Interferon regulatory factor 3; IB, 
inhibitor B; NFB, Nuclear factor B ; AP-1, activator protein 1. 
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1.4.3.2 Nod Like Receptors 
A different type of pattern recognition receptors (PRR) recognizes pathogens after 
invasion in the cytosol. Of particular relevance to the intensivist are the nucleotide 
binding oligomerization domain and leucine rich repeat containing molecules (NLRs). 
The best studied of these proteins, Nucleotide Oligomerization Domain 1 NOD1 and 
NOD2, both contain N-terminal caspase recruitment domain (CARD) domains and are 
specialised in detection of bacterial peptidoglycan components. Two types of 
activation occur: NOD1 and NOD2 ligation causes their oligomerization, which in 
turn induces downstream gene expression via NFB activation. Alternatively, NLRs 
activate caspase-1 activating complexes, also known as inflammasomes, which in turn 
mature cytokines IL1- and IL18.(Inohara and Nunez 2003) Inflammasomes may be 
seen as sensors for danger. For instance, loss of cell integrity activates the 
inflammasome and hence the potent pro-inflammatory cytokine IL-1. The 
significance of this pathway is increasingly recognized. Recent data shows the 
inflammasome to be integral to the pathogenesis of severe S. aureus 
infections.(Munoz-Planillo, Franchi et al. 2009) 
 
1.4.4 Downstream signalling 
 
Ligation of a cell surface TLR will activate a sequence of events, ultimately leading to 
gene transcription and translation to form proteins. These proteins, in turn, activate 
and dampen processes to allow for an appropriate host defence. Figure 1-5 provides an 
example of downstream signalling in response to LPS binding to the TLR4 complex. 
Toll-like receptors dimerize and change in conformation; this allows for recruitment of 
adaptor molecules to the TIR domain of the receptor. Four adaptor molecules are 
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known: MyD88, Mal (TIRAP), TICAM1 and TRAM. Different TLR ligands induce 
selected recruitment of these adaptor molecules explaining some of the distinct 
responses after TLR ligation. 
MyD88 is essential for all downstream signalling via TLRs (except for TLR3). In 
addition, Mal is essential for TLR2 and TLR4 signalling, arguably the most important 
TLRs in critical care. 
After activation of these adaptor molecules IL-1receptor associated kinase 4 (IRAK4) 
and IRAK1 are recruited. These, in turn catalyze a cytoplasmic cascade that ultimately 
leads to mitogen-activated protein kinases (MAP kinases) p38, ERK1, ERK2 and 
consequently NFB mediated gene transcription in the cell nucleus. A MyD88 
independent pathway exists, which has a role in DC maturation and interferon / 
production.(O'Neill 2008) 
 
1.4.5 Cytokines  
Cytokines are polypeptide intercellular messengers. Cytokines have actions 
stimulating or inhibiting the immune response.  ‘Pro-inflammatory’ cytokines include 
TNF, INF, IL-1, IL-6 and IL-8, whereas IL-10 and  IL-4 are thought to have 
predominantly anti-inflammatory properties.  This dichotomy of pro- and anti-
inflammatory cytokines does not do justice to the pleiotropic functions of these 
proteins.(Cavaillon, Adib-Conquy et al. 2003) For instance, dependent on timing and 
location, the prototypical pro-inflammatory cytokine TNF may have a function in 
pro-inflammation or in resolution of inflammation. One key issue is the 
appropriateness of the TNF action – an injection of TNF to a healthy volunteer 
causes temperature and signs of systemic inflammation (and perhaps shock if the dose 
is high).  This is the cost of TNF without the potential benefit of immune activation 
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to kill an invading micro-organism.  The cost-benefit of a cytokine such as TNF is 
dependent on the scale of the infective insult being faced.  Meta-analysis of animal 
models and human trials with agents that block TNF or its receptor suggest that 
TNF is useful when the insult is mild, but harmful when the insult is very 
severe.(Eichacker, Parent et al. 2002) This dose-dependent complexity is typical of 
cytokine responses.   
One extreme example of a pro-inflammatory overactivation is secondary 
hemophagocytic lymphohistiocytosis. This multisystem disease results from a 
persistence of the inflammatory response to a systemic viral infection beyond its 
useful phase.  The bone marrow and liver fail as they are infiltrated by activated cells 
derived from monocytes/macrophages.  This typically occurs in patients with a 
congenital predisposition in which lymphocyte apoptosis is abnormal.  The resultant 
abnormal persistence of the inflammatory response induces excessive 
monocyte/macrophage activation. (Castillo and Carcillo 2009) 
The prototypical anti-inflammatory cytokine is Interleukin 10 (IL10).  IL10 inhibits 
the activity of monocytes, macrophages. It reduces HLA-DR expression and limits 
production of the pro-inflammatory chemokines IL8, MIP-2, RANTES, MCP-1, 
MCP-2 and cytokines IL1, IL6, TNF, IL12 and IL18. (Moore, de Waal Malefyt et al. 
2001) 
Thus it is a key regulatory cytokine with a function to limit a potentially harmful pro-
inflammatory response that may in itself overwhelm the host in its attempt to 
neutralise infectious threat. (Couper, Blount et al. 2008) 
Bearing in mind that the dichotomy in pro- and anti-inflammatory cytokines is crude, 
this classification may be useful in describing an overall inflammatory state or 
capacity to respond to threats. Table 1-2 summarizes the primary cytokines in sepsis 
and injury.(Cavaillon, Adib-Conquy et al. 2003, Perl, Chung et al. 2006)  
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Cytokine Function 
TNF Pro-Inflammatory 
MCP1 Pro-Inflammatory 
MIP 1 Pro-Inflammatory 
RANTES Pro-Inflammatory 
INF Pro-Inflammatory 
IL1 Pro-Inflammatory 
IL6 Pro-Inflammatory 
IL8 Pro-Inflammatory 
TGF Anti-Inflammatory 
IL1ra Anti-Inflammatory 
IL4 Anti-Inflammatory 
IL10 Anti-Inflammatory 
Table 1-2 Cytokines in systemic inflammation 
TNF Tumor Necrosis Factor alpha, MCP1 monocyte chemotactic protein-1, (also 
known as Chemokine (C-C motif) ligand 2 (CCL2) MIP 1 Macrophage inflammatory 
protein-1β (also known as Chemokine (C-C motif) ligand 4 or CCL4), RANTES 
Regulated on Activation, Normal T Cell Expressed and Secreted (also known as 
Chemokine (C-C motif) ligand 5 (CCL5), INF Interferon gamma, IL Interleukin, 
TGF transforming growth factor beta 
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Cytokines appear in the circulation within hours after a severe insult. There are 
different time frames for the plasma profile of the different compounds. Initially the 
systemic inflammatory response syndrome and compensatory anti inflammatory 
response syndrome were thought to occur sequentially. (Figure 1-6) Longitudinal 
studies, however, have shown that SIRS and CARS occur simultaneously, albeit 
maybe in different compartments of the body (Figure 1-7). 
After a severe insult TNF occurs very early and decreases quickly, whereas IL10 
may stay elevated over a longer time frame. The circulatory compartment may be 
hyporeactive to inflammatory stimuli, while simultaneously the tissues might still be 
in an active inflammatory phase.(Cavaillon and Annane 2006) 
CARS may be seen as a reduced capacity to respond to acute inflammatory threats. 
This state has been also called anergy or immunoparalysis. Monocytes sequester the 
surface molecule HLA-DR and these monocytes have reduced capacity to respond to 
noxious ligands, such as LPS. (Docke, Randow et al. 1997) This is relevant to the 
paediatric population as well. Children with reduced monocyte surface HLA-DR after 
cardiopulmonary bypass were at risk of developing nosocomial infections.(Allen, 
Peters et al. 2002)This immunoparalysis may be a target for therapeutic intervention. 
In a small open label study children with multiple organ dysfunction were given GM-
CSF. Monocyte capacity to produce TNF was restored and the children in the 
intervention arm suffered significantly less nosocomial infections.(Hall, Knatz et al. 
2011) 
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Figure 1-6 SIRS and CARS traditional view 
The traditional model of the Systemic Inflammatory Response Syndrome (SIRS) and 
the Compensatory Anti Inflammatory Response Syndrome  (CARS) is of a sequential 
change from excessive pro-inflammatory to excessive anti-inflammatory state.(Bone 
1996) 
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Figure 1-7 SIRS and CARS simultaneous model 
The current understanding of the Systemic Inflammatory Response Syndrome (SIRS) 
and Compensatory Anti inflammatory Response Syndrome (CARS) is that both states 
occur simultaneously. Different compartments may, however, be in different 
inflammatory states.(Cavaillon and Annane 2006) 
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1.5 Crosstalk between systems 
1.5.1 Coagulation and platelets 
The innate immune system does not operate in isolation. It informs and interacts with 
the phylogenetically younger adaptive immune system. In addition, coagulation, 
neuro-endocrine, cardiovascular and autonomic nervous systems all influence, and are 
influenced by, immune responses.  At the simplest level this is shown by many 
molecules having important properties in multiple systems, e.g. acetylcholine is a 
neurotransmitter as well as a paracrine regulator of lymphocytes, and epinephrine 
stimulates the bone marrow to release neutrophils into the circulation.  
Several examples of well-characterised “crosstalk” between these systems are outlined 
below. 
Plasminogen activator inhibitor 1 (PAI-1) is a potent inhibitor of fibrinolysis. It 
achieves this response by inhibiting both tissue and urinary type plasminogen 
activator.(Lijnen 2005)  Levels are increased after trauma and sepsis, especially so in 
severe meningococcal sepsis.(Hazelzet, Risseeuw-Appel et al. 1996) Inflammatory 
mediators TNF, IL-1 and IL-6, complement 5a, and LPS all act to increase PAI-1 
production. In turn, PAI-1 contributes to a pro-coagulant state and inhibits neutrophil 
apoptosis. Although this may help to contain inflammation at the site of infection, 
genotypes associated with high levels of PAI-1 production are associated with worse 
outcome in septic shock.(Hermans and Hazelzet 2005) The PAI1 4G/5G insertion 
deletion promoter polymorphism influences PAI1 plasma concentration such that 4G 
is associated with higher concentration.(Eriksson, Kallin et al. 1995) This implies a 
direct link between how readily the immune system triggers an increased clotting 
tendency in critical illness and a poor outcome. 
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Similarly, the inflammatory mediator IL-6 stimulates release of the potent coagulation 
activator tissue factor (TF) from activated endothelial cells, monocytes and 
macrophages. This promotes thrombin formation, which, in turn, converts fibrinogen 
to fibrin. Thrombin and fibrin generation are increased in inflammation, in part, 
because fibrinolysis is impaired due to increased activity of PAI-1, but also secondary 
to diminished activated protein C (APC) and tissue factor pathway inhibitor 
(TFPI).(Levi and van der Poll 2008) These processes have been the targets for 
numerous clinical trials of drugs with anticoagulant / pro-fibrinolytic actions – all 
aiming to achieve anti-inflammatory effects by targeting coagulation systems. 
Unfortunately, results have been disappointing. This is most likely a reflection of the 
complexity of sepsis; it requires more than one pathway to be manipulated to change 
clinical outcome. 
An example of a novel interaction between the coagulation and immune systems is 
that TLR4-activated platelets interact with neutrophils to trap and kill bacteria in so-
called ‘neutrophil extracellular traps’ (NETs). In vitro studies showed that LPS as well 
as plasma from septic adults could induce this phenomenon.(Clark, Ma et al. 2007)  
Other investigators have shown platelets to be integral to the immune system. For 
example, platelet CD40 ligation activated platelet-leukocyte adhesion, which promotes 
the inflammatory process.(Inwald, McDowall et al. 2003) 
 
1.5.2 The autonomic nervous system 
The nervous system is an integral part of inflammation. At a local level, inflammatory 
responses induce pain- one of the defining elements of inflammation. Regionally, 
sympathetic and parasympathetic activation will, in general, inhibit inflammation. 
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Centrally, the hypothalamic-pituitary-adrenal axis has an overarching 
immunomodulatory role by activating many neuro-endocrine responses. 
Importantly, immune cells carry the receptors for neurotransmitters, neuropeptides and 
neurohormones, including adrenergic and cholinergic receptors. These receptors may 
respond in an auto- or paracrine manner. Alternatively, the autonomic nervous system 
and innate immunity may be linked directly by the “cholinergic anti-inflammatory 
reflex”. In vivo sepsis models suggest that vagal stimulation may directly dampen 
TNF production via NACHR7 receptors on macrophages.(Borovikova, Ivanova et al. 
2000) 
The sympathetic-immune interface is another area of growing interest. At a local level 
sympathetic activation may have pro- as well as anti-inflammatory effects. Based on 
current understanding, the most prominent general effect is inhibition of inflammation. 
(Elenkov, Wilder et al. 2000) Adrenergic activation via a 2 mediated pathway down 
regulate pro-inflammatory cytokines TNF, IL6 and IL1, while upregulating  anti-
inflammatory cytokines such as IL10.(de Montmollin, Aboab et al. 2009)  
As this is a new field and many questions remain unanswered, it is of little surprise 
that there exists debate about the clinical significance of neural modulation of the 
immune response. (Sternberg 2006) 
One way to measure a modulatory effect of the autonomic nervous system on the 
immune response is correlating heart rate variability with markers of immune 
activation. Heart rate variability (HRV) has been shown to correlate with CRP. CRP 
levels, arguably a measure of systemic inflammation were lower in individuals who 
showed higher vagal tone as measured by HRV.(Thayer and Fischer 2009)HRV 
mirrored response to anti-viral therapy in a longitudinal study on hepatitis 
C.(Osztovits, Horvath et al. 2009) Earlier work had shown that women who had 
survived a myocardial infarction exhibited higher IL6 levels and concomitant reduced 
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HRV. (Janszky, Ericson et al. 2004)Both CRP and IL6 serum levels were inversely 
related to HRV indices in a large cohort of healthy adults. This prompted the authors 
to state that vagal autonomic activation counteracts inflammation.(Sloan, McCreath et 
al. 2007) 
HRV was not universally found to correlate with an immune response. No association 
was found with HRV indices and NK cells in response to mental stress.(Owen and 
Steptoe 2003)Conversely, in an adult cohort of critically ill patients, mortality 
associated with multiple organ dysfunction (MODS) was correlated with reduced 
HRV.(Schmidt, Muller-Werdan et al. 2005) It may be that there is a threshold effect in 
severity of insult or stressor. 
 
1.6 Host factors in the acute inflammatory response 
In paediatric critical care all children will exhibit an acute phase response, by nature 
and/or severity of the insult that required them to be admitted to the PICU. The 
severity of their morbidity varies not only with severity of insult, but also individually.  
Premature death from infectious disease is attributable to genetic influences to a higher 
extent than cardiovascular disease or cancer. In a landmark adoptee study Sorensen 
showed that the relative risk for premature death (before the age of 50 years) due to 
infectious disease was 5.81 (95% confidence interval 2.47 to 13.7) (Sorensen, Nielsen 
et al. 1988). In other words, in 1988 the case was made that susceptibility to severe 
infectious disease has a strong genetic background. Twenty years later some of the 
specific genetics has been elucidated, but many question remain. (Opal 2005) Other 
compelling evidence that the immune response is, at least in part, under genetic 
control comes from our knowledge of primary immune deficiencies. (Ballow 2008). 
Conversely, the hereditary periodic fever syndromes such as Familial Mediterranean 
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Fever are characterized by a too sensitive innate immunity response.(Bodar, Drenth et 
al. 2009) These rare disorders are increasingly better genetically characterized, but 
form but a small part of the genetic variability in the general population. One method 
to further understand hereditary differences is the candidate gene approach. With the 
advent of methods to identify subtle changes in genes coding for components in the 
innate immune system it became possible to search for specific genetic predisposition 
to an inappropriate innate immune response. Gene variations occur as single 
nucleotide polymorphisms (SNPs), insertion or deletion or copy number variation. 
 
1.6.1 Candidate gene study- Single Nucleotide Polymorphisms 
Genetic variability is, for a large part, made up of Single Nucleotide Polymorphisms 
(SNPs). (Wang, Fan et al. 1998) A SNP is a variation in a gene at 1 base pair. Figure 
1-8 shows an example. 
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Figure 1-8 Single Nucleotide Polymorphism 
Nucleotide sequence differs at the nucleotides printed in red. T denotes Thymidine, C 
Cytidine, G Guanosine, and A Adenosine. 
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In this example individual A carries a C allele and individual B a G allele. Dependent 
on where the SNP is located in the gene, this may or may not have functional 
consequences to the gene product. The protein itself may be altered, or it may result in 
a change in the amount of protein production, or there may be no discernible change at 
all. The latter category is still of interest, as this type of SNP might be in linkage 
disequilibrium with a SNP that does have an impact on protein synthesis. 
 
1.6.2 Gene structure examples 
A good example of a gene with several polymorphisms is MBL2. Figure 1-9 shows a 
schematic of the gene with polymorphisms in the promoter region and in exon 1. 
These changes give rise to differences in expression of the protein and structural 
changes that interfere with the subunits forming hexamers. 
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Figure 1-9 MBL2 gene and gene products 
The MBL2 gene consists of a promoter region and four exons. The promoter region 
holds three polymorphisms as does exon 1. The gene product is a polypeptide that 
conforms to a structural subunit, which in itself organises itself in multimers.  
 56 
1.6.3 SNPs in Critical Illness 
Early work on genetic polymorphisms showed that a high TNF and low IL-10 
pattern, suggesting a vigorous pro-inflammatory potential, was associated with better 
outcome in meningococcal disease.(Westendorp, Langermans et al. 1997) Conversely, 
more recent work suggested that a polymorphism associated with high TLR1 mediated 
inflammatory cytokine production was strongly associated with increased mortality 
and organ dysfunction in sepsis.(Wurfel, Gordon et al. 2008)  
Genetic association studies in areas with more uniformity in disease definition and 
better understanding of the pathophysiology of disease have isolated some effects of 
polymorphisms.  For instance, NOD2 variations are clearly associated with an 
increased susceptibility to Crohn’s disease.(Hugot, Chamaillard et al. 2001) 
Interestingly, in adults,  this same mutation was shown to increase risk for 
bacteraemia, especially in combination with TLR4 variants.(Henckaerts, Nielsen et al. 
2009) Although of dubious methodological rigour this finding was mirrored in 
children.(Tekin, Dalgic et al. 2012) 
The innate immune system is complex with many redundancies. It may be unrealistic 
to identify those parts that have a discernible effect on outcome in the complex 
outcome called critical illness by analysing variance in individual mediators.  This is 
effectively the same issue that has confound randomized clinical trials in severe 
sepsis.(Dellinger, Vincent et al. 2008) Given these issues, design and execution of 
genetic association studies need to be held against robust and reproducible end-points 
and rigorous quality markers.(Clark and Baudouin 2006) (Little, Higgins et al. 2009) 
Despite all these difficulties, there are some observations that contribute to our 
understanding of innate immune variability in critical illness. The following is a 
sample of studies that illustrate some of these issues.  
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A recent systematic review and meta-analysis showed susceptibility to pneumococcal 
disease with mannose binding lectin (MBL) deficiency (odds ratio 2.57(95% CI 1.38-
4.8) but not for the single TLR2 polymorphism Arg753Gln. It may be that 
complement activation is a more important part of innate immunity than TLR2 or that 
this specific TLR2 polymorphism does not exert a strong enough difference in 
response. Similarly, no evidence was found for a susceptibility to meningococcal 
disease for TLR4 Arg299Gly or the PAI1 4G/5G insertion deletion promoter 
polymorphism. (Brouwer, de Gans et al. 2009) However, the PAI1 4G/5G 
polymorphism was shown to influence the severity of disease in meningococcal septic 
shock: children who were homozygous for the high producing 4G were more likely to 
have vascular complications or to die. (Haralambous, Hibberd et al. 2003) It may be 
more interesting to study the influence of genetic differences on the specific pattern of 
disease severity rather than the overall outcome which reflects the sum of so many 
pathophysiology processes. 
Genetic variation does not necessarily confer an increased risk for susceptibility or 
severity of disease. It may well exert a beneficial effect. The adaptor molecule Mal 
(TIRAP) may be one such an example. This molecule is an essential part of TLR2 and 
TLR4 downstream signalling. In a large multi-ethnic cohort (n= 6106) the effect of 
Mal polymorphism S180L was studied with respect to invasive pneumococcal disease, 
malaria and tuberculosis. (Khor, Chapman et al. 2007) Heterozygosity was associated 
with reduced disease severity. The authors postulated that this was due to reduced 
NFB medicated cytokine response. Homozygous variant allele carriers would thus 
mount an inadequate antimicrobial response and wildtype carriers would mount an 
excessive response.  
A better-known heterozygote protection against infectious disease is sickle cell trait 
that protects against malaria. Homozygous sickle cell anaemia however predisposes to 
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increased susceptibility to infectious disease. Children with sickle cell anaemia were 
25 times more likely to present with bacteremia than control subjects in a recent study 
from sub-Saharan Africa.(Williams, Uyoga et al. 2009) 
There are many studies of genetic variability in critical illness but very few provide 
compelling evidence of genetic variation influencing outcome. One reason may be the 
complexity of the clinical phenotype: i.e. heterogeneity in patients, grouped as 
“SIRS”, “sepsis”, or “ARDS”. These definitions may be insufficiently precise in 
clinical critical illness where patient differ widely in, for example, the contribution of 
chronic disease to the acute state. (Marshall 2008) 
 
1.7 Outcome - Challenges in measuring the acute phase response 
Given that the acute phase response is a complex dynamic physiological state it is a 
challenge to define it accurately. One possibility is the international consensus 
definition of “SIRS”.(Levy, Fink et al. 2003) The Systemic Inflammatory Response 
Syndrome (SIRS) was defined for adults according to parameters outside the norm for 
heart rate, respiratory rate, temperature and white cell count. This configuration of 
clinical findings is derived from a consensus meeting between a small group of critical 
care investigators. It discriminates poorly and its use has been debated heavily. To 
date, however, there is no superior measure.(Marshall 2008) Validity of the SIRS 
construct increased with the findings of a genetic basis for a predisposition to 
SIRS.(Carcillo 2004) 
Attempts to better delineate the clinical SIRS phenotype include molecular techniques 
such as gene array analysis (Johnson, Lissauer et al. 2007). These are time consuming 
and costly modalities. Importantly, the complex interplay of immunology and 
autonomic nervous system is not reflected in these techniques. Rather than trying to 
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answer the question by looking at inflammatory mediators a different approach is to 
focus on features that reflect the sum of these components. One potential method is 
physiological signal analysis. Physiological signals such as heart rate are dynamic and 
reflect physiological states. Heart rate variability (HRV) is the dynamic of beat-to-beat 
changes in heart rate. HRV metrics are thought to be a reflection of health in general 
(Goldberger 2001) as well as acute inflammatory disease states (Gang and Malik 
2002). 
 
1.7.1 Physiological signal analysis- Heart Rate Variability 
Heart rate variability is the normal beat-to-beat variation in heart rate. Changes in this 
normal variation occur with aging and disease. There exist many metrics to describe 
HRV, most of which have been applied in critical care medicine. (Bravi, Longtin et al. 
2011) For the purpose of this thesis, the application of HRV is limited to one metric, 
i.e. power spectral analyis. Power spectral analysis quantifies heart rate variability 
across the frequency spectrum. This measure has been shown to identify and predict 
sepsis in several patient cohorts (Ellenby, McNames et al. 2001, Moorman, Lake et al. 
2006, Ahmad, Ramsay et al. 2009) and predict mortality in trauma (Norris, Morris et 
al. 2005). 
 
1.8 Focussed Therapeutic Interventions  
Numerous attempts have been made to intervene in the acute response to infection 
either with agents that block elements of the acute response or those which add 
endogenous or innate immune or anticoagulant molecules (e.g. recombinant BPI 
(Levin, Quint et al. 2000) or activated protein C (Goldstein, Nadel et al. 2006). None 
have shown convincing evidence of benefit.  There are powerful arguments that even 
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very effective agents would have failed in the methodology of inclusive randomised 
clinical trials because of wide variability in inclusion severity criteria and control 
group mortality between centres.(Eichacker, Parent et al. 2002) (Wong, Cvijanovich et 
al. 2008) It may be that it is just not feasible to intervene with a single agent in the 
complex system with the redundancy as discussed above. Or it may be that anti-
inflammatory drugs cause harm to many patients who were already at very low risk of 
bad outcomes.  One way forward would be to characterise the inflammatory and 
coagulation responses in individual patients and target intervention to the specific 
needs of that patient.  
 
1.9 Aims of this thesis 
This thesis addresses two areas of investigation into the acute phase response in 
children. The first is a prospective observational cohort study taking a candidate gene 
approach on the influence of genetic polymorphisms on the acute phase response. The 
second is a pilot study characterizing the acute phase response in terms of heart rate 
variability as an integrated biomarker of systemic inflammation. 
Chapter 3 aims to describe potential pitfalls in interpreting results from a large genetic 
association study. 
Chapter 4 aims to identify variation in the acute phase response associated with 
endotoxin recognition. 
Chapter 5 describes variation in complement activation as a reason for variation in 
systemic inflammation. 
Chapter 6 specifically probes the interplay between MBL genotype and phenotype in 
systemic inflammation. 
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Chapter 7 aims to distinguish infective from sterile systemic inflammation based on 
physiological signal analysis. 
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Chapter 2 Materials and General Methods 
2.1 Clinical methods 
2.1.1 Recruitment 
The Great Ormond Street Hospital for Children NHS Trust / Institute of Child Health 
and Southampton & South West Hampshire Local Research Ethics Committees 
approved this study.  Written parental informed consent was obtained in accordance 
with the Declaration of Helsinki guidelines(Association). 
 
2.1.2 Inclusion and exclusion criteria 
Children aged 0 to 18 years with at least one organ system failure for 12 hours or 
longer (or death within 12 hours of admission). 
In order to identify a cohort that would allow for potential underlying genetic 
differences to become apparent mild severity of illness and known causes for a more 
severe illness course were excluded. Thus children were excluded in the following 
instances: anticipated short stay on ICU (<24 hours) or multiple congenital 
abnormalities, known immunodeficiency, haematological or lymphoid malignancies, 
systemic immunosuppressive drug therapy other than corticosteroids, known severe 
central neurological or neuromuscular disease, persistent pulmonary hypertension of 
the newborn, weight less than 2.2 kg, corrected gestational age less than 37 weeks and 
non-accidental injury. Multiple congenital abnormalities, pulmonary hypertension and 
known immunodeficiency were permitted in the subset of children admitted for 
cardiac surgery if they were part of the congenital heart disease phenotype. 
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2.1.3 Recruitment centres 
The majority of this work pertains to patients recruited from Great Ormond Street 
Hospital for Children NHS Trust general PICU in London, UK. Other recruitment 
areas are the cardiac PICU (CICU) at Great Ormond Street Hospital for Children 
NHS Trust, the PICU at Southampton General Hospital NHS Foundation Trust and 
the Wessex Cardiothoracic Unit at Southampton General Hospital NHS Foundation 
Trust. 
 
2.1.4 Recruitment time periods 
Subjects were recruited consecutively in three recruiting time-periods from three 
tertiary paediatric intensive care units between 2000 and 2006 and one tertiary adult 
cardiothoracic unit prior to 2002, see Table 2-1. The time periods are discontinuous 
due to availability of research staff. Recruiters were research nurses and critical care 
physicians involved in the project 
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Population Time period 1 Time period 2 Time period 3 
GOSH General Feb 2002-Dec 2002 March 2003-June 2004 May 2005-Dec 2006 
GOSH Cardiac
a 
Jan 2000-July 2002 March 2003-Dec 2006  
Southampton PICU
a 
  Nov 2005-Nov 2006 
Southampton Adult
a 
Prior to 2002   
Table 2-1 Recruitment time periods 
a
Part of the TLR4 gene association study only; GOSH Great Ormond Street Hospital 
for Children NHS Trust. 
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2.1.5 Blinding 
Clinical variables were collected while blinded to the genotype or physiological data 
and vice versa. 
 
2.2 Population definition 
2.2.1 Admission diagnosis 
The on-call admitting consultant PICU clinician made the admission diagnosis. On 
the basis of this primary diagnosis, children in the study were then allocated to the 
groups ‘Bypass’ (elective cardiac surgery requiring cardiopulmonary bypass), 
‘Infection’ and ‘Non-infection’ (including elective general or non-bypass cardiac 
surgery, trauma, and other). Diagnoses were verified at a later time point. 
 
2.2.2 Ethnicity 
Participants came from three tertiary paediatric intensive care units in South East 
England, UK. The demographics of the units differ as regards to the population they 
serve. One hospital (Great Ormond Street Hospital for Children) serves as an 
international, national and regional referral centre for specialist paediatric care. The 
other recruiting hospital (Southampton General Hospital, Southampton, UK) has a 
regional function only. 
It was thus expected that the ethnic background would be inhomogeneous. To account 
for this possible confounder ethnicity data were collected. This was done according to 
parental self-reported ethnic heritage as routinely collected in the National Health 
Service in the UK and then recoded according to the continental classification (Risch, 
Burchard et al. 2002) as adopted by the Hapmap consortium (2003). 
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2.2.2.1 Population stratification 
The population in this study reflects a predominantly urban population with high level 
of immigration. This population is thus expected to be heterogeneous. The frequency 
of many genetic variants is not equal in all parts of the world.(Bamshad, Wooding et 
al. 2004) Population stratification is the observation of a systematic difference in 
polymorphic allele frequencies between sub-populations in a given cohort due to 
differences in ancestry. Identification of sub-populations based on ancestry may be 
done based on self-reported ethnicity or based on a variety of genetic markers, such as 
microsatellites(Bowcock, Ruiz-Linares et al. 1994, Rosenberg, Pritchard et al. 2002) 
Alu insertion polymorphisms (Bamshad, Wooding et al. 2003) or SNPs (Li, Absher et 
al. 2008). 
If the risk of disease varies between ethnic groups, any other ethnically linked 
characteristic, either genetic or environmental, will appear to be associated with the 
disease. Controlling for ethnicity is one way to reduce bias. Interestingly, it was found 
that with increasing numbers of ethnic groups bias tended to decrease rather than 
increase, despite expected larger differences in allele frequency.(Wacholder, Rothman 
et al. 2000) 
 
2.2.2.2 Definition of ethnicity 
In the absence of genetic ancestral markers a surrogate measure for ancestry is self-
reported ethnicity. Researchers have used the terms race and ethnicity interchangeably 
to denote an individual’s heritage in studies focussed on health risk. Neither race nor 
ethnicity, however, are terms with generally agreed upon definitions. There are 
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complex connotations that reflect culture, history, socio-economic, and political status 
and ancestral geographic origins.(Long and Kittles 2003) The current understanding is 
that all human populations come from a common ancestral group, geographically 
located in East Africa, with subsequent migration to Eurasia and the Americas. 
(Goldstein, Ruiz Linares et al. 1995, Long and Kittles 2003) Differences occurred as a 
consequence of history and geography. Generally speaking, the human genetic 
variation encountered outside Africa is a subset of variation seen within Africa. With 
increasing geographical distance from Africa there is a decrease in heterozygosity and 
population specific alleles. African populations show higher genetic variation and less 
linkage disequilibrium (non-random association of alleles) than others.(Reich, Cargill 
et al. 2001, Tishkoff and Williams 2002) 
Nevertheless, most variation, approximately 85%, is seen within populations, rather 
than between them.(Lewontin 1972, Rosenberg, Pritchard et al. 2002, Serre and 
Paabo 2004) 
Notwithstanding the above, it is possible to cluster populations by geographic region 
and assign individuals to predefined group based on continental geography. Using 
377 microsatellite DNA markers in 52 global populations it was possible to cluster 
individuals in five groups that correspond to geographical regions: Africa, Middle 
East and Europe, Asia, Oceania and Americas. It was also noted that high levels of 
inbreeding and genetic drift could lead to clustering, as exemplified by a sixth cluster 
specific to one Pakistani population. Individuals from populations from 
geographically intermediate locations showed partial membership in more than one 
cluster. Thus populations are more of a continuum rather than discrete entities. 
(Cavalli-Sforza 1994, Serre and Paabo 2004) 
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If all four grandparents came from the same part of the world, based on genetic 
variation, one can predict an individual’s geographical origins to the geographical 
regions Africa, Europe, East Asia, Oceania-Pacific and the Americas as used by the 
Hapmap project. In many cases this also correlates with self-identified race or 
ethnicity.(Rosenberg, Pritchard et al. 2002) 
The categorisation of people into continental ancestry is thus possible, but is more 
crude than the continuum that is closer to reality. For the purpose of analysing the 
data taking into account the different allele frequencies at sub-population level the 
study cohort was divided into continental ancestry groups. 
In order to differentiate within this population self-reported ethnicity was used as a 
surrogate marker for genetic ancestry. Although some studies have shown a good 
correlation between self-reported ethnicity and geographical ancestry (as opposed to 
current geographical location) (Tang, Quertermous et al. 2005) there remains the real 
possibility that is not the case in the current study. The self-identified ethnic 
categories as reported in the NHS are imperfect proxies for geographical ancestry as 
they also contain self-identified culture, history, socio-economic, and political status. 
As such it is a socially determined categorisation and may not reflect genetic 
diversity. Each population has a unique genetic and social history. Individuals carry 
within them the genetic result (allele frequency) of ancestral patterns of migration, 
mating practices, reproductive bottlenecks and expansions and stochastic variation. 
Admixture occurs in varying degree not only due to geographical distance, but also 
socio-cultural barriers. The effect of admixture is compounded when the disease of 
interest is more prevalent in one subgroup within a given population, because alleles 
that are more prevalent in this subgroup can appear to be associated with the disease, 
even when unlinked to the disease promoting variant. Thus confounding or population 
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stratification needs to be guarded against in case-control studies. This is especially so 
as the many categories as collected routinely in the UK NHS (based on the UK 2001 
census) have been paired down to four categories in the current study. 
 
2.2.2.3 Functional polymorphisms across ethnicities 
Most polymorphisms examined in the above-mentioned studies were neutral, non-
functional. Functional polymorphisms also differ in frequency between groups. These 
differences may be larger, because functionality infers some natural 
selection.(Bamshad, Wooding et al. 2004) Examples of such monogenic traits that 
differ across populations in frequency are 508-CFTR (cystic fibrosis) (Schrijver, 
Oitmaa et al. 2005), HbS (sickle cell anaemia)(Streetly, Latinovic et al. 2010) and 
HEXA 1278insTATC (Tay Sachs disease)(Bach, Tomczak et al. 2001). Other 
functional polymorphisms differ in frequency across populations with less well-
known relationships between functionality and differences in morphology or 
morbidity. NOD2/CARD15 polymorphisms have been associated with Crohns 
Disease in Caucasians, but not in African-American and Hispanic children. 
(Kugathasan, Loizides et al. 2005) Similarly, the ACE I/D polymorphism is in linkage 
disequilibrium with the functional gene responsible for different levels of ACE in 
European populations (Rigat, Hubert et al. 1990), but not in individuals of African 
descent (Payne, Dhamrait et al. 2007). The frequency of common and private 
polymorphisms differed widely in a mixed population in the US, consisting of self-
identified African, Asian, Latino/Hispanic, and European Americans. (Guthery, 
Salisbury et al. 2007) Therefore, knowledge of geographical ancestry is of importance 
when assessing presumed functional SNPs in relation to health outcomes. There 
remains, however, a requirement to substantiate differences based on ancestry in a 
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robust scientific way. Given our social history where science has been used to 
rationalize discrimination between human groups one should be aware of the social 
ramifications in the nuances of reporting findings, including the possibility of 
perpetuating racism. (Knerr, Ramos et al. 2010) 
A different approach is to ignore (self-assigned) ethnicity and use microsatellite 
markers to cluster individuals into groups of homogeneous genetic structure by means 
of a computer programme named STRUCTURE.(Wilson, Weale et al. 2001).  
One method is to genotype a population for a panel of unlinked ancestry informative 
SNP markers, to adjust for spurious associations caused by stratification. Allele 
frequencies, which differ substantially between ancestral populations can then be used 
to detect, quantify and correct hidden population structure when relying on self-
identified ethnicity. (Shriver, Mei et al. 2005) This analysis was not done because of 
the added time and expense that these methods would incur. 
 
2.2.2.3.1 UK 2001 Census definitions of ethnic groups 
The United Kingdom 2001 Census broke down the population into the following 16 
discrete groupings:(2008) 
White 
 British 
 Irish 
 Other white 
Mixed 
 White and Black Caribbean 
 White and Black African 
 White and Asian 
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 Other mixed 
Asian or Asian British 
 Indian 
Pakistani 
Bangladeshi 
Other Asian 
Black or Black British 
 Caribbean 
African 
Other Black 
Chinese or other ethnic group 
 Chinese 
 Other ethnic group 
 
As of April 2001 the National Codes were introduced into the NHS Data Model and 
Dictionary under Data Set Change Notices DSCN 2/2001 in accordance with the ONS 
2001 Population Census Ethnic categories. The basis of this categorisation in the NHS 
was to follow the government standard. Thus it is a categorisation for administrative 
reasons. Local NHS trusts may add more detailed ethnic categorisation, however, 
these still need to fit in the larger categories above. (Department of Health 2005 )The 
Great Ormond Street Hospital for Children NHS Trust (GOSH) has broadened ethnic 
categorization to include those as depicted in Table 2-2. This categorization was then 
translated to the continental division.(Risch, Burchard et al. 2002) 
GOSH Categorisation Continental Ancestry 
White Caucasian 
 White British/UK Caucasian 
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 White Irish Caucasian 
 White European Caucasian 
 White Other Caucasian 
 Turkish/Turkish Cypriot Caucasian 
 Jewish Caucasian 
 Maltese Caucasian 
 Greek/Greek Cypriot Caucasian 
Mixed Other/Mixed 
 White and Black Caribbean Other/Mixed 
 White and Black African Other/Mixed 
 White and Asian Other/Mixed 
 White and Black Other Other/Mixed 
Asian Caucasian 
 Indian Caucasian 
 Bangladeshi Caucasian 
 Pakistani Caucasian 
 Other Asian Asian 
Black African 
 Black Caribbean African 
 Black African African 
 Black British/UK African 
 Black - Other African 
Chinese/Other Asian 
 Middle Eastern/Arab States Caucasian 
 Arab Caucasian 
 Japanese Asian 
 North African Caucasian 
 Other Ethnic Group Other/Mixed 
Table 2-2 Translation of ethnicity classification 
GOSH Great Ormond Street Hospital 
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2.3 Clinical severity scores 
Measuring severity of critical illness is essential for phenotype description. It allows 
for comparison and benchmarking. The scores that can be used across the spectrum of 
critically ill children are the mortality prediction scores Paediatric Index of Mortality 
(PIM) (Shann, Pearson et al. 1997), PIM2 (Slater, Shann et al. 2003) and Pediatric 
Risk of Mortality (PRISM) III (Pollack, Patel et al. 1996). For organ dysfunction 
scores there exist the Pediatric Logistic Organ Dysfunction score (PELOD) 
(Leteurtre, Martinot et al. 1999) and the Paediatric-Multiple Organ Dysfunction Score 
(P-MODS) (Graciano, Balko et al. 2005).  
The PIM and PIM2 scores were validated in Australia, New Zealand and the United 
Kingdom; the PRISM III score is validated in the USA.  
The only validated organ dysfunction score is PELOD, with participating centres 
from France, Switzerland and Canada. (Leteurtre, Martinot et al. 2003) 
PIM2 is based on a combination of type of illness and admission, generating low risk 
and high risk categories in addition to physiological and intervention data in the first 
hour of encounter with a critical care team, see Table 2-3. (Slater, Shann et al. 2003)  
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Item Response 
Elective Admission Yes/no 
Recovery post procedure Yes/no 
High risk diagnosis Yes/no 
Low risk diagnosis Yes/no 
Pupils fixed and >3mm Yes/no/unknown 
Mechanical ventilation Yes/no 
Systolic blood pressure Value 
Base Excess Value 
FiO2*100/PaO2 Value 
Table 2-3 PIM2 score 
The PIM2 score gives a value of 1 to “yes” answers and a 0 for “no or unknown”. 
High risk diagnoses are cardiac arrest preceding ICU admission, severe combined 
immune deficiency, leukaemia or lymphoma after first induction, spontaneous 
cerebral haemorrhage, cardiomyopathy or myocarditis, hypoplastic left heart 
syndrome, HIV infection, liver failure is the main reason for ICU admission, neuro-
degenerative disorder. Low risk diagnoses for the main reason for ICU admission are 
asthma, bronchiolitis, croup, obstructive sleep apnoea and diabetic keto-acidosis. 
The predicted death rate is calculated with the following equation: 
Logit = (-4.8841) + (values * Beta) + (0.01395 * (absolute (SBP-120))) + (0.1040 * 
(absolute base excess)) + (0.2888 * (100*FiO2/PaO2)) 
Predicted death rate = e
Logit
/ (1+e
Logit
) (Slater, Shann et al. 2003) 
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PELOD gives a score of 0, 1, 10 or 20 for criteria in domains of organ dysfunction, 
see Table 2-4.  
The score has been criticized for being discontinuous. Because it is not possible to 
have a score between 14 and 20 or between 24 and 30 there is no prediction of 
mortality between 3.1% and 16.2% or between 40% and 80% respectively.(Garcia, 
Eulmesekian et al. 2006). The PELOD score has nonetheless performed well in 
several cohorts in determining severity of illness (Leteurtre, Martinot et al. 2003, 
Leclerc, Leteurtre et al. 2005). 
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Domain Maximum Potential Score 
Cardiovascular 
 Heart rate 
 Blood pressure 
20 
 10 
 20 
Neurologic 
 GCS 
 Pupillary reaction 
20 
 20 
 10 
Pulmonary 
 PaO2/FiO2 
 PaCO2 
 Mechanical ventilation 
10 
 10 
 10 
 1 
Haematologic 
 WBC count 
 Platelet count 
10 
 10 
 1 
Renal 
 Serum Creatinine 
10 
 10 
Hepatic 
 SGOT (AST) 
 Prothrombin Time/ INR 
1 
 1 
 1 
Table 2-4 PELOD score 
GCS Glasgow Coma Scale, WBC White Blood Cell, SGOT serum glutamic 
oxaloacetic transaminase, AST Aspartate transaminase, INR International Normalised 
Ratio. Heart rate, blood pressure and serum creatinine are scored according to age. 
The scores corresponding with the variables are then entered into the following 
equation: Logit = -7.64 + 0.30*(PELOD) . Predicted death rate = 1 / (1 + e
-Logit
). 
(Leteurtre, Martinot et al. 2003) 
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This study uses the PIM, PIM2 (as appropriate for recruitment time period) and 
PELOD to score risk of mortality and severity of organ dysfunction respectively. 
2.4 Definition of outcome measures 
The Systemic Inflammatory Response Syndrome (SIRS) was defined according to the 
most recent consensus statement for adults (Levy, Fink et al. 2003) and amended for 
paediatric normal values (Fidler, Wilson et al. 2004). The four variables that are taken 
into account are white cell count, temperature, heart rate and respiratory rate. SIRS is 
defined as  2 variables outside age specific values, one of which has to be either 
temperature or white cell count as follows: 
White cell count > 12x10
9
 or < 4x10
9
; 
Temperature >38C or < 36 C; 
Heart rate: newborn to 3 months 95-145/min, 3-12 months 110-175/min, 1-3 years 
105-170/min, 3-7 years 80-140/min, 7-10 years 70-120/min and 10 years 60-
100/min. 
Respiratory rate was not included, given the high number of children who are 
ventilated on the GOSH PICUs. 
Paediatric specific criteria for SIRS and sepsis were published in 2005 (Goldstein, 
Giroir et al. 2005). The above criteria, however, were maintained for two reasons. 
First, to be able to build on work already done in this area (Fidler, Wilson et al. 2004, 
Stephens, Fidler et al. 2006) and second because there was no experience with these 
amended criteria. 
Children with SIRS and proven (with microbiological evidence) or suspected 
infection (clinical diagnosis and antibiotic treatment in line with sepsis) were 
classified as sepsis. 
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The differences that occur between these definitions are depicted in Figure 2-1, Figure 
2-2, and Table 2-5. 
Generally speaking, heart rate, white cell and temperature cut off points are more 
liberal in the 2005 criteria, thus it is more difficult to attain a definition of SIRS based 
on heart rate, white cell count and temperature. 
For some children only white cell count and heart rate were available to score as 
abnormal because their temperature was artificially controlled and the respiratory 
score was not taken into account for any of the children. This therefore means that 
scoring SIRS was set at a higher threshold.  
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Figure 2-1 SIRS definitions heart rate values 
SIRS denotes Systemic Inflammatory Response Syndrome. Heart rate values by age 
for the two definitions of SIRS. 2005 refers to (Goldstein, Giroir et al. 2005); 
Amended 1992 refers to (Fidler, Wilson et al. 2004) and (Bone, Sibbald et al. 1992) 
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Figure 2-2 SIRS definitions white cell count 
SIRS denotes Systemic Inflammatory Response Syndrome. White cell count values 
by age for the two definitions of SIRS. 2005 refers to (Goldstein, Giroir et al. 2005); 
Amended 1992 refers to (Fidler, Wilson et al. 2004) and (Bone, Sibbald et al. 1992) 
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Criterium Amended 1992 2005 
Temperature > 38C or < 36 C > 38.5C or < 36 C 
Table 2-5 SIRS definitions temperature 
SIRS denotes Systemic Inflammatory Response Syndrome. Temperature values are 
given for the two definitions of SIRS. Amended 1992 refers to (Fidler, Wilson et al. 
2004) and (Bone, Sibbald et al. 1992); 2005 refers to (Goldstein, Giroir et al. 2005) 
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Platelet count data on admission was defined as the first platelet count result after 
admission to the intensive care unit (paediatric data) or prior to angiography (adult 
data). These data were extracted from the electronic medical records. 
 
2.5 Clinical database 
Detailed and accurate phenotypic data on each patient were essential for interpreting 
the results. This included patient demographic data, clinical and laboratory diagnostic 
results and daily review of the Intensive Care bedside electronic charting system 
(Care Vue, Hewlett Packard, USA). 
Patient data were entered and stored in a purpose designed password protected Access 
database (Microsoft Office’98/XP) according to the data protection policies of 
University College London and Great Ormond Street Hospital.  Two research nurses 
and one clinician entered the data prospectively. 
For quality control purposes, a random sample of 5% was audited by one of the 
research nurses. All entries for heart rate, temperature and white cell count were twice 
checked against SIRS criteria. First platelet count on admission to PICU was verified 
before final analysis. 
All were blinded to genotype and heart rate variability data. 
 
2.6 Laboratory methods 
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2.6.1 Blood sample collection and processing 
Blood (2 to 3 mls) was collected from subjects from an indwelling intravenous or 
intra-arterial catheter. The sample was divided into ethylenediaminetetraacetic acid 
(EDTA) and plasma collection tubes. Whole blood was stored at -80C until DNA 
extraction. Plasma samples were spun immediately, aliquoted into two nunc tubes and 
frozen at -80C until analyzed. 
 
2.6.1.1 Preparation of samples for genotyping 
Samples were stored at -80C as whole blood in EDTA until processed. DNA was 
extracted from thawed whole blood according to the manufacturer’s instructions 
(QIAamp DNA blood midi kit, Qiagen, Crawley, UK). DNA collected at 
Southampton PICU (analysed for TLR4 D299G only) was extracted from blood by a 
simple salt extraction method (Miller, Dykes et al. 1988). 
After extraction DNA samples were resuspended in 450 l sterile water and frozen at 
-80C. These samples constituted the DNA library.  
Samples previously prepared as above, resuspended in sterile water and frozen at -
80C were defrosted (PICU samples 1-147; CICU samples array A and B). 
DNA content was assessed by spectroscopy (Digilab Hitachi U-1800 
spectrophotometer). From the DNA library sample 20 l was diluted with 480 l 
water and read at 260 nm (DNA) and 280 nm (total protein) absorbance. The expected 
optical density (OD) 260:280 ratio for DNA lies between 1.8 and 2.0. (Glasel 1995) 
For each well the DNA content was calculated with the formula: 
[DNA] in ng/l= OD (at 260 nm) x dilution (1:20) x 50 
assuming that one OD unit at 260 nm equals 50 ng of double-stranded DNA/l. 
 84 
DNA content was standardized to 250 l 15 ng/l in 96 well stock arrays. From these 
stock arrays, 96 well working arrays were made at 50 l 15 ng/l. 
Genotyping was done from these working arrays. This process minimized 
contamination and the number of freeze-thaw cycles of the DNA library.  
 
DNA storage was done as follows: 
1. DNA library in nunc tubes at 450 l (accessed twice only, once to determine 
DNA content and once to create stock arrays) 
2. Stock array DNA at 15 ng DNA/l in volume of 250 l per well in 96 well 
array 
3. Working 96 well array at 15 ng DNA/l in volume of 50 l per well 
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2.6.2 Reagents and materials 
Name Company Product code 
MBL ELISA kit Bioporto Diagnostics KIT 029 
MilliQ Water from 
Millipore Q plus 
purification system 
Millipore  
Nuclease free water Severn Biotech 20-9000-01 
QIAMP DNA midikit 
extraction kit (100) 
Qiagen 51185 
Table 2-6 Media and kits 
 
 
Name Company Product code 
ELISA plate reader 
Multiscan EX 
Thermo Electron 
Corporation 
 
Laptop  NX260X Gateway 0037264721 
Laptop M675 Gateway 0034386339 
Patient Monitor Philips Merlin CMS 
RS232 board Philips M1170A  
Socket serial card dual PC 
PCMCIA RS232 I/O 
Socket SOC0703081 
Mfr port # SL0703-081 
Socket serial cable Socket Mfr # 8100-00016 
Spectrophotometer  Digilab Hitachi U-1800 
Spectrophotometer  Labtech International Nanodrop ND-1000 v 
3.1.0 
T25-pin RS232 serial 
adapter cable 
Oregon Electronics  
Table 2-7 Equipment 
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2.7 Candidate gene study 
One method to study genetic variability in relation to the host response is the 
candidate gene approach.  The premise is that an association between an allele and a 
phenotype is due to either a functionality of the genetic polymorphism itself or it is in 
tight linkage disequilibrium with a polymorphism with a functional effect. Linkage 
disequilibrium is the extent to which alleles at two or more loci are associated with 
each other. The third possibility is that of confounding or selection bias.(Silverman 
and Palmer 2000) A major concern is the possibility of random chance leading to a 
false association between genetic polymorphsims and phenotype. Candidate gene 
studies therefore require rigorous statistical analysis. 
 
2.7.1 Background 
Patients vary in their susceptibility and response to injury and infection. This variation 
is explained, in part, by age, gender, underlying chronic illness or environmental 
factors such as crowding or pathogen virulence. Genetic heterogeneity is one aspect 
that may explain some of the observed variation in presentation and course of illness. 
Premature death due to infection was found to have a strong genetic component, even 
more so than cardiovascular disease. The relative risk for an offspring to die of an 
infectious cause if their parent had died prematurely (before the age of 50) of an 
infectious disease was 5.81 (95% confidence interval 2.47 to 13.7). This compared 
with 4.52 (1.32 to 15.4) for cardiovascular and cerebrovascular causes. (Sorensen, 
Nielsen et al. 1988)This earlier work was updated recently.(Petersen, Andersen et al. 
2010) 
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The next step is to identify the specific genes and genetic variability that may underlie 
this hereditability. The mapping of the human genome and its variation allows 
potential identification of specific genetic variability in the context of disease.(2003) 
2.7.2 Number and variation in genes 
The number of candidate genes is immense. Humans are estimated to be 99.9% 
identical at the DNA sequence level. Initially it was estimated that the number of 
genes encoding for proteins was about 30.000 (approximately twice that of a 
worm)(Lander, Linton et al. 2001) Only recently has the ENCODE project elucidated 
that the human genome contains about 21,000 protein-coding genes and that there are 
4 million regulating areas. 80% of the human genome has biochemical 
functions.(Consortium, Dunham et al. 2012) Only a fraction of the total genome, 10 
million of 3 billion nucleotides, accounts for variability among populations.(Tishkoff 
and Kidd 2004) 
Any one of these genes encoding a protein that contributes to inflammatory processes 
is a candidate gene to explain interindividual differences in the host response to 
infection or injury. Also, there exist in these genes structural variants of different 
kinds: e.g. single nucleotide polymorphisms (SNPs), copy number variations (CNVs), 
and insertions and deletions.(Feuk, Marshall et al. 2006) 
This thesis focuses mainly on SNPs as most genetic variability was thought to arise 
from coding SNPs in exons. The National Center for Biotechnology Information 
(NCBI), United States National Library of Medicine and National Institutes of Health 
(NIH), curates the Single Nucleotide Polymorphism Database (dbSNP). The latest 
build of this database (June 26 2012), holds over 53 million SNPs, 38 million of 
which are validated and 36 million of which have frequencies (dbSNP build 137, 
Genome Build 37.3) (NCBI 2012). The original definition of a SNP included a 
 88 
frequency of at least 1% in a population. The current database hosts submissions 
without frequency data. Thus many sequence variants ultimately may not qualify as 
SNPs.(Day) 
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2.7.3 Contribution of single genes to phenotype in complex disease 
The acute phase response to injury and infection is complex. Many processes occur 
simultaneously and consecutively in a network that includes the innate immune, 
coagulation and neuro-endocrine systems.  There are two models for understanding 
genetic contributions to complex diseases: There is the mono-genic model, in which 
one allele change in a single gene explains much of the phenotypic difference. One 
example is the T>A substitution in codon 6 of the  globin gene resulting in the 
amino acid valine rather than glutamic acid, which, in turn, leads to malaria infection 
protective Haemoglobin S(Ingram 1957). More recent examples include mutations in 
the NOD2 gene in Crohn’s disease (Cuthbert, Fisher et al. 2002) and the Y402H CFH 
amino acid substitution in age related macular degeneration (Klein, Zeiss et al. 2005). 
The second model is that of many genes exerting additive small influences on the 
phenotype. (Pritchard 2001, Hill, Goddard et al. 2008) Recently it was proposed that 
genetic variant secondary to SNPs may account for much of the susceptibility to 
common diseases(Bodmer and Bonilla 2008, 2010, Yang, Benyamin et al. 2010).  
To focus on candidate genes with the most potential the following questions were 
asked in accordance with recommendations from the literature regarding gene 
association study design (Ioannidis, Ntzani et al. 2001, Tabor, Risch et al. 2002):  
1. Is there biological plausibility of association? 
2. Is it likely that the candidate gene contributes to the phenotype? 
3. Does the SNP likely have a functional biological effect on the protein? 
4. Is the SNP prevalent enough to be able to make an association? 
5. Is there evidence of association from previous studies? 
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Thus candidate genes were identified for this gene association study of the acute 
phase response. 
 
2.7.4 Functional consequences of polymorphisms 
The protein coding gene structure lies between the boundaries of transcription start 
and end. The coding region contains codons, the sequences of three nucleotides from 
which the amino acids are translated. It starts with the initiation codon, usually the 
nucleotide sequence ATG (Adenine, Thymine, Guanine) and ends with a termination 
codon (TAA, TAG or TGA). On both sides of the coding region there are DNA 
sequences that are transcribed, but not translated: the untranslated regions 5’UTR and 
3’UTR. The coding regions consist of exons interrupted by introns. Exons translate to 
m-RNA, while intervening sequences, introns, are not expressed. The regulatory 
promoter region contains specific sequences including the TATA box that are binding 
sites for transcription factors.(Roeder 2005) 
A SNP may occur in any part of a gene, i.e. in the promoter, intron, exon or 3’UTR 
part (Figure 2-3). In the event the SNP is part of the promoter it may result in 
increased or decreased translation, in turn, leading to an increased or decreased 
amount of produced protein. A change in an exonic nucleotide may be silent, i.e. there 
is no resultant amino-acid change. A change may result in gain or loss of function.  
Intronic and 3’ UTR SNPS may affect RNA stability. In addition, there is the 
possibility that it is not the SNP under investigation, but another SNP in complete 
linkage disequilibrium that is the cause of the observed change in biological 
function.(Tabor, Risch et al. 2002) 
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Figure 2-3 Potential positions for SNPs 
Schematic of a gene with potential positions for polymorphisms. Three types of SNPS 
may occur in an exon. 1 depicts a silent change, 2 a resultant amino-acid change with 
gain of function and 3 an amino-acid change with loss of function. 
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2.7.5 The International Union of Pure and Applied Chemistry (IUPAC) 
nomenclature 
The IUPAC Amino acid nomenclature was used to denote changes (if any) to the 
amino acid sequence secondary to a given SNP (see Table 2-8 and Table 2-9). (1984) 
(Cornish-Bowden 1985) 
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Abbreviation Code Amino acid name 
Ala A Alanine 
Arg R Arginine 
Asn N Asparagine 
Asp D Aspartic acid (Aspartate) 
Cys C Cysteine 
Gln Q Glutamine 
Glu E Glutamic acid (Glutamate) 
Gly G Glycine 
His H Histidine 
Ile I Isoleucine 
Leu L Leucine 
Lys K Lysine 
Met M Methionine 
Phe F Phenylalanine 
Pro P Proline 
Ser S Serine 
Thr T Threonine 
Trp W Tryptophan 
Tyr Y Tyrosine 
Val V Valine  
Table 2-8 IUPAC Nomenclature for amino acids 
 
IUPAC Code Meaning 
M A/C 
R A/G 
W A/T 
S C/G 
Y C/T 
K G/T 
Table 2-9 IUPAC Code for nucleotide change  
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2.7.6  Identification of candidate genes 
A literature search was performed to identify functional common single nucleotide 
polymorphisms (SNPs) in the innate immune system. The innate immune system was 
approached in terms of genes that contribute to the acute phase response. In addition, 
expert advice was obtained on potential candidate genes.  
To optimize predictive power of this study an arbitrary cut-off point of > 5% was 
chosen as the minor allele frequency in the Caucasian population. 
Polymorphisms of interest were defined as: 
1. Part of the innate immune system 
2. Minor allele frequency >5% in the Caucasian population 
3. Established functionality or association with relevant inflammatory disease 
 
The a priori assessment whether a specific polymorphism would be likely to have a 
significant impact on phenotype was assessed as best as could be at that time, on the 
basis of known functionality, previous association studies and presumed importance 
in the acute phase response. 
 
The set of chosen genes was divided into the following categories: 
1. Complement activation 
2. Pattern Recognition Receptors 
3. Cytokines 
4. Regulatory Receptors 
5. Acute phase proteins 
6. Other 
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Complement Activation Cascade 
MBL-2, lectin pathway activation; 
CFH, alternative pathway inhibition; 
CFB, alternative pathway activation; 
C1qA, classical pathway activation; 
 
Pattern Recognition Receptors 
TLR2; Lipoteichoic Acid (LTA) on gram-positive bacteria, endogenous ligands 
 
Endotoxin recognition complex 
TLR4, signal transduction of LPS, endogenous ligands; 
CD14, binds LPS to TLR4-MD2 complex; 
LBP shuttles LPS to CD14; 
 
Cytokines 
TNF, pro-inflammatory; 
IL6, pro-inflammatory; 
IL10, anti-inflammatory; 
 
Regulation 
CHRNA7, regulates cytokine production, down-regulates TLR4; 
ADRB2, regulates cytokine production; 
MHC2TA, regulates HLA-DR expression; 
PTPN22, regulates T Cell response; 
SELS, protects against metabolic stressors 
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Acute Phase Reactants 
CRP, C-Reactive Protein potentiates pro-inflammatory reponse; 
ADM, Adrenomedullin is pluripotent, binds to CFH; 
PAI-1; Plasminogen Activator Inhibitor-1 pro-inflammatory and inhibits fibrinolysis 
 
Other 
ACE,  Angiotensin Converting Enzyme vaso-active; 
APOE; Apolipoprotein E cholesterol carrier lipoprotein 
 
This list is limited for several reasons. There are many more genes that would qualify 
as part of innate immunity with a putative important role in the acute phase response. 
Two examples of genes not included in the analysis follow here: 
MD2, (LYP 96) binds LPS to TLR4 in the endotoxin recognition complex and is 
pivotal for a robust response (Fitzgerald, Rowe et al. 2004), however, no common 
SNPs were identified. 
The IL1 group is a potent pro-inflammatory cytokine family. It includes agonists 
IL1, IL1 and the IL1 receptor antagonist IL1ra. There are several polymorphisms 
in all three genes, with a complex interplay (Waterer and Wunderink 2003). Given 
that genetic variation in this cytokine was difficult to interpret, this cytokine was not 
chosen in the gene set. 
Most importantly, adding genes “on spec” without a robust hypothesis would 
decrease the power of the study because of undue correction for multiple 
testing.(Hattersley and McCarthy 2005) 
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2.7.6.1 Identification of nucleotide sequence 
The positions of the polymorphisms were established using NCBI dbSNP ID rs 
numbers on the NCBI SNP website, dbSNP build 126, Genome Build 36.1 (May 4, 
2006). Current URL:(2010) The website identifies the position of the requested 
polymorphism using the unique identifiying rs number. (Figure 2-4) 
The thus obtained nucleotide sequence output was then emailed from the NCBI 
website in a FASTA text file format. Figure 2-5 shows an example for rs1800871 
(IL10). 
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Figure 2-4 NCBI SNP identification website 
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Figure 2-5 Nucleotide sequence for IL10 SNP rs1800871 
Nucleotides are denoted by AGTC and the polymorphism by Y. 
(A Adenine; G Guanine; T Thymine; C Cytosine; Y (C/T)). 
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Nucleic acid sequences were then counted 50 base pairs upstream and downstream of 
the thus identified polymorphic site. If rs numbers were not available for the position 
then Genbank reference numbers, original manuscripts and/or personal 
communication with the authors describing the polymorphism were used. 
These sequences were imported to an excel spreadsheet and emailed to the 
commercial facility KBiosciences (Hoddesdon, Herts, UK). 
This facility then designed and validated the oligonucleotides on the basis of the 
nucleic acid sequences. 
Sealed plate arrays were couriered to the genotyping facility on dry ice.  Telephone 
contact with the facility established arrival in good order. Samples were not 
contaminated during transport. The 50l samples were diluted 1:4 to allow for all 
SNPS to be run. 
Table 2-10 summarizes the chosen genes, locus, positions SNP names and 
functionality as described in the literature as well as common haplotypes. 
 101 
Gene Locus Position SNP rs number Function Haplotype  
MBL2 10q11.2-
q21 
Exon 1 “D” 
52C→T 
Arg>Cys 
5030737 T less HYPA: high 
LYQA: wildtype 
(Dommett, Klein et 
al. 2006) 
MBL2  Exon 1 “B”  
54G→A 
Gly>Asp 
1800450 A less LYPA: intermediate 
LXPA: intermediate 
 
MBL2  Exon 1 “C” 
57G→A 
Gly>Glu 
1800451 A less HYPD: low 
LYQC: low 
 
MBL2  Promoter -221 G/C 
X/Y 
7096206 G less LYPB: low  
MBL2   Promoter -550 C→G 
L/H 
11003125 C less   
MBL2  Promoter +4 C→T 
P/Q (KB 
GA) 
7095891 
 
NA   
        
C1QA 1p36.12 Exon 2 276G>A; 
Gly70GGA 
172378 AA deficient  (Racila, Sontheimer 
et al. 2003) 
        
CFB 6p21.3 Exon 1 L9H 
Leu9His 
TA 
4151667 A low 
In signal peptide 
 (Gold, Merriam et al. 
2006) 
CFB  Exon 2 
 
 
 
 
R32Q 
95 GA 
or CT 
Arg32Gln 
 
641153 
 
 
 
 
A reduced hemolytic 
activity; 
 
 
 
  
 102 
Exon 2 
 
R32W 
94 CT 
Arg32Trp 
12614 Trp no effect 
Functionality -  
        
CFH 1q32 Exon 9 
 
Tyr402His 
T>C; 
Y402H; 
1277T→C 
1061170 C defective 
C allele high risk 
AMD 
 (Haines, Hauser et 
al. 2005) 
        
ADM 11p15.4 Promoter -1984A>G 3814700 G high  (Li, Staessen et al. 
2006) 
        
TLR2 4q32 TIR domain 
Exon 3 
Arg753Gln 
R753Q 
G2258A 
G→A 
5743708 
 
A has reduced 
response (missense) 
?Signalling 
function 
 (Lorenz, Mira et al. 
2000) 
TLR2  Intron 1 TagSNP 
16933A→T 
4696480 AA more infections 
 
 (Sutherland, Walley 
et al. 2005) 
TLR2  Exon 3; 
Pseudo snp 
(Malhotra, Relhan 
et al. 2005) 
Arg677Trp 
C2029T 
N/A Reduced 
intracellular 
signalling; 
 (Kang and Chae 
2001, Bochud, Hawn 
et al. 2003) 
        
TLR4 9q33.1 Exon 3 Thr399Ile 
C>T 
4986791 T low 299G/399I low (Arbour, Lorenz et 
al. 2000) 
TLR4  Exon 3 Arg299Gly 
A>G 
4986790 G low   
        
CD14 5q31.1 Promoter C-159T; 2569190 TT high  (Hubacek, Rothe et 
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C-260T al. 1999) 
        
LBP 20q11.23-
q12 
Exon 3 Pro97Pro 
C/T 
2232582 T worse outcome  (Hubacek, Stuber et 
al. 2001, Barber and 
O'Keefe 2003) 
        
CHRNA7 15q13-
q14 
Promoter_6 -46G→T No rs 
numbers 
T low  (Leonard, Gault et 
al. 2002) 
  Promoter_5 -86 C→T  T low   
  Promoter_4B -92 G→A AF029837 
sequence 
used 
A low   
  Promoter_4A -143G→A  A low   
  Promoter_3 -178 -G  - low   
  Promoter_2 -194G→C  C or T low   
  Promoter_1 -241A→G  G low   
ADRB2 5q31-q32 Exon1 Arg16Gly 
A/G 
1042713 Gly/Gly and Gly/Arg 
downregulates 
Arg is WT 
 (Brodde and 
Leineweber 2005) 
ADRB2  Exon1 Gln27Glu 
C/G 
1042714 Glu/Glu 
Very resistant to 
downreg 
Gln is WT 
  
ADRB2  Exon1 Thr164Ile 
C>T 
1800888 TT less affinity 
binding 
  
ADRB2  ‘5 LC (leader 
cistron); at 
translational level 
influence  
-47T>C 
Arg-19Cys 
1042711 
(identified 
later) 
CC greater 
expression 
 (McGraw, Forbes et 
al. 1998) 
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     Gly16 dominant over 
Glu27; Arg16/Glu27 
double mutant 
completely resistant 
to downregulation 
CysGlyGln 
haplotype more 
susceptible to b 
agonist 
desensitization 
 (Oostendorp, Postma 
et al. 2005) 
IL10 1q31-q32 Promoter -1082G→A 1800896 G/A GCC/GCC high (Turner, Williams et 
al. 1997) 
IL10  Promoter -819C→T 1800871 C/N   
IL10  Promoter -592C→A 1800872 C/N   
     High/low   
MHC2TA 16p13 Promoter III (B 
cells) 
-168A→G 3087456 G high  (Swanberg, Lidman 
et al. 2005) 
        
IL6 7p21 Promoter -174G→C 1800795 G/C (CC low)  (Terry, Loukaci et al. 
2000) 
IL6  Promoter -572G→C 1800796 G/G GGG/GGG high 
CGA/CGA low 
 
IL6  Promoter -597G→A 1800797 G/A   
     High/Low   
DCP1= 
ACE 
17q23.3 Intron 16 
 
287 bp Alu 
rpt 
4646994 DD high 
(50%) 
 (Rigat, Hubert et al. 
1990) 
DCP1= 
ACE 
 Exon 17 Thr776Thr 
G2350A 
4343 GG lowest 
GA int 
AA high 
 (Glenn, Du et al. 
2009) 
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(19%); complete LD 
with rs4646994  
DCP1= 
ACE 
 Promoter 
 
A-240T 4291 AA lowest 
AT interm 
TT high 
(6%) 
 (Zhu, Bouzekri et al. 
2001) 
DCP1= 
ACE 
 Intron 16  4341 In complete LD with 
rs4646994 
 (Tanaka, Kamide et 
al. 2003) 
        
(Serpine-
1) PAI-1 
7q21.3-
q22 
Promoter -765 4G/5G 1799889 4G/4G high  (Dawson, Wiman et 
al. 1993) 
        
TNF (TNF 
alpha) 
6p21.3 Promoter -308 G→A 1800629 AA high  (Kroeger, Carville et 
al. 1997) 
SELS 
(SEPS1) 
15q26.3 Promoter -105G→A 28665122 A  (Curran, Jowett et al. 
2005) 
        
PTPN22 
(Lyp) 
1p13.3-
p13.1 
Exon 14 R620W 
C1858T 
2476601 TT high 
Inhibitor T-cell 
activation 
 (Bottini, Musumeci 
et al. 2004, Zuo, 
Lubischer et al. 
2004) 
        
CRP 1q21-23  -717A/G  2794521 Tag snp  Personal 
communication Dr 
Aroon Hingorani 
CRP   -305G/A  3093062 Tag snp   
CRP   -286C/T/A  3091244 Tag snp   
CRP   +1444C/T 1130864 Tag snp   
CRP  1. Exon 2 C/T +2302G/A  1205 Tag snp   
 106 
untrans  
CRP   +4899T/G  3093077 Tag snp   
        
APOE 19q13.2 Exon 4 Arg112Cys 
Arg130Cys 
C/T 
429358  2, 3, 4 
E2 Cys
112
-Cys
158 
E3 Cys
112
-Arg
 158 
E4 Arg
112
-Arg
 158
 
(Teasdale, Nicoll et 
al. 1997) 
APOE  Exon 4 Arg158Cys 
Arg176Cys 
C/T 
7412 
 
   
Table 2-10 Candidate gene characteristics 
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The table contains polymorphisms that were previously mistyped. This information 
became apparent after the genotyping requests had already been made. 
LBP P97P: Originally thought to affect outcome in adults with sepsis (Hubacek, 
Stuber et al. 2001), but found to be identified wrongly (Barber and O'Keefe 2003).  
TLR2 Arg677Trp was originally thought to occur in Korean patients with tuberculosis 
at higher frequency (Kang and Chae 2001), but found to be identified incorrectly 
(Malhotra, Relhan et al. 2005). 
The CHRNA7 promoter polymorphism choices were based on a study by(Leonard, 
Gault et al. 2002). Subsequent work showed the variant frequency to be very 
low.(Stephens, Logel et al. 2009) (Table 2-11) 
Ultimately 52 SNPs in 24 genes were identified. These SNPs were hypothesized to 
modify the primary outcome measures as outlined in Table 2-12. 
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SNP Position Frequency 
Caucasian 
Frequency African 
American 
Promoter_6 -46G→T 0.003 0.097 
Promoter_5 -86 C→T 0.064 0.004 
Promoter_4B -92 G→A 0.006 0.004 
Promoter_4A -143G→A Rare in original 
already 
Rare in original already 
Promoter_3 -178 -G 0.004 0.076 
Promoter_2 -194G→C 0.042 0.02 
Promoter_1 -241A→G 0.001 0.0 
Table 2-11 CHRNA7 Promoter variant frequencies 
SNP Single Nucleotide Polymorphism 
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Gene Category 
MBL2 Early SIRS 
C1QA Early SIRS 
CFB Early SIRS 
CFH Early SIRS 
ADM Modified HRV 
TLR2 Early SIRS 
TLR4 Early SIRS/ 
platelet count on admission 
CD14 Confounder 
LBP Confounder 
CHRNA7 Confounder 
ADRB2 Modified HRV 
IL10 Confounder 
MHC2TA Nosocomial infection 
IL6 Confounder 
DCP1= ACE AHRF 
(Serpine-1) PAI-1 Confounder 
TNF (TNF alpha) Confounder 
SELS (SEPS1) Early SIRS 
PTPN22 (Lyp) Early SIRS 
CRP Early SIRS 
APOE Worse neurological outcome after severe TBI 
Table 2-12 Candidate genes linked to outcome measure 
HRV, heart rate variability; AHRF, acute hypoxic respiratory failure; TBI traumatic 
brain injury 
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2.8 Genotyping methods 
2.8.1 KASPAR technology (KBioscience) 
Most SNPs were determined by the KASPar assay system (KBioscience, Herts, UK). 
KBioscience is a commercial genotyping facility. The company has developed a 
fluorescent-based competitive allele-specific PCR method.  
The principle works as follows: 
Based on the genotyping sequence that was sent to the facility they designed 
oligonucleotide probes to synthesize allele specific primers. 
The DNA was distributed in 96 well plates. DNA was diluted and pipetted onto 
working plates. KASPmix was then added to the DNA. This mix contains two 
competitive allele-specific tailed forward primers, one common reverse primer and a 
combination of components to allow the PCR reaction to work. This included the 
universal fluorescent reporting system and their proprietary KTaq polymerase, which 
is a recombinant thermostable DNA polymerase. The polymerase originated from the 
thermophilic bacterium Thermus aquaticus and was obtained from high level gene 
expression in E coli. 
The plates were then sealed and put through the following thermocycle: 
(1) 95 for 15 minutes 
(2) 95 for 30 seconds 
(3) 61 for 30 seconds 
(4) 72 for 1 minute 
Steps (2) to (4) are repeated 34 times 
(5) 72 for 5 minutes 
 
(1) 94 °C for 15 minutes 
Hot‐start enzyme activation 
(2) 94 °C for 20 seconds 
Touchdown over 65‐57°C for 60 seconds 
10 cycles (dropping 0.8°C per cycle) 
(3) 94°C for 20 seconds 
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57°C for 60 seconds 
26 cycles 
 
After cooling to room temperature the plates were read on a fluorescent reader. 
 
The genotyping results were generated in a comma separated text file (.csv) listing 
each of the samples with each SNP and its genotype. These then could be imported in 
excel for further analysis. In addition, these results could be viewed graphically using 
the SNP viewer tool (KBioscience). 
Figure 2-6 shows the excel file for SNP rs1800871 (IL10) and Figure 2-7 shows the 
SNP viewer graph for SNP rs1800871 (IL10). 
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Figure 2-6 Excel file raw data for rs1800871 
The output from KBioscience shows the name of the daughter plate as created by 
KBioscience, the name of the masterplate created by me, the position of the 
masterwell, the interpretation of genotype, the X and Y value to be viewed in the 
programme SNP viewer, the SNPID rs number and the subject ID.  
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Figure 2-7 Graphic representation of results for SNP rs1800871 
Red dots denote genotype T:T, green dots T:C, blue dots C:C, pink dots could not be 
called and yellow dots denote insufficient quality DNA. The bottom left corner shows 
the master array plate (PICU3 in this instance). 
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2.8.2 Taqman Method 
Taqman methodology is a fluorescent real-time PCR assay. The polymorphisms 
TLR4 D299G (rs 4986790) and ACE rs4341 were analysed with this technique. 
 
TLR4 
The TLR4 D299G polymorphism was determined by a TaqMan assay (Applied 
Biosystems, Warrington UK, Assay ID: C_11722238_20) according to the 
manufacturers protocol. 
 
TaqMan (Applied Biosystems, Warrington UK) primers and probes were as follows: 
Context sequence: 
GCATACTTAGACTACTACCTCGATG[A/G]TATTATTGACTTATTTAATTGTT
TG 
Forward primer: 5'-TGACCATTGAAGAATTCCGATTAGCA 
Reverse primer: 5'-ACACTCACCAGGGAAAATGAAGAA 
Probe (wild-type allele): (FAM label) 5'-TACCTCGATGATATTATT-MGB 
Probe (variant allele): (VIC label) 5'-CCTCGATGGTATTATT-MGB 
 
ACE 
The ACE polymorphism rs4341 C>G, is reported to be in 100% linkage 
disequilibrium (LD) with the ACE I/D polymorphism rs4646994 (Tanaka, Kamide et 
al. 2003) (CC with II and GG with DD). One DNA array plate (PICU plate 1, n=91) 
was genotyped for both ACE rs4341 and ACE I/D rs4646994 to confirm this LD in 
the current patient cohort. 
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TaqMan (Applied Biosystems, Warrington UK) primers: 
Forward -CCTTACAAGCAGAGGTGAGCTAA 
Reverse -CCATCACATTCGTCAGATCTGGTA 
and probes: 
VIC -TCAAGCCATTCAAAC 
FAM -CAAGGCATTCAAAC 
A specific set of primers amplifies a DNA region to allow specifically designed 
probes to anneal within that DNA region. A fluorophore is attached to the 5’-end of 
the oligonucleotide probe and a quencher is attached at the 3’-end. The fluorophore 6-
carboxyfluorescein (FAM) labeled probe detects one allele and the (VIC) labeled 
probe detects the other potential allele. The emission spectrum peaks are 530 nm for 
FAM 550 nm for and VIC respectively. The cycler’s light source excites the 
fluorophore via Fluorescence Resonance Energy Transfer (FRET). The quencher 
molecule then quenches this emitted fluorescence. 
Taq polymerase extends the primer and synthesizes the nascent strand, while the 5' to 
3' exonuclease activity of the polymerase degrades the probe that has annealed to the 
template. This degradation of the probe causes the fluorophore to be released from it 
and also breaks the close proximity to the quencher. In turn, the quenching effect 
ceases to be which allows the fluorophore to fluoresce. This way, the fluorescence 
that is detected in the real-time PCR thermal cycler is directly proportional to the 
fluorophore released and the amount of DNA template present. 
Fluorescent reporter probes only detect DNA that contains the probe sequence. This 
significantly increases specificity because it enables quantification even in the 
presence of non-specific DNA amplification.  
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2.8.3 Three Primer PCR method 
The specifications are outlined as supplied by the Department of Cardiovascular 
Genetics, Rayne Institute, University College London, London, UK. 
The ACE I/D polymorphism protocol is a 3 primer PCR method that generates two 
PCR products. Counter intuitively, the larger product corresponds with the deletion 
allele and the smaller product with the insertion allele. The protocol is depicted in 
Figure 2-8 and the nucleotide sequence with primers and PCR products is given in 
Figure 2-9. 
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Figure 2-8 ACE I/D polymorphism protocol 
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ggcaacagagtgagaccctgtctcagaaagaaaaaaaaaaaaaaaggag
aggagagagac 
 
tcaagcacgcccctcacaggactgctgaggccctgcaggtgtctgcagc
atgtgcccagg 
         FH76 
ccggggactctgtaagccactgctggagaccactcccatcctttctccc
atttctctaga 
 
cctgctgccta/tacagtcactttttttttttttttgagacggagtctc
gctctgtcgccc 
 
aggctggagtgcagtggcgggatctcggctcactgcaacgtccgcctcc
cgggttcacgc 
 
cattctcctgcctcagcctcccaagtagctgggaccacagcgcccgcca
ctacgcccggc 
 
taattttttgtatttttagtagagacggggtttcaccgttttagccggg
atggtctcgat 
           FH77 
ctcctgacctcgtgatccgcccgcctcggcctcccaaagtgctgggatt
acaggcgt/gat 
          FH78 
acagtcacttttatgtggtttcgccaattttattccagctctgaaattc
tctgagctccc 
 
cttacaagcagaggtgagctaagggctggagctcaagccattcaacccc
ctaccag 
 
Figure 2-9 ACE I/D polymorphism 3 primer PCR method  
 
 fh76 5’ primer 
 fh77 5’ primer 
 fh78 3’ primer 
 
 
PCR products 
 85bp deletion allele 
 65bp insertion allele 
 
ACE intron 16 I/D polymorphism (rs4646994). 3 primer PCR method. Insertion 
marked by /.  
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The genotyping for this project was therefore done using several techniques at 
different facilities. I performed DNA extraction and analysis. 
A subset of the current cohort had previously been genotyped by other researchers. 
These historical genotyping data were not available to those currently conducting the 
actual genotyping. This subset consisted of PICU patients number 1-147. The 
researchers or facility involved in prior genotyping are denoted by their initials in 
Table 2-13. These results were available to me and used as a quality control measure. 
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Gene RSnumber Facility Subset prior 
genotyped 
PTPN22  2476601 Kbioscience 1   
C1QA 172378 Kbioscience 1   
CRP 3093077 Kbioscience 1   
CRP 1205 Kbioscience 1   
CRP 1130864 Kbioscience 1   
CRP 3091244 Kbioscience 1   
CRP 3093062 Kbioscience 1 and 2   
CRP 2794521 Kbioscience 1 and 2   
IL10 1800872 Kbioscience 1   
IL10 1800871 Kbioscience 1   
IL10 1800896 Kbioscience 1  KF 
CFH 1061170 Kbioscience 2   
TLR2 N/A *   
TLR2 4696480 Kbioscience 1   
TLR2 5743708 Kbioscience 1 Innogenetics, Belgium 
CD14 2569190 Kbioscience 1 Innogenetics, Belgium 
ADRB2 1042711 (5'LC) Kbioscience 1   
ADRB2 1042713 Kbioscience 1   
ADRB2 1042714 Kbioscience 1   
ADRB2 1800888 Kbioscience 1   
TNFA 1800629 Kbioscience 1  KF 
CFB 4151667 Kbioscience 1   
CFB 641153 Kbioscience 1   
IL6 1800797 Kbioscience 1   
IL6 1800796 Kbioscience 1   
IL6 1800795 Kbioscience 2  KF 
PAI-1 1799889 Kbioscience 1  KF 
TLR4 4986790 Southampton Innogenetics, Belgium 
TLR4 4986791 Kbioscience 1 Innogenetics, Belgium 
MBL2 1800451 Kbioscience 1  KF 
  1800450 Kbioscience 1  KF 
  5030737 Kbioscience 1  KF 
  7095891 Kbioscience 1   
  7096206 Kbioscience 1  KF 
  11003125 Kbioscience 1   
ADM 3814700 Kbioscience 1   
CHRNA7 -241A→G Kbioscience 1 and 2   
  -194G→C Kbioscience 1 and 2   
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  #NAME? Kbioscience 1 and 2   
  -143G→A Kbioscience 1 and 2   
  -92 G→A Kbioscience 1 and 2  
  -86 C→T Kbioscience 1  
  -46G→T Kbioscience 1  
CHRFAM7A TG/- Kbioscience 1  
CHRFAM7A TG/- Kbioscience 1  
SELS (SEPS1) 28665122 Kbioscience 1 and 2  
MHC2TA 3087456 Kbioscience 1  
DCP1= ACE 4291 Kbioscience 1  
DCP1= ACE 4646994 Rayne KF 
DCP1= ACE 4341 Rayne  
DCP1= ACE 4343 Kbioscience 1  
APOE 429358 Kbioscience 1 and 2  
APOE 7412 Kbioscience 1  
LBP 2232582 Kbioscience 1  
Table 2-13 Genotyping facilities 
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2.8.4 Collaboration 
I performed DNA extraction, sample handling and despatching, quality control and 
data analysis. Genotyping was done by the commercial facility KBioscience and the 
following collaborators (bolded): 
 
ACE genotyping: 
Ms KaWah Li, Laboratory Technician 
Professor Steve E Humphries, BHF Professor of Cardiovascular Genetics 
Centre for Cardiovascular Genetics, Rayne Institute, Department of Medicine, 
University College London, London, UK. 
 
TLR4 D299G genotyping: 
Mr Matthew Rose-Zerilli, Research Technician 
Dr John Holloway, Reader Infection, Inflammation & Repair 
Human Genetics Division, University of Southampton, UK 
 
TLR4 adult data: 
Dr Shu Ye, Reader in Human Genetics 
Clinical Pharmacology, William Harvey Research Institute, 
Barts and the London School of Medicine 
David Pontefract, Human Genetics Division, University of Southampton, UK 
 
Clinical data Southampton PICU: 
Ms Kerry Illing, Medical student 
Dr John Pappachan, Consultant and Honorary Senior Lecturer,  
Paediatric Intensive Care Unit, Southampton University Hospitals NHS Trust 
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Comparison dataset genotyping and clinical data 
PICU samples 1-147 
Dr Katy Fidler, SpR 
Department of Infectious Diseases & Microbiology, 
Institute of Child Health 
University College London 
Dr Peter Wilson, SpR  
Ms Helen Tighe, Research Nurse 
Paediatric Intensive Care Unit, Great Ormond Street Hospital NHS Trust London 
 
Comparison CICU dataset genotyping and clinical data 
Dr Meredith Allen, SpR 
Ms Annette McQuillan, Research Nurse 
Cardiac Intensive Care Unit, Great Ormond Street Hospital NHS Trust London 
 
2.8.5 Hardy Weinberg Equilibrium 
In a randomly mating infinite size population there exists a relationship between allele 
frequency and genotype frequencies at an autosomal locus. This equilibrium is 
expected in a diploid population that mates randomly and is free from evolutionary 
forces, e.g. genetic drift, mutation and migration. The expected genotype frequencies 
major homozygote: heterozygote: minor homozygote for a bi-allelic gene under this 
law are p
2
:2pq:q
2
.(Gillespie 2004) Deviations from this equation are thought to occur 
because of genotypic errors or population characteristics such as recent migrations or 
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mixture of sub-populations that do not completely interbreed.(Schaid, Batzler et al. 
2006) 
2.8.6 Linkage disequilibrium 
Because several genes harboured more than one SNP the potential of linkage 
disequilibrium occurs. Linkage disequilibrium (LD) is the extent to which alleles at 
two or more loci are associated with each other; it may occur within one gene but also 
between genes (Hajeer and Hutchinson 2001). LD among alleles arises from various 
influences: mutation, random genetic drift, migration, and selection in response to 
environmental factors. Thus different patterns of LD may occur across bio-
geographical groups. This may be of most relevance to genes with a strong selection 
advantage. Resistance to malaria is one example: variants in the genes G6PD, HBE1, 
Duffy (FY) are associated with malaria resistance.(Williams 2006) 
Measures of LD are D’, r2, which are the correlation coefficient between two alleles at 
different loci and the logarithm of the odds (LOD) score. The Hapmap Consortium 
views a LOD score over +2 (i.e 100 to 1 odds) to indicate evidence for linkage. 
If markers occur at significantly different rates in the affected group vs. the non-
affected group, then one can assume that the allele itself or an allele in LD with it is 
associated with the disease. 
The software package Haploview (Barrett, Fry et al. 2005) was used to investigate 
linkage disequilibrium. Briefly, two separate data files were created in text format: 
one with the genotyping results as bi-allelic data and one with the chromosome 
position of the SNPs. The human genome build 37.1 and the rsnumbers (2010) 
formed the basis for the SNPs’ chromosome positions.  Haploview could then analyse 
these two files and calculate Hardy Weinberg equilibrium, LD, haplotype blocks as 
well as quality indicators such as percentage of successful genotyping. 
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LD was calculated for the whole cohort as well as for Caucasians only. 
Linkage data was formatted in the Haploview Linkage Format textfile: 
FamilyID Individual ID FatherID MotherID Sex Outcome Gene1Allele1 Gene1Allele2 
Missing data were entered as 0. 
The SNP position data file is depicted in Table 2-14. 
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Gene Rsnumber Chromosome Chromosome position 
PTPN22 
(Lyp) 
2476601 1p13.3-p13.1 114377568 
C1QA 172378 1p36.12 22965438 
CRP 3093077 1q21-23 159679636 
CRP 1205  159682233 
CRP 1130864  159683091 
CRP 3091244  159684665 
CRP 3093062  159684684 
CRP 2794521  159685096 
IL10 1800872 1q31-q32 206946407 
IL10 1800871  206946634 
IL10 1800896  206946897 
CFH 1061170 1q32 196659237 
TLR2 4696480 4q32 154607126 
TLR2 5743708  154626317 
CD14 2569190 5q31.1 140012916 
ADRB2 1042711 5q31-q32 148206348 
ADRB2 1042713  148206440 
ADRB2 1042714  148206473 
ADRB2 1800888  148206885 
TNFA  1800629 6p21.3 31525175 
CFB 4151667 6p21.3 31896215 
CFB 641153  31896371 
IL6 1800797 7p21 22766221 
IL6 1800796  22766246 
IL6 1800795  22766645 
PAI-1 1799889 7q21.3-q22 100769710:100769711 
TLR4 4986790 9q33.1 120475302 
TLR4 4986791  120475602 
MBL2 1800451 10q11.2-q21 54531226 
MBL2 1800450  54531235 
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MBL2 5030737  54531242 
MBL2 7095891  54531461 
MBL2 7096206  54531685 
MBL2 11003125  54532014 
ADM 3814700 11p15.4 10324658 
CHRNA7* -241A→G 15q13-q14 30109849 
CHRNA7* -194G→C   30109896 
CHRNA7* -178 -G  30109912 
CHRNA7* -143G→A  30109947 
CHRNA7* -92 G→A  30109998 
CHRNA7* -86 C→T  30110004 
CHRNA7* -46G→T  30110044 
CHRFAM7A* 67158670  30237167:30237168 
CHRFAM7A 67158670  30665281:30665282 
SELS 
(SEPS1) 
28665122 15q26.3 101817727 
MHC2TA 3087456 16p13 10970902 
DCP1= ACE 4291 17q23.3 61554194 
DCP1= ACE 4646994  61565904:61565905 
DCP1= ACE 4341  61565990 
DCP1= ACE 4343  61566031 
APOE 429358 19q13.2 45411941 
APOE 7412  45412079 
LBP 2232582 20q11.23-q12 36979265 
Table 2-14 Haploview SNP position data 
*Based on  ref_assembly 36.3 (Stephens, Logel et al. 2009) 
SNPs in red were not entered into the linkage analysis because of inability to 
genotype (APOE, SELS, CHRNA7) or because they were not bi-allelic (PAI-1, 
CHRFAM7A, ACE I/D). 
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Haploview criteria for LD blocks are based on (Gabriel, Schaffner et al. 2002) and 
Hardy Weinberg Equilibrium (HWE) calculations are based on (Wigginton, Cutler et 
al. 2005). The output of the Haploview programme is both graphical as well as 
textual.  The legend for the graphical display is depicted in   
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. 
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 D' < 1 D' = 1 
LOD < 2 White   Blue 
 
 
LOD ≥ 2 Shades of pink/red  Bright red  
Table 2-15 Legend colour coding haploview 
LD Values: measures of linkage disequilibrium 
r
2
 is the raw r
2
 value, the square of the correlation coefficient for a given marker pair. 
SNPs that have not been separated by recombination have r
2
 = 1. Lower r
2
 values 
correlate with a lower degree of LD, implying that some recombination would have 
taken place in this population.(Hill and Robertson 1966) 
D' shows the raw D' value, which is the normalized covariance for a given marker 
pair. A D' value of 1, i.e. complete LD indicates that two SNPs have not been 
separated by recombination. Lower values indicate evidence of recombination in the 
history of that population. Only D' values near 1 are a reliable measure of LD. Lower 
values are difficult to interpret because sample size strongly influences the value of 
D'.(Lewontin 1988) No clear cut off point below 1 has been defined to indicate alleles 
not to be  in LD (Ardlie, Kruglyak et al. 2002), although a D’ value > 0.5 has been 
used as a cut off point for assessing potential LD.(Reich, Cargill et al. 2001)  
The default score for Haploview shows D’/LOD, which displays D’ and the log odds 
score for linkage disequilibrium between a given marker pair as a measure of 
confidence of the value of D’. (Insitute 2010) 
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2.9 Quality Control 
Phenotype databases: 
Designated members of the team (n=6) entered data onto the database. The complete 
records of subjects were audited in 5% of the cases. Data and conclusions for all 
outcome measures were double checked against source data. All study numbers were 
double checked against hospital numbers. 
 
Genotyping: 
All EDTA blood samples were labelled immediately with study number and/or 
subject name. After DNA-extraction, samples were collected in pre-labelled vials and 
stored in a racking system until use. Where possible, DNA handling, i.e. DNA 
extraction, library and array plate assembly, was done in the presence of two 
researchers. 
Five percent of samples were analysed in duplo. Genotype data was available for a 
limited number of SNPs (ACE I/D, PAI-1 4G/5G, MBL-2 X/Y promoter and gene, 
IL10 -1082 G/A, IL6 -174 G/C, TNF -308 G/A and TLR4 Arg299Gly) that had been 
previously genotyped in a subset of the population (n=147). In the current analysis for 
ACE one array plate (n=91) was genotyped twice using the three primer PCR method 
for the I/D polymorphism as well as the Taqman method for rs4341. 
2.10 Statistical analysis 
The statistical analysis is described in the methods section of each chapter separately. 
 
2.11 Physiological signal analysis 
The autonomic nervous system plays an integral part in the systemic inflammatory 
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response.(Borovikova, Ivanova et al. 2000, Elenkov, Wilder et al. 2000) One way to 
quantify autonomic nervous system activity is the measurement of heart rate 
variability. Heart rate variability is the dynamic of beat-to-beat differences in heart 
rate. This measurement is well established as a marker of severity of disease in 
cardiac failure (Ho, Moody et al. 1997) and overall fetal distress (1997). More 
recently it has been used as predictor of sepsis in premature infants (Moorman, Lake 
et al. 2006) and adult haematopoetic stem cell transplantation (Ahmad, Ramsay et al. 
2009) and as a measure of multi-organ dysfunction in adults (Schmidt, Muller-
Werdan et al. 2005) and children (Tibby, Frndova et al. 2003).  
Inflammation is a key part of these disease entities, which has prompted research 
groups to investigate HRV as a correlate of systemic inflammation. This yielded 
insight into cytokine production, e.g. IL-6 levels were shown to be inversely related to 
HRV (Aronson, Mittleman et al. 2001, Janszky, Ericson et al. 2004). 
 
2.11.1 HRV metrics 
There are several methods to quantify HRV. Most research groups have used time or 
frequency domain metrics.  
A time series can be plotted graphically as a set of measurements in two-dimensions. 
Time is usually on the horizontal axis, and the magnitude of the measurable quantity 
is on the vertical axis. One can represent any periodic function of time as a sum of 
sines and cosines. This is called the Fourier series expansion of the function or 
frequency domain. 
Heart rate variability or the pattern of change in heart rate over time can be expressed 
in the frequency domain. The variation in heart rate over time may be depicted by a 
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time series of ECG tracing sequential RR’ intervals. These RR’ intervals in a given 
time period are a sum of oscillations with distinct frequencies. These functions can be 
expressed in a frequency domain. The French mathematician Jean-Baptiste Fourier 
described the transformation of a time domain to a frequency domain in 1807. The 
resultant spectrum analysis contains the sum of each sine and cosine within the signal. 
The relative contribution of each wave is determined by its amplitude (or power) and 
the frequency with which it is represented in the signal.(Seely and Macklem 2004) 
Computer programs can perform this fast Fourier transformation. The resultant power 
spectrum density plot depicts the relative contribution of the different frequencies in 
the original time series. The square of the contribution of each frequency is the power 
of that frequency to the total spectrum. The total power of the spectrum analysis, 
which is the area under the curve of the power spectrum is equal to the variance in the 
time domain.(Electrophysiology 1996) 
 
2.11.1.1 Fast Fourier Transform Analysis 
Power spectrum analysis of heart rate was first performed by (Sayers 1973). Although 
the power spectrum of a heart rate time series is a cumulative of all frequencies in that 
epoch with an infinite number of frequencies, there exists a physiological 
classification of predefined frequencies. In 2-5 minute ECG recordings these peaks 
are in the following range: very low frequency (VLF, cycle  0.04 Hz or a cycle 
length of  25 seconds); low frequency (LF, cycle 0.04-0.15 Hz or a cycle length of 6-
25 seconds) and high frequency (HF, cycle 0.15-0.4 Hz or a cycle length of 2.5-6 
seconds). In adults these discrete frequency peaks were associated with temperature 
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and humoral regulation and sympathetic/parasympathetic and vagal respiratory 
rhythms modulating heart rate respectively (Stauss 2003). 
These discrete bandwidths have been adopted as standards in adults 
(Electrophysiology 1996). Children and infants show peaks at different bandwidths, 
which represents their different age-dependent physiology. It is, therefore, not useful 
to use the same bandwidths as those used in adults. Unfortunately no validated 
classification for children exists. The areas in which differences are most prominent 
are the bandwidth of the respiratory rhythm and the baseline heart rate, both of which 
are inversely related to age. Investigators thus have used different cut-off points that 
reflect these differences. Chapter 7 discusses these choices in more depth. 
In order to transform the time series to the frequency domain without the introduction 
of artifact the following need to be adhered to: 
The sampling frequency must be at least twice the highest frequency present in the 
sample (Nyquist theorem) in order to prevent aliasing. Aliasing is the phenomenon 
where the number of sampling points is insufficient to reproduce the original 
waveform and the ensuing frequency is different from the original waveform. 
The signal must be stationary. In other words, over the sampled time period there 
must not be a significant change in mean and standard deviation of the signal.  
The sample must be free of artifacts. The raw data must be inspected for premature 
atrial and/or ventricular beats, movement artifacts or lead dysfunction. 
The heart rate variability data analysis was performed in collaboration with  
Mr Timothy Ellis, MSc candidate and Dr James McNames, Professor - Electrical and 
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Computer Engineering, Portland State University, OR, USA. 
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Chapter 3 Potential pitfalls in genotyping 
 
3.1 Introduction 
This chapter aims to discuss several areas of potential error in large genotyping 
studies and how these potential errors were addressed in the current study. 
 
3.2 Genotyping quality 
There were n= 318 samples available for the PICU cohort. This included n=3 
unintentional duplicates (i.e. children that had been recruited before, but not 
recognized as such) and 12 intentional duplicates. 
To address potential contamination because of transport one array was tested for 
admixture of DNA. This array showed no contamination (Figure 3-1). 
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Figure 3-1 KBioscience test plate at 1:4 dilution 
KBioscience test plate at 1:4 dilution. Array PICU 1 shows no contamination. All 
wells have a single output, correlating with the colours as depicted.  
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The KBioscience facility was consistently unable to yield results n= 9 samples. Most 
of these samples (7/9) contained less than 15 ng/l DNA.  
The initial candidate gene set consisted of 52 SNPs in 24 genes. The genotyping 
facility KBioscience was requested to genotype 50 SNPs. The initial results yielded 
genotypes on 38 SNPs (one SNP was inadvertently genotyped twice, thus yielding 39 
results). A second attempt was made using oligos on the other DNA strand, which 
yielded 2 more genotypes. Then a third attempt was made using the Taqman method 
for one SNP, which failed also. 
Southampton laboratory and the Rayne Institute genotyped one SNP each. Thus 42 
SNPs were successfully typed and 10 SNPs in 5 candidate genes remained 
unanalysed. The unanalysed SNPs are shown in Table 3-1. 
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Identification Gene Kaspar both 
DNA strands 
Taqman Reason 
rs429358 APOE Not worked Not worked Unknown 
rs2794521 
-717A/G 
CRP Not worked Not available Unknown 
rs3093062 
-305G/A 
CRP Not worked Not available Unknown 
rs28665122 SELS Not worked Not available Unknown 
AF029837_1 
-241 A/G 
CHRNA7 Not worked Not available Extremely high 
CG content 
AF029837_2 -194 
G/C  
CHRNA7 Not worked Not available Extremely high 
CG content 
AF029837_3 
-178 -/G 
CHRNA7 No assay 
designable 
Not available Unknown 
AF029837_4 
-143 G/A 
CHRNA7 Not worked Not available Extremely high 
CG content 
AF029837_4' -92 
G/A OR C/T 
CHRNA7 Not worked Not available Extremely high 
CG content 
arg677trp R677W TLR2 Not worked Not available Pseudo SNP 
Table 3-1 SNPs that failed genotyping 
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The rs3091244 -286 C/T/A CRP tri-allelic SNP was genotyped as bi-allelic (C/T). 
Because the A allele is very rare in Caucasians, the bi-allelic analysis results would be 
a fair approximation in this ethnic group only. 
 
Given their interest and expertise in CRP genotyping, the UCL Rayne laboratory was 
requested to perform genotyping on the outstanding CRP SNPs. Unfortunately, the 
time line was such that it precluded timely analysis. 
 
Subsequent to further reading it transpired that TLR2 R677W is not a true SNP and 
therefore unclassifiable. The initial report pertained to variation in TLR2 exon 3 
duplication. (Malhotra, Relhan et al. 2005) 
The two remaining SNPs in the genes that remained of interest (APOE and SELS) 
unfortunately could not be genotyped. APOE was tried with three different 
approaches and SELS with two. Time restrictions precluded further pursuit. 
 
Analysis of SELS would have allowed for testing the hypothesis whether this 
regulatory gene would have modified the outcome SIRS. SELS codes for 
Selenoprotein S, which is a transmembrane protein found in plasma membranes and 
endoplasmic reticulum. Selenoprotein S is thought to be involved in the prevention of 
ER stress reactive oxygen species production and as such modifies signaling 
secondary to severe insults. (Huang, Rose et al. 2012)Crucially, SELS protects the 
functional integrity of the ER against potential metabolic stressors. In this sense, low 
expression of SELS may increase inflammatory cytokines through increased ER 
stress. The SELS promoter polymorphism (-105 G-A) impaired Selenoprotein S 
expression and was strongly associated with higher circulating levels of IL-1b, TNF-a 
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and IL-6.(Curran, Jowett et al. 2005)If added to the overall logistic regression model 
in the TLR4 analysis pertaining to SIRS, there may have been an increase in 
explanation of genetic variability on the outcome of SIRS. 
 
Analysis of APOE would have allowed for an analysis of nosocomial infection in 
those children admitted with a non-infectious insult. The APOE gene codes for three 
isoforms of the protein, 2, 3, and 4. The wild type isoform is apoE3 and the two 
variant isoforms differ by a single amino acid substitution. These polymorphisms 
have been shown to be functional (Mahley and Rall 2000) in that the low-density 
lipoprotein (LDL) receptor binding affinities may be ranked as 4 > 3 >>> 2. APOE 
wildtype was associated with reduced incidence of severe sepsis post elective surgery 
(Moretti, Morris et al. 2005). It is currently unclear what the underlying mechanisms 
might be, although lymphocyte activity has been implicated. 
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3.3 Aggregate results 
The potential for spurious conclusions in genotyping analysis is increased if there are 
subjects that have not been included in the analysis because of inability to genotype. 
Therefore an overall assessment was done to ascertain the percentage calls per SNP. 
Table 3-2 shows the aggregate data on KBioscience’s results. Next, the yield of the 
individual SNPS was analyzed. Table 3-3 and Table 3-4 show the calls made per 
SNP.   
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KBioscience 1    
Plate SNPs Subjects Percentage called 
CICU1 39 92 98.9 
CICU2 39 80 98.5 
CICU3 39 84 98.3 
CICU4 39 91 98.1 
CICU5 39 80 98.5 
PhD Array 1A 39 87 99.0 
PhD Array 2B 39 88 98.7 
PICU1 39 86 98.5 
PICU2 39 77 98.7 
PICU3 39 91 99.0 
PICU4 39 42 98.8 
KBioscience 2    
Plate SNPs Subjects Percentage called 
CICU1 2 91 98.3 
CICU2 2 75 99.3 
CICU3 2 81 96.9 
CICU4 2 90 99.4 
CICU5 2 79 97.4 
PhD Array 1A 2 86 97.6 
PhD Array 2B 2 88 97.7 
PICU1 2 84 98.8 
PICU2 2 72 100 
PICU3 2 88 99.4 
PICU4 2 39 100 
Table 3-2 Aggregate genotype data KBioscience 
The origin of samples was denoted CICU for Cardiac Intensive Care Unit; PICU for 
Paediatric Intensive Care Unit; PhD Array for Cardiac Intensive Care Unit PhD work 
M Allen. 
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SNP Gene Calls Percentage 
called 
Absolute 
missed 
rs4291 ACE 846 89.8 96 
rs7412 APOE 887 94.1 55 
rs1061170 CFH 895 95.0 47 
CHRFAM7A CHRFAM7A 907 96.2 35 
rs3091244 CRP 916 97.2 26 
rs641153  CFB 920 97.6 22 
AF029837_6 GT  CHRNA7 921 97.7 21 
rs172378 C1QA 921 97.7 21 
rs1800795 IL6 921 97.7 21 
rs2569190 CD14 922 97.8 20 
rs4343 ACE 923 97.9 19 
AF029837_5 CT CHRNA7 930 98.7 12 
ADRB2 5LC ADRB2 932 98.9 10 
rs1042713 ADRB2 932 98.9 10 
rs1130864 CRP 932 98.9 10 
rs1800450 MBL2 932 98.9 10 
rs1800797 IL6 932 98.9 10 
rs1800872 IL10 932 98.9 10 
rs1800888 ADRB2 933 99.0 9 
rs2232582 LBP 934 99.1 8 
rs5743708 TLR2 934 99.1 8 
rs1800896 IL10 935 99.2 7 
rs1799889 PAI-1 935 99.2 7 
rs11003125 MBL2 936 99.3 6 
rs1800871 IL10 936 99.3 6 
rs3087456 MHC2TA 936 99.3 6 
rs3814700 ADM 936 99.3 6 
rs1800796 IL6 936 99.3 6 
rs4696480 TLR2 936 99.3 6 
rs4986791 TLR4 936 99.3 6 
rs1205 CRP 937 99.4 5 
rs4696480 TLR2 937 99.4 5 
rs7095891 MBL2 937 99.4 5 
rs1800451 MBL2 937 99.4 5 
rs2476601 PTPN22 938 99.5 4 
rs3093077 CRP 938 99.5 4 
rs5030737 MBL2 938 99.5 4 
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rs1042714 ADRB2 939 99.6 3 
rs1800629 TNFA 939 99.6 3 
rs4151667 CFB 939 99.6 3 
rs7096206 MBL2 941 99.8 1 
Total  942 100  
Table 3-3 KBioscience aggregate genotyping results per SNP 
 
 
SNP Gene Calls Percentage 
called 
Absolute missed 
rs4986790 TLR4 965 98.2 17 
rs4646994 ACE 86 94.5 5 
rs4341 ACE 901 97.0 27 
Table 3-4 Aggregate data genotyping Southampton and Rayne Institute 
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3.3.1 PICU failed samples 
There were 8 samples that showed a very high failure rate (41 SNPs), 3 of those 
samples were duplicates.  A further 13 samples failed  3 genotyping, 2 of which 
were duplicates. (Figure 3-2)  
Failure was defined as an inability to assign the identity of a nucleotide at the location 
of the polymorphic site. 
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Figure 3-2 Failed PICU samples 
The total number of children was 299, of these, 123 samples showed failed 
genotyping in 1 SNP. 
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The potential effect of these failures is allele dropout, thus influencing HWE; change 
in population with regards to clinical characteristics and reduction of quality control 
efficacy. Most failures were due to low DNA content and most were samples obtained 
at the early stages of the study, 15/21 (71%). 
Given that the failures are thought to be random (secondary to reduced amount of 
DNA availability) there should not be a systematic change in the early population. 
One potential effect might have occurred, which is that the influence of the latter part 
of the PICU cohort exerts a higher degree of influence on the overall outcome 
measures. However this seems unlikely, given that there were 5 major dropouts in the 
early cohort (n=165) and 1 major dropout in the late cohort (n=134), p = 0.23, Fishers 
exact test. 
The number of children recruited in the PICU cohort was n=305. Of these, 3 were 
repeat admissions and 3 did not have a blood sample available. The cohort thus 
consisted of n=299 children. 
 
3.4 Hardy Weinberg Equilibrium (HWE) 
Heterozygosity and Hardy Weinberg Equilibrium were calculated using the Tufts 
University Pharmacogenomics Laboratory HWE calculator and confirmed by 
Haploview (Barrett, Fry et al. 2005). 
Given the heterogeneity of the cohorts, integral to a cosmopolitan city London with 
high migration and interbreeding there was a real possibility that SNPs may not have 
been in HWE, even when accounting for ethnicity. 
In fact, for the PICU cohort the following genes were not in HWE: CRP rs3091244; 
CFB rs641153; MHC2TA rs3087456 and IL6 rs1800796. 
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This was further explored by categorizing the cohort into the sub populations 
according to ethnicity. Table 3-5, Table 3-6 and Table 3-7 show this for the PICU 
cohort.  
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CRP rs3091244 PICU Caucasian African Asian Other/Unknown 
CC 132 96 12 9 15 
CT 275 89 10 7 3 
TT 122 26 8 1 10 
2 
p value 
7.32 
<0.01 
    
CFB rs641153 
(R32Q) 
PICU Caucasian African Asian Other/Unknown 
CC 234 173 22 13 26 
CT 42 29 9 3 1 
TT 14 9 4 1 0 
2 
p value 
29.2 
<0.001 
19.7 
<0.001 
   
IL6 rs1800796 (-
572G>C) 
PICU Caucasian African Asian Other/Unknown 
GG 235 177 28 8 22 
GC 48 30 6 7 5 
CC 10 5 2 2 1 
2 
p value 
11.9 
<0.001 
6.3  
<0.02 
   
MHC2A 
rs3087456 
PICU Caucasian African Asian Other/Unknown 
AA 121 105 0 5 11 
AG 108 77 14 6 11 
GG 65 31 22 6 6 
2 
p value 
16.6 
<0.001 
6.7  
<0.02 
   
Table 3-5 PICU cohort SNPs not in HWE.   
Red denotes the population that is not in HWE. 
  
 152 
CRP 
rs3091244 
PICU Caucasian African Asian Other/Unknown 
CC 122 94 10 9 9 
CT 130 94 15 7 13 
TT 35 24 6 1 4 
      
CFB 
rs641153 
(R32Q) 
PICU Caucasian African Asian Other/Unknown 
CC 224 167 20 12 26 
CT 62 42 13 4 1 
TT 4 3 2 1 0 
      
IL6 
rs1800796 (-
572G>C) 
PICU Caucasian African Asian Other/Unknown 
GG 229 174 26 8 21 
GC 60 36 9 7 6 
CC 4 2 1 2 1 
      
MHC2A 
rs3087456 
PICU Caucasian African Asian Other/Unknown 
AA 104 97 2 4 10 
AG 142 94 11 8 13 
GG 48 23 23 5 5 
      
Table 3-6 PICU cohort expected genotype distribution if in HWE 
The number of heterozygotes is lower than expected. 
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Table 3-7 Heterozygosity compared in PICU cohort 
SNP Observed Expected P value 
CRP rs3091244 0.32 0.43 1.1*10
-11 
CFB rs641153 (R32Q) 0.14 0.21 6.0*10
-14 
MHC2A rs3087456 0.38 0.46 1.8*10
-6 
IL6 rs1800796 (-572G>C) 0.16 0.20 1.5*10
-9 
P value derived from Tufts University Pharmacogenomics Laboratory HWE 
Calculator 
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Given that the different ethnic populations were in HWE for CRP rs3091244, the 
reason that the total PICU cohort was not in HWE for this SNP may have been the 
lumping together of ethnic groupings. This was not the case for CFB R32Q and 
MHC2A rs3087456, both SNPs were not in HWE in the Caucasian group.  
A different explanation may have been a skewing of the population because of allelic 
dropouts. The number of missed genotypes, however, was low (1 per plate), therefore 
allelic dropout is very unlikely (Table 3-8.) 
  
 155 
Plate Samples rs641153 
PICU1 86 85 
PICU2 77 76 
PICU3 91 90 
PICU4 42 41 
Table 3-8 CFB R32Q rs641153 dropouts PICU cohort 
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Next, genotyping error was assessed by viewing the results spatially in SNPviewer. 
There were no “close calls” and genotypes were well separated in three groups 
(homozygous for wildtype, heterozygotes and homozygous for minor allele). 
Figure 3-3 shows this for CFB R32Q rs641153.  
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Figure 3-3 CFB R32Q visual inspection PICU arrays 1-4 
Red dots denote CC, green dots CT, pink dots unclassifiable and blue TT   
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Finally, the minor allele (T) frequency for CFB R32Q rs641153 was assessed against 
what is known in the literature. For cohorts of European descent frequencies have 
been quoted between 0.06 and 0.12 (Maller, George et al. 2006, Ferrara, Merriam et 
al. 2008, 2010) and for cohorts of African descent 0.25 (2010). 
In the PICU cohort overall T allele frequency was 0.12 for the Caucasian and African 
subgroups it was 0.11 and 0.24 respectively. The Cardiac cohort showed similar allele 
frequencies (0.11 and 0.22 for Caucasians and Africans respectively). These results 
concur with previously published results. 
Thus a genotyping error is unlikely. This is specifically of concern for this SNP, 
because of the existence of a non-functional SNP at the adjoining position 94 C>T 
(rs12614) leading to CFB R32W.  
 
Thus the allele frequency is as expected, but the number of homozygotes is too high. 
What remain as explanations are the following possibilities: selection, inbreeding and 
the Wahlund effect (subpopulations that do not interbreed). Given the recruiting 
strategy (“allcomers” from anywhere in the UK) the most likely reason is that the 
Caucasian population is actually made up of sub-populations that are each in good 
Hardy-Weinberg equilibrium and the deviation is due to pooling of these separate 
populations. It may be that “Caucasian” was too heterogeneous for these two SNPs. 
To test this hypothesis the PICU Causasian population was re-analysed for Hardy 
Weinberg Equilibrium for the original ethnic category White British UK only, thus 
excluding the other Caucasian subjects from the following descent: Middle Eastern, 
Arab States, Pakistani, Bangladeshi, Indian, White Irish, White, White European, 
White other, Jewish and Malteser for rs641153 (CFB R32Q) allele frequencies. 
This showed that allele frequencies in the White British UK group were still not in 
HWE: CC/CT/TT 124/22/7 (expected 119/32/2), 2 14.4, P value 0.00014. 
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Only if the London area were not taken into account was the British UK White 
population in HWE (n=79). 
It has been postulated previously that urban areas are not the most optimal for genetic 
association studies, given the high likelihood of cryptic sub populations (Cooper, 
Tayo et al. 2008). 
Population stratification does occur in European populations. Based on microarray 
genotype data of approximately 10.000 SNPs two axes of stratification were 
observed: the main one was north-south, but there was also an east-west 
trend.(Bauchet, McEvoy et al. 2007) 
Thus cryptic subpopulation, or the Wahlund effect may be the underlying reason for 
the results of the rs641153 (CFB R32Q) allele frequencies. Why this was then not the 
case for other SNPs remains unexplained.  
Another explanation for exclusion of the London population to arrive at a White 
British population that is in HWE is that the resultant cohort is very small (n=79), 
which allows for an easier fit to HWE. 
Finally, it may be that the departure of HWE is not a technical or sampling error and 
neither a statistical fluke. It may be that the heterozygote population is more robust 
than the homozygotes and thus are protected from being admitted to PICU. 
To explore this hypothesis the PICU cohort was stratified according to admission 
diagnosis. The two groups were defined according to primary inflammatory/infectious 
process or primary trauma/elective surgery. This would allow testing for reduced 
innate robustness in predisposition to severe inflammatory processes, assuming that 
trauma and elective surgery are random admission events from an inflammatory point 
of view. 
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This generated a potential explanation for departure of HWE for IL6 rs1800796 (-
572G>C) and MHC2A rs3087456. Both SNPs still showed a large departure from 
HWE in the infection/inflammation group, but not at all in the trauma/elective surgery 
group (Table 3-9). 
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SNP Presumed reduced  
robustness 
Presumed random 
occurrence 
IL6 rs1800796 (-572G>C) Infection/Inflammatory Trauma/Elective 
postoperative 
GG 131 104 
GC 21 27 
CC 8 2 
 Total 160 133 
 2; p value 20.5; <0.001 NS 
MHC2A rs3087456 Infection/Inflammatory Trauma/Elective 
postoperative 
AA 68 53 
AG 51 57 
GG 42 23 
Total 161 133 
2; p value 19.6; <0.001 NS 
Table 3-9 Sub classification IL6 departure HWE in PICU cohort 
Red denotes departure from HWE. 
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To test this hypothesis further the independent cardiac cohort was queried for 
MHC2A rs3087456 HWE. If the abovementioned hypothesis of a random sterile 
inflammatory insult in relation to HWE holds true then this cohort should be in HWE, 
corrected for ethnicity as needed. Indeed this was the case (Table 3-10). The notion 
that MHC2A rs3087456 homozygosity reduces innate robustness in the face of acute 
inflammation/infection was further strengthened. 
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MHC2TA Cardiac Caucasian African Asian Other/Unknown 
1 247 237 2 3 5 
2 225 199 9 3 14 
3 85 46 30 1 8 
dropped 22 16 1 1 4 
2; p value 11.2; 
<0.001 
    
Table 3-10 MHC2TA distribution in cardiac cohort 
Red denotes not in HWE. Cardiac cohort in HWE when adjusted for ethnicity. 
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Similarly, IL6 rs1800796 (-572G>C) was not in HWE for the whole PICU cohort. 
Genotyping for this SNP did not show ambiguous calling (Figure 3-4) and the success 
rate for genotyping was high (n=1 dropout). Subgroup analysis showed the genotypes 
to be in HWE for all but the Caucasian subgroups (Table 3-9). 
Comparing the PICU cohort with a cohort of white Europeans (n=100) (Muller-
Steinhardt, Ebel et al. 2007) showed that the Caucasian subgroup was similar in 
genotype frequencies and that the African subgroup differed significantly from both 
groups (P<0.0001, 2). Therefore the initial HWE result for this polymorphism is 
probably, in part, attributable to population stratification. The Caucasian subgroup, 
however, was still not in HWE. Again, the departure from HWE may be due to 
reduced innate robustness as described above. 
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Figure 3-4 IL6 rs1800796 results for PICU 1-4 
The results for IL6 1800796 show no ambiguous calling.  
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MHC2TA was not analysed further for this thesis. The outcome measure “nosocomial 
infection” was not pursued. The hypothesis that homozygosity for MHC2TA 
rs3087456 carries a penalty for reduced robustness in the face of an acute infectious 
or inflammatory event is potentially of interest. Given the limited influence of single 
SNPs on complex outcomes it is, however, unlikely. 
In summary, the observed departures in HWE may be due to genotyping error (CFB 
R32Q), population stratification (CRP rs3091244) or reduced innate robustness, (IL6 
rs1800796 (-572G>C) and MHC2TA rs3087456). 
 
3.5 Linkage Disequilibrium 
Linkage disequilibrium (LD) is the non-random association of alleles at several loci. 
Haploview is a freely available software program that is developed and maintained by 
the Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard 
University (Barrett, Fry et al. 2005). The program allows for calculation and graphical 
display of linkage disequilibrium between SNPs.  Haploview criteria for LD blocks 
are based on (Gabriel, Schaffner et al. 2002) and HWE calculations are based on 
(Wigginton, Cutler et al. 2005).  
“These empirical assessments led to the following validated block definitions. In 
all cases, the outer-most marker pair was required to be in strong LD with an upper 
confidence limit (CU) that exceeds 0.98, and a lower confidence limit (CL) that 
exceeds 0.7. 
Two marker rules: pairs of markers with confidence bounds of 0.8<CL/0.98<CU, 
and spanning no more than 20 kb in the European and Asian samples, and no more 
than 10 kb in the Yoruban and African-American samples. 
Three markers rules: sets of three consecutive markers for which all pairs have 
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confidence bounds of 0.5<CL/0.98<CU and span <30 kb in the European and Asian 
samples, and for which all pairs have 0.75<CL/0.98<CU and span <20 kb in the 
Yoruban and African-American samples. 
Four markers: the fraction of informative pairs in strong LD (0.7<CL/0.98<CU) was 
required to be > 95%, and to span no more than 30 kb. 
For runs of five or more markers, the fraction of informative pairs in strong LD must 
be >95%, and were allowed to span any distance.” (Gabriel, Schaffner et al. 2002). 
 
Linkage disequilibrium for the PICU cohort was determined as follows: 
Analysis settings: 299 subjects, 40 SNPs in 18 genes. 
HWE p-value cut off 0.001 and minimum genotype percentage 50%.  
This yielded the following results: 
Five individuals were excluded because of insufficient percentage known genotype 
and four SNPs were excluded, two (MHC2TA rs3087456 and CFB R32Q rs641153 
because of violation of HWE), one because it was not polymorphic (CHRNA7 -
46G>T AF029837_6 GT CHRNA7) and one because of insufficient genotyping data 
(45.9% for ACE I/D rs4646994). 
 
This resulted in 630 comparisons for identification of LD between SNPs. Of these 
630 comparisons 16 qualified for strong LD. These 16 pairs showed a high D’, 
defined as 0.7< Confidence Interval (CI) low and 0.98< CI high as well as a LOD 
score > 2. Table 3-11 depicts these 16 SNPs in 6 genes. 
The r
2 
values range between 0.095 and 1. Those SNP pairs that have an r
2 
value of 1 
are thought not to have separated by recombination. In essence, from a point of 
genotyping, one of the SNPs from such a pair would be superfluous. For SNP pairs in 
which the r
2 
value is <1, recombination has occurred. 
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The Logarithm of the odds (LOD) score is a measure of LD. The Hapmap Consortium 
applies a cut off LOD score over +2 (i.e 100 to 1 odds) as evidence for linkage. 
(2005) 
D’ is reported to measure only recombinational history and r2 to summarize both 
recombinational and mutational history (Devlin and Risch 1995, Jorde 2000). 
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Locus 1 Locus 2 D' LOD CI low CI high r^2 Distance 
rs1800797(IL6-597G>A) rs1800795(IL6-174G>C) 0.99 97.85 0.96 1 0.971 424 
rs1800451(MBL57C) rs7095891(MBL+4PQ) 1 8.63 0.78 1 0.095 235 
rs5030737(MBL52D) rs11003125(MBL-550LH) 1 10.25 0.83 1 0.131 772 
rs7095891(MBL+4PQ) rs7096206(MBL-221XY) 1 11 0.85 1 0.103 224 
rs7095891(MBL+4PQ) rs11003125(MBL-550LH) 1 19 0.91 1 0.204 553 
rs7096206(MBL-221XY) rs11003125(MBL-550LH) 1 11.78 0.86 1 0.135 329 
rs4341(ACE) rs4343(ACE) 1 82.78 0.97 1 0.745 41 
rs1042711(ADRB25LC) rs1042713(ADRB2Arg16Gly 1 44.93 0.95 1 0.398 92 
rs1042711(ADRB25LC) rs1042714(ADRB2Gln27Glu) 1 128.28 0.98 1 1 125 
rs1042713(ADRB2Arg16Gly rs1042714(ADRB2Gln27Glu) 1 45.87 0.95 1 0.397 33 
rs1205(CRP) rs1130864(CRP) 1 17.28 0.9 1 0.16 858 
rs1205(CRP) rs3091244(CRP) 0.953 21.53 0.85 0.99 0.206 2432 
rs1130864(CRP) rs3091244(CRP) 0.97 68.39 0.92 1 0.703 1574 
rs1800872(IL10) rs1800871(IL10) 1 118.73 0.98 1 1 227 
rs1800872(IL10) rs1800896(IL10) 1 35.65 0.94 1 0.32 490 
rs1800871(IL10) rs1800896(IL10) 1 35.35 0.94 1 0.321 263 
Table 3-11 Linkage Disequilibrium PICU cohort quantitative measures 
 170 
Blocks were identified in the following genes: IL6, MBL2, ACE, ADRB2, CRP and 
IL10. The TLR4 SNPs showed some LD (D’ 0.78 (CI 0.61-0.9), LOD15.55 and r2 
0.49). This is to a lesser extent than one would expect, given that the literature quotes 
these two SNPs to be commonly co-segregated.  
Figure 3-5 shows the overall LD depicted in colour coded diamonds. Bright red 
diamonds without a number denote a D’ of 1. 
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Figure 3-5 Linkage Disequilibrium in colour coding 
PICU (n=299) Color Scheme LD plot 
 D' < 1 D' = 1 
LOD < 2 White  Blue  
LOD ≥ 2 Shades of pink/red  Bright red  
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Linkage disequilibrium blocks that were thus identified within genes are: 
 
IL6, MBL2 (except MBL57C and 52D), ACE, TLR4, ADRB2, TLR2, CRP (except 
for rs3093077 and rs3091244) and IL10. 
 
In this cohort two pairs of SNPs were identified to be in complete LD with each other: 
rs1042711(ADRB25LC) with rs1042714(ADRB2Gln27Glu); D’ =1(CI 0.98 - 1), 
LOD =128.28, r
2
 =1 and rs1800872(IL10) with rs1800871(IL10); D’=1 (CI 0.98-1), 
LOD = 118.73, r
2
 =1. 
 
 
Rather than relying on general terms given in the literature it is advisable to assess the 
extent of LD for the actual cohort, especially if of mixed heritage. 
The strong LD between rs1800795 (IL6 -174G>C) and rs1800797 (IL6 -597G>A) as 
previously reported in Caucasians (r
2
 0.95)(Hamid, Rose et al. 2005) was validated in 
the current PICU cohort across ethnicities (see Table 3-12). This, however, cannot be 
said for the TLR4 LD. 
In addition, aside from genotyping errors, LD parameters are not only influenced by 
population admixture but also by population size. To illustrate this Figure 3-6 shows 
the LD plot for the same SNPs as in Figure 3-5, but this time for the combined cardiac 
and general population. The number of LD blocks is higher in this larger cohort of n= 
878 vs. n=299. Of note, the difference in LD may also be due to a higher proportion 
of Caucasians in the cardiac cohort (424/494 vs. 216/299, P <.0001, 2), see Table 
3-12. 
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Ethnicity PICU CICU 
Caucasian 216 (72) 424 (86) 
African 36 (12) 39 (8) 
Asian 18 (6) 6 (1) 
Mixed/Unknown 29 (10) 25 (5) 
Total 299 494 
Table 3-12 PICU and CICU cohorts according to ethnicity 
Absolute numbers, percentage in brackets. 
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Figure 3-6 Linkage Disequilibrium in PICU and CICU cohorts combined 
(n= 793) 
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3.5.1 MBL2 
To illustrate how cohort size and ethnic background influences linkage disequilibrium 
magnitude and probability, the MBL2 SNP LD blocks are used here (Figure 3-8). 
Results are based on the raw genotypes of subjects of mixed ethnicity recruited from 
paediatric intensive care (n= 299) and cardiac intensive care (n=494). 
As a reminder of the MBL2 polymorphisms Figure 1-9 reproduced here as  
Figure 3-7. 
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Figure 3-7 MBL 2 Gene and polymorphisms   
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All (n=793) PICU (n=299) 
 
 
  
Caucasian (n= 640) African (n=75) 
Figure 3-8 MBL2 Linkage Disequilibrium in PICU and CICU cohorts compared 
according to ethnicity 
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Interestingly the two SNPs that were least in LD (57C and 52D) are the two that are 
very close in distance (16 base pairs) but phylogenetically most removed from each 
other. (Figure 3-9 from (Garred, Larsen et al. 2006)) 
  
 179 
 
Figure 3-9 MBL2 Evolutionary Tree 
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An unexpected LD occurred between rs2232582 LBP and rs1800450 MBL 54B (D’ 
1.0, LOD 5.3). Given that this LD did not occur with any of the other MBL SNPs it 
may well be a false positive. More so, because MBL2 lies on Chromosome 10 and 
LBP on Chromosome 20 and thus doesn’t qualify for LD as it is commonly 
understood. LD, however, may occur between loci on different chromosomes, 
possibly due to other mechanisms than permutations.(Huttley, Smith et al. 1999) 
Interestingly this LBP SNP was previously found to impact outcome in sepsis in a 
Caucasian adult cohort. (Hubacek, Stuber et al. 2001)Although this finding was not 
replicated in a different adult cohort (Barber and O'Keefe 2003), one might speculate 
that the first finding may be attributed to MBL B rather than LBP. The MBL B 
genotype has indeed been found to modify sepsis in both adults (Garred, Strom et al. 
2003, Gordon, Waheed et al. 2006) and children (Fidler, Wilson et al. 2004). 
 
3.5.2 Linkage disequilibrium in ACE 
The linkage disequilibrium for ACE in the PICU cohort is shown in Figure 3-10. 
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All (n=299) Caucasians (n=216) Africans (n=36) 
Figure 3-10 Linkage disequilibrium for ACE in PICU cohort 
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In Caucasians the ACE I/D Alu polymorphism (rs4646994; rs1799752; rs4340; 
rs13447447) is thought to be in tight LD with the ACE allele that is actually 
responsible for the hereditary difference in ACE activity. In Africans, however, this is 
less the case.(Payne, Dhamrait et al. 2007) 
ACE is a very illustrative candidate gene to highlight the many potential pitfalls in 
elucidating the underlying susceptibility or quantitative trait locus (QTL) of complex 
inherited diseases. Many studies have identified ACE as a modulator of 
cardiovascular disease, e.g. (Pfeffer, Braunwald et al. 1992, Lewis, Hunsicker et al. 
1993). ACE inhibition is an integral part of the pharmacopoeia available to medicine 
today. Serum ACE levels are fairly static when measured repeatedly in the same 
individual over time (Dux, Aron et al. 1984), but can differ up to five fold between 
individuals (Alhenc-Gelas, Richard et al. 1991). The first study to identify that ACE 
serum levels are under considerable genetic control was done in 87 healthy French 
families.(Cambien, Alhenc-Gelas et al. 1988)The authors speculated that there may be 
polymorphisms responsible for these familial differences. Soon after the ACE gene 
was located to chromosome 17q23 (Mattei, Hubert et al. 1989) and a genetic marker 
was found that accounted for half the variance in ACE serum levels in healthy French 
Caucasians. This marker was identified as a Mendelian inherited intronic 250 base 
pair long Insertion (I)/Deletion (D) polymorphism. The allele frequencies were 0.406 
for the I and 0.594 for the D allele in 80 subjects. (Rigat, Hubert et al. 1990)These 
alleles accounted for 47% of the variance in ACE serum levels in an additive way. 
Highest levels were seen with the homozygous D allele and lowest with the 
homozygous I allele. The I/D polymorphism was located to intron 16 of the ACE 
gene and measured to be 287 bp long. The same group investigated this relationship 
in a separate healthy cohort of 404 Caucasian subjects from the same geographical 
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area near Nancy, France. They concluded that the I/D polymorphism was a marker for 
a causative allele that explained 44% of the variance in serum ACE levels.(Tiret, 
Rigat et al. 1992) 
Further independent validation in a British Caucasian cohort showed this. 
In contrast to Caucasians the ACE I/D polymorphism was not highly associated with 
serum ACE level in a family study of Black African Nigerians (n=1343). This study 
found that two polymorphisms accounted for 19% (A2350G; A11860G; rs4343) and 
(A-240T; A-262T; rs4291) 6% of the variance in ACE activity respectively. In fact 
the A allele for A-240T was associated with increased serum ACE levels (Zhu, 
Bouzekri et al. 2001), which is opposite to that found in British (Keavney, McKenzie 
et al. 1998) and French (Villard, Tiret et al. 1996) populations. A2350G (rs4343) is a 
silent substitution in exon 17. It has been proposed as being in complete LD with the 
I/D polymorphism in Caucasians, A corresponding to I (Abdollahi, Huang et al. 
2008). 
A few studies have addressed ACE polymorphisms other than the I/D in populations 
of African descent. Payne et al showed in South African Xhosa that the I/D 
polymorphism accounted for 0.7% and the A22982G polymorphism (rs4363) for 
3.7%. (Payne, Dhamrait et al. 2007)In a study of n=376 Kenyans it was found that the 
I/D polymorphism accounted for 13% and the A22982G for 24% in variance of ACE 
serum levels, with A carriers having lower ACE serum levels. In Europeans there was 
complete LD between the I/D and A22982G genotype, I corresponding to A and D 
with G respectively.(Scott, Moran et al. 2005) Consequently, the A allele has been  
associated with lower circulating ACE levels than the G allele (Cox, Bouzekri et al. 
2002). Another study, however, found that the A allele was associated with higher 
ACE levels.(Zhu, McKenzie et al. 2000) 
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Given that the polymorphism is located in an intron, it was deemed unlikely that this 
polymorphism, in itself, was directly responsible for the observed serum ACE level 
differences, but rather in linkage disequilibrium with a polymorphism that had 
regulatory effects on the ACE gene. 
 
The ACE I/D polymorphism is technically challenging to genotype. Therefore an 
alternative was sought: The SNP rs4341 is in 100% LD with the ACE I/D SNP 
rs4646994.(Tanaka, Kamide et al. 2003) 
 
3.5.3 ACE serum and tissue levels are under genetic control 
ACE levels in healthy adults show large inter-variability that was postulated to be, in 
part, under genetic control(Cambien, Alhenc-Gelas et al. 1988). Subsequently it was 
found that a 250 bp insertion/deletion polymorphism caused two different sized 
alleles. The insertion and larger allele was designated I and the deletion (shorter) 
allele D. 
Family studies confirmed mendelian inheritance of the polymorphism. The observed 
allele frequencies in 80 healthy Caucasian French subjects were 0.406 for the I allele 
and 0.594 for the D allele. Genotype distribution was .18 for II, .46 for ID and .36 for 
DD, in Hardy Weinberg Equilibrium. 
ACE genotypes showed a significant additive relationship between the polymorphism 
and the serum levels, explaining 47% of the variance in serum levels.(Rigat, Hubert et 
al. 1990)The mean serum ACE level was found to be nearly twice as high in 
homozygous DD genotypes when compared with II genotypes.(Rigat, Hubert et al. 
1990)Tissue levels showed a similar association(Costerousse, Allegrini et al. 1993). 
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This correlation is strongly dependent on ethnicity. White children with DD genotype 
showed about twice as high ACE serum levels compared with II genotype, whereas in 
black children no association was found (Bloem, Manatunga et al. 1996) Similarly, in 
South African blacks no association was found with the ACE I/D polymorphism and 
ACE serum level, however ACE serum levels were significantly associated with the 
ACE A22982G (rs4363) genotype.(Payne, Dhamrait et al. 2007) 
 
3.5.4 ACE I/D genotype distribution in different ethnic populations 
 The distribution of the I and D alleles differs markedly between populations of 
Caucasian, Asian and African descent (Table 3-13). This requires that the ethnicity of 
the populations studied is taken into account before conclusions may be drawn about 
predispositions. 
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Ethnicity Country Sample 
size (n) 
Insertion Deletion Reference 
Caucasian French 199 .427 .573 (Rigat, Hubert et al. 
1992) 
Caucasian French 35 .47 .53 (Costerousse, 
Allegrini et al. 1993) 
Caucasian British 1906 .49 .51 (Marshall, Webb et 
al. 2002) 
Caucasian Flemish 1461 .496 .504 (Staessen, Wang et 
al. 2001) 
Asian Japanese 100 .58 .42 (Nakai, Itoh et al. 
1994) 
Asian Japanese 5014 .65 .35 (Higaki, Baba et al. 
2000) 
Caucasian USA 139 .46 .54 (Bloem, Manatunga 
et al. 1996) 
Black USA 62 .36 .64 (Bloem, Manatunga 
et al. 1996) 
Black South Africa 200 .32 .68 (Payne, Dhamrait et 
al. 2007) 
Table 3-13 ACE I/D distribution in different populations  
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3.5.5 Genotyping methods for ACE I/D polymorphism 
In Caucasians the markers for differences in ACE level traditionally has been the 
ACE 287 kb Alu Insertion Deletion polymorphism (rs4646994) in intron 16. 
The first genotyping method used the cDNA of 15 subjects and identified a two-allele 
restriction fragment length polymorphism (RFLP), identified by the restriction 
enzyme Hind III. The larger allele was designated I (Insertion) and the shorter D 
(Deletion).(Rigat, Hubert et al. 1990) 
After this initial discovery a PCR genotyping process was developed. In the presence 
of the insertion the PCR product is 490 bp long and in the absence of the insertion the 
PCR product is 190 bp long.(Rigat, Hubert et al. 1992) 
This 2 primer genotyping process for the ACE I/D polymorphism has been noted to 
be difficult, time consuming and prone to errors, especially mistyping IDs for DDs. 
(Shanmugam, Sell et al. 1993). A modification was therefore required to identify the 
mistaken ID genotypes from DD genotypes.(Lindpaintner, Pfeffer et al. 1995) 
An alternative is to use a 3 primer process, which precludes mistyping.  This method 
yields a PCR product that is 84 bp long for the ACE D allele and 65 bp for the ACE I 
allele. Counter-intuitively, the PCR product for the I (insertion) is actually shorter 
than the D (deletion).(Evans, Poirier et al. 1994) 
The method is still cumbersome and time consuming. Therefore alternative markers 
were sought. The ACE polymorphism rs4341 (G/C) is in complete linkage 
disequilibrium with the ACE I/D polymorphism and can be genotyped with specific 
primer techniques.(Tanaka, Kamide et al. 2003) 
After this discovery, another SNP (rs4343) was found to be in complete LD with both 
rs4341 as well as the ACE I/D SNP in Caucasians.(Glenn, Du et al. 2009) 
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3.5.6 Interpretation errors in ACE I/D polymorphism results 
The Department of Cardiovascular Genetics, Rayne Institute, University College 
London, London, UK where the rs4341 polymorphism was genotyped for this project 
had previously identified the C allele to correspond with the I polymorphism. 
(personal communication Prof S.E.Humphries)  
The original article, however, identified the rs4341 G allele to be in LD with the I 
allele (Figure 3-11), (Tanaka, Kamide et al. 2003)). Of note, the ACE I/D 
polymorphism was identified as rs4340 in this paper (which corresponds to 
rs4646994, rs1799752, rs13447447). 
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Figure 3-11 ACE rs4341 and ACE I/D association 
From (Tanaka, Kamide et al. 2003)  
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The described allele frequencies for ACE I/D are in keeping with previous studies 
describing Asian populations (Table 3-13). 
The method used in this paper has been cited 44 times, but the method has been 
actually used by few other groups (Muthumala, Montgomery et al. 2007, Weger, 
Hofer et al. 2007, Glenn, Du et al. 2009),(Lely, Heerspink et al. 2010),(Gu, Kelly et 
al. 2010, Camos, Cruz et al. 2012). None specified the linkage between the alleles 
explicitly. 
To further confound matters, a subset of the current PICU cohort (n=141) had been 
previously genotyped for the ACE I/D allele using the 3-primer method (Fidler 2007). 
These results were opposite to that of the current interpretation of the rs4341 data. 
Unfortunately, the raw data were not available to make a direct comparison. 
 
The discrepancy between the Rayne laboratory interpretation of the rs4341 
genotyping results vs. the original rs4341 literature and historical PICU genotyping 
required resolution. 
Two methods were used to clarify this issue. First, a subset of the PICU cohort  
(n=91) was genotyped again for the actual ACE I/D polymorphism using the three 
primer method. This confirmed that the allele matching between rs4341 and ACE I/D 
was exactly opposite to the one described by Tanaka et al. The rs4341 C allele 
corresponded with the Insertion allele and the G allele with the Deletion allele. 
Second, linkage analysis and allele frequencies were calculated for three ACE 
polymorphisms: the I/D polymorphism, rs4341 and rs4343. 
The reason to choose rs4343 was the finding that this polymorphism was in complete 
linkage disequilibrium LD with both the I/D as well as rs4341. Moreover, a direct 
comparison of alleles had been performed, linking the rs4343 A allele to the I 
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polymorphism (Kehoe, Katzov et al. 2004, Abdollahi, Huang et al. 2008). Last, the 
rs4343 G allele was associated with higher plasma ACE levels (Zhu, Bouzekri et al. 
2001). 
Figure 3-12 shows the Haploview LD plot for 4 ACE polymorphisms (n=147 with the 
original ACE I/D results) for the Caucasians in the PICU cohort. This confirms a 
100% LD between rs4341 and rs4343 (D’ 1, LOD score 81.09 and r2 0.9). The LD for 
the original ACE I/D results is lower for both rs4341 and rs4343 (D’ 0.95, LOD score 
32 and r
2
 0.8). This may be a result of genotyping errors. The promoter polymorphism 
rs4291 will not be discussed here. 
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 Figure 3-12 ACE Linkage Disequilibrium 
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Given that rs4341 and rs4343 were indeed in complete LD a comparison was then 
made with allele frequencies. 
This showed that the allele frequencies for rs4343 G and rs4341 G were the same.  
Given that three independent groups have shown the rs4343 G to be associated with 
the D genotype, based on the allele frequency and LD results, rs4341 G is associated 
with ACE D. 
Only very recently did a Japanese group (Takeuchi, Yamamoto et al. 2012) specify 
which rs4341 allele is in LD with the I or D genotype. This group identified the 
rs4341 G allele as the risk allele, corresponding with the ACE risk D allele. The risk 
G allele frequency was .35 in a cohort of n=21851 Japanese subjects. This risk allele 
frequency is in keeping with previously described D allele frequencies (Table 3-13). 
These recent results are in conflict with the original manuscript. 
In summary, the original paper on rs4341 must have mistakenly equated the rs4341 G 
allele with the ACE I/D I allele. The original 3 primer PICU genotyping results for 
the ACE I/D polymorphism were probably misinterpreted because of the counter 
intuitiveness of labelling a shorter allele I (insertion) rather than D (deletion). 
This conundrum was resolved by re-genotyping a PICU cohort subset as well as by 
using linkage disequilibrium in combination with data from the literature. These 
results were recently confirmed in a large cohort of Japanese subjects. 
 
3.6 Conclusions 
Quality control for large genotyping studies is essential. Methods include Hardy 
Weinberg Equilibrium and linkage disequilibrium to identify potential genotyping 
errors.  
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Chapter 4 Polymorphisms in the endotoxin recognition 
receptor complex  
4.1 Endotoxin is a key Pathogen Associated Molecular Pattern (PAMP) 
Lipid A or Endotoxin is the component of the Gram-negative bacteria cell wall that 
the innate immune system recognizes. It is highly immune stimulatory, even at low 
concentrations.(Sauter and Wolfensberger 1980, Warren, Fitting et al. 2010) 
 
4.2 TLR4 activation in platelets and white cells 
Recognition of endotoxin occurs via the endotoxin recognition receptor complex 
consisting of Toll-Like receptor 4 (TLR4), and the proteins CD14 and Myeloid 
Differentiation 2 (MD2); Lipopolysaccharide binding protein (LBP) delivers 
endotoxin to this complex.(Schumann, Leong et al. 1990, Wright, Ramos et al. 1990, 
Poltorak, He et al. 1998, Shimazu, Akashi et al. 1999) 
Many human cell types including monocytes/macrophages, endothelium and platelets 
express functional TLR4 (Zarember and Godowski 2002, Andonegui, Kerfoot et al. 
2005, Dauphinee and Karsan 2006). Monocyte TLR4 ligation initiates a cascade of 
intracellular signalling events culminating in gene transcription and the ensuing 
production of inflammatory mediators (Figure 4-1). Activated TLR4 recruits adapter 
molecules such as MyD88 and TRIF, which in turn continues signalling via the 
cytoplasmic IKK complex to phosphorylate IKB and thus activates NFB. NFB then 
translocates to the nucleus to upregulate the transcription of inflammatory genes, 
including TNF and Interleukins. These compounds then contribute to the clinical 
picture of systemic inflammation and in severe cases, shock and multiple organ 
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dysfunction. 
Events relating to platelet endotoxin binding are less well described, but include 
soluble CD14 and CD62P (P-Selectin) in addition to TLR4 (Figure 4-1)(Cognasse, 
Lafarge et al. 2006, Stahl, Svensson et al. 2006). Recently, platelets were shown to 
contain the intracellular signalling apparatus commensurate with TLR4 signalling. In 
addition to TLR4, platelets expressed MyD88, IB-a and NFB p65, TRIF, TBK-1, 
IRAK-1, JNKs, MAPk, TRAF3, TRAF6, IRF-3 and IKK-I.(Berthet, Damien et al. 
2010) 
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A.
 
B. 
Figure 4-1 The endotoxin recognition complex on A. white cells and B. platelets  
TLR4 Toll Like Receptor 4, MD2 Myeloid differentiation protein 2, LBP 
Lipopolysaccharide binding protein, LPS Lipopolysaccharide, CD14 Cluster of 
Differentiation 14, JNK c-Jun N-terminal kinase, p38 p38 kinase, NFB Nuclear 
factor B, CD40L Cluster of Differentiation 40 Ligand, GPIIb/IIIa  Glycoprotein 
IIb/IIIa, sCD14 soluble CD14, CD62 Cluster of Differentiation 62  
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Thrombocytopenia, production of TNF(Aslam, Speck et al. 2006) and enhancement 
of neutrophil bactericidal properties via neutrophil extracellular traps or NETs(Clark, 
Ma et al. 2007) are both thought to occur as a consequence of platelet TLR4 ligation.  
More evidence that platelets play an active role in LPS mediated immune response 
was gained in an ex vivo human model. LPS induced platelet secretion of dense and  
granules (ATP release and P-selectin expression), and enhanced platelet aggregation 
through a TLR4/MyD88- and cGMP/PKG-dependent pathway.(Zhang, Han et al. 
2009) 
A different group investigated the nature of pro-inflammatory compounds in an in 
vitro human model. Here, LPS activated a kinase cascade in platelets leading to 
stimulated IL-1b production. Moreover, LPS signaling promoted the production of 
pro-inflammatory platelet microparticles that expressed caspase-1–dependent IL-
1b.(Brown and McIntyre 2011) 
 
4.3 TLR4 recognizes endogenous ligands 
Although initially seen as the endotoxin receptor, TLR4 is now also implicated in an 
endotoxin independent response to injury. Despite discussion that endogenous 
signalling via TLR4 ligation may be due to LPS contamination (Tsan and Gao 2004), 
fibrinogen, heat shock proteins, reactive oxygen species, hyaluronic acid and haeme 
are all ligands for TLR4 in the absence of endotoxin (Takeda, Kaisho et al. 2003, 
Taylor, Trowbridge et al. 2004, Zhang, Shan et al. 2005, Figueiredo, Fernandez et al. 
2007). 
An appropriate host response to the common (Lockhart, Brennan et al. 2008) transient 
bacteraemia secondary to tooth brushing is not to mount a systemic response 
(Bahrani-Mougeot, Thornhill et al. 2008). Conversely, systemic inflammation occurs 
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in response to severe infection and injury. Given the multitude of potential ligands in 
both infection as well as injury the TLR4 complex is an essential step in the 
development of inflammation. Individuals differ in their inflammatory response to 
insults. The pivotal role of the TLR4 complex means that it is an important candidate 
site as a source of some of this variability. This concept is consistent with previous 
observations indicating that circulating anti-endotoxin core antibodies act as a 
modifier of SIRS in children.(Stephens, Fidler et al. 2006) 
 
4.4 TLR4 Polymorphisms may contribute to variability in host response 
Some of the variability in host response to infections was explained by human TLR4 
polymorphisms that are thought to have a deleterious effect on host response to 
meningococcal disease.(Smirnova, Mann et al. 2003) The two common single 
nucleotide polymorphisms (SNPs) are D299G and T399I. Both lie in the extra-
cellular domain and are thought to cause less effective endotoxin binding and hence a 
decreased sensitivity to endotoxin.(Rallabhandi, Bell et al. 2006) Functionality of 
these SNPs has been shown (Arbour, Lorenz et al. 2000, Fageras, Hmani-Aifa et al. 
2004) but also contested (Erridge, Stewart et al. 2003, Heesen, Bloemeke et al. 2003, 
van der Graaf, Kullberg et al. 2005). 
Those studies that showed the SNPs to have direct functional consequences were 
studies that explored this functionality in airway related models. 
Arbour et al showed that adults inhaling LPS showed different responsiveness as 
measured by FEV1. Eleven subjects, two of whom were homozygous for the TLR4 
SNP D299G showed reduced bronchial reactivity when compared with 73 subjects 
with the wild type genotype (P .029). The authors used a one-tailed test. Had they 
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used a two-tailed test, however, it would still have been significant (P .035, Fisher’s 
exact). 
Airway epithelial cells, harvested from subjects with known TLR4 genotypes were 
stimulated with LPS and differed in their production of IL1, where TLR4 wildtype 
exhibited higher responsiveness than variant genotypes. Last, the authors transfected 
THP-1 cells and measured NFB activity following activation with LPS. This showed 
WT to have the highest activation, TLR4 SNP D299G the lowest and TLR4 T399I an 
intermediate activation. Over expression of TLR4 wildtype alleles in variant cells 
restored LPS responsiveness. Thus, functionality was observed in airway cells and 
lung physiology. 
A study on TLR4 polymorphisms and its potential role in paediatric asthma showed 
that children with TLR4 variant genotypes were more likely to be asthmatic and 
PBMCs from children with variant genotypes were less responsive to stimulation with 
LPS. IL12(p70) production was lower in PBMC isolates from TLR4 variant carriers 
than from wildtype.(Fageras, Hmani-Aifa et al. 2004) 
In contrast, there exist studies that have demonstrated no difference in LPS 
responsiveness between TLR4 wildtype and variant status.  
Three TLR4 wildtype and 3 TLR4 variant subjects were identified from a cohort of 
80 Scottish adults. Monocytes from these individuals were isolated and challenged 
with LPS at different concentrations and from different bacteriae (Escherichia coli, 
Neisseria meningitidis, Bacteroides fragilis, Yersinia pestis, Chlamydia trachomatis, 
Porphyromonas gingivalis, and Pseudomonas aeruginosa. No difference was 
observed in the capacity to produce IL1.(Erridge, Stewart et al. 2003) 
A review published in 2008 identified 25 studies that had compared functionality of 
the two common TLR4 variants to TLR4 wildtype genotype.(Ferwerda, McCall et al. 
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2008) From these studies one may conclude that, aside from questionable statistical 
choices, before a robust answer can be given to whether or not TLR4 variants have 
functional consequences the following other parameters need to be addressed: cell 
type, type and purity of LPS, LPS dose, timing of data collection, choice of 
phenotype, compound heterozygosity and other genetic variability.  
Thus it is difficult enough to identify mechanistic and biological substrates for TLR4 
polymorphisms. This is even more the case in the clinical arena. 
There exist few clinical studies with convincing data that TLR4 SNPs D299G and 
T399I influence the course of critical illness in general (Imahara and O'Keefe 2004). 
The early clinical studies that did show a difference in clinical outcome were 
hampered by small sample size (n=77)(Agnese, Calvano et al. 2002), (n=159) 
(Barber, Aragaki et al. 2004), (n=91) and questionable choices in statistics (Lorenz, 
Mira et al. 2002). More specific associations were made between TLR4 
polymorphisms and an increased vulnerability to bacteraemia in critically ill patients 
(Henckaerts, Nielsen et al. 2009) and aspergillosis in stem cell transplantation patients 
(Bochud, Chien et al. 2008). 
 
4.5 Definition of outcome measures 
The observed inconsistencies between studies may reflect no functional relevance of 
the TLR4 SNPs. Deficiencies in study design, or alternatively, any signal from altered 
endotoxin recognition could be drowned in the noise of other elements of host 
variability and environmental determinants in the acute inflammatory response. 
Further, the limitations of SIRS as an end-point to describe the acute inflammatory 
response have long been recognised in adults.(Vincent 1997, Marshall, Vincent et al. 
2003) This concern is compounded in the paediatric age group given the variability in 
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the age-related normal values of the components that define SIRS (heart rate, 
respiratory rate and white cell count). Paediatric SIRS criteria had only been 
established recently (Goldstein, Giroir et al. 2005), and had not been validated at the 
time of this study. A second marker of severe inflammation, namely platelet count on 
admission was therefore chosen. 
This outcome measure was chosen for several reasons:  
Platelets actively contribute to systemic inflammation (Levi and Lowenberg 2008). 
Clinically, platelet count has been recognized as a sensitive marker of severity of 
critical illness in both adults (Akca, Haji-Michael et al. 2002) and children (Peters, 
Ross-Russell et al. 2001, Nguyen and Carcillo 2006). Thrombocytopenia was found 
to be associated with mortality in a recent prospective observational cohort 
study.(Krishnan, Morrison et al. 2008) Endotoxin has been shown to directly reduce 
platelet count (Ohtaki, Shimauchi et al. 2002) to which TLR4 activity may be 
relevant, as shown in both mice (Aslam, Speck et al. 2006) and humans (Clark, Ma et 
al. 2007). 
 
4.6 Potential confounding polymorphisms in other genes 
Systemic inflammation is under genetic control of several mediators.(Calvano, Xiao 
et al. 2005) Other genetically variable mediators in the innate immune system were 
analysed in order to establish whether the influence of genetic variability in the 
endotoxin recognition complex was robust in the context of multiple variability in the 
innate immune system. 
The rationale underlying the choice from many candidate genes is given in paragraph 
2.7.6. 
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Briefly, these genes were chosen because of reported functionality, commonality in 
the population, modulation of the TLR4 complex and/or previous association studies 
in relevant cohorts. 
4.7 Validation 
Finally, to validate the findings in this cohort, the relationship was assessed between 
the TLR4 polymorphisms and platelet count on admission in a cohort of 1170 adults 
with atherosclerosis. This is a well-described previously genotyped cohort with a 
severe inflammatory insult.(Yang, Holloway et al. 2003)  
 
4.8 Methods 
4.8.1 Subjects 
Between 2000 and 2006 children were recruited consecutively in three recruiting 
time-periods from three tertiary paediatric intensive care units. Inclusion and 
exclusion criteria are outlined in paragraph 2.1.2. 
Subjects were categorized by primary diagnosis into ‘Bypass’, ‘Infection’ and ‘Non-
infection’. Patients admitted for heart surgery on cardiopulmonary bypass were 
assigned to the category  ‘Bypass’, those children with an infectious process as the 
admitting diagnosis were assigned to the category ‘Infection’ and the category ‘Non-
infection’ was used in case of all other admission diagnoses, mainly trauma and 
elective surgery. 
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4.8.2 Identification of polymorphisms 
A literature search revealed functional common single nucleotide polymorphisms 
(SNPs) in the endotoxin recognition complex.  TLR4 D299G and TLR4 T399I and 
the CD14 promoter -159C>T were identified. LBP P97P was included as a common 
SNP of unknown functionality, which may influence outcome from sepsis. (Table 
4-1) Polymorphisms in MD2 were rare SNPs and thus not included.  
The polymorphisms in TLR4 D299G and T399I are both located in the extracellular 
domain of the molecule. They are each thought to reduce the “docking” properties of 
the ligand, with the largest effect being when both polymorphisms are present. 
(Rallabhandi, Bell et al. 2006)  
Human in vitro studies show functionality in varying degrees. Airway epithelial cells 
and macrophages stimulated with LPS secreted less IL1 and TNF when 
polymorphic for TLR4 than when wildtype. The clinical substrate consisted of 
reduced sensitivity to inhaled LPS.(Arbour, Lorenz et al. 2000) 
In contrast, no difference was found between TLR4 wildtype or polymorphic 
monocyte production of TNF or IL10 after stimulation with LPS, Aspergillus 
fumigatus, Cryptococcus neoformans, or heat shock protein 60. (van der Graaf, 
Kullberg et al. 2005) 
Several clinical studies have shown differences in outcome in severe inflammatory 
and infectious diseases associated with TLR4 polymorphisms. Most show increased 
severity for those with the polymorphic genotype. These include, but are not restricted 
to RSV bronchiolitis (Tal, Mandelberg et al. 2004), invasive aspergillosis infection 
(Bochud, Chien et al. 2008), atherosclerosis(Kiechl, Lorenz et al. 2002) and 
sepsis(Agnese, Calvano et al. 2002, Lorenz, Mira et al. 2002, Barber, Aragaki et al. 
2004, Henckaerts, Nielsen et al. 2009, Shalhub, Junker et al. 2009). Other studies did 
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not show associations between TLR4 polymorphisms and sepsis (Feterowski, 
Emmanuilidis et al. 2003, Jessen, Lindboe et al. 2007). 
To account for genetic variability in other areas SNPs that have either been shown to 
have an effect on the acute inflammatory response or are thought to have modifier 
effects on TLR4 activity were analysed: Mannose Binding Lectin (MBL-2) (Fidler 
2007), CHRNA7 (Leonard, Gault et al. 2002, Hamano, Takahashi et al. 2006) , IL-6 
(Ahrens, Kattner et al. 2004), IL-10 (Nakada, Hirasawa et al. 2005), TNFα 
(Westendorp, Langermans et al. 1997)and PAI-1 (Hermans and Hazelzet 2005).  
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Gene 
name
a
 
Gene locus Region Nucleotide change 
and position 
Amino acid change NCBI SNPid
b
 Effect of SNP; Presumed mode 
of inheritance 
TLR4 9q32-q33 Exon 3  A>G +896 D299G 4986790 Less transcription of NFκB; 
decreased response to inhaled 
LPS(Arbour, Lorenz et al. 2000); 
Dominant 
 
TLR4  Exon 3 C>T+ 1196 T399I 
 
4986791 Less binding of 
ligand(Rallabhandi, Bell et al. 
2006); Dominant 
CD14 5q31.1 Promoter C>T-159 (also known 
as -260) 
Not applicable 2569190 Higher expression of mCD14
c
 on 
monocytes, higher plasma level of 
sCD14
 d
 increased response to 
LPS(Baldini, Lohman et al. 1999, 
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Hubacek, Skodova et al. 2004); 
Recessive 
LBP 20q11.23-q12 Exon 3 T>C+291 P97P 
 
2232582 Unknown; Unknown, may be 
associated with greater mortality 
in sepsis (Hubacek, Stuber et al. 
2001, Barber and O'Keefe 2003) 
Table 4-1 Main features of the SNPs in the endotoxin recognition complex 
a
Components of the endotoxin recognition complex: TLR4 toll-like receptor 4; CD14, Cluster of Differentiation 14 molecule, codes for both 
c
 
membrane bound protein mCD14 as well as 
d
 soluble protein sCD14; LBP, Lipopolysaccharide binding protein. 
b
NCBI reference sequence 
number found at http://www.ncbi/nlm.nih.gov/SNP
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4.8.3 Outcome measures 
The primary outcome measures were: ‘development of SIRS in the first three days of 
intensive care stay’ and ‘platelet count on admission’.  SIRS was defined according to 
the 1992 ACCP-SCCM consensus (1992), with adjustments as described previously 
(Fidler, Wilson et al. 2004, Stephens, Fidler et al. 2006) and given in detail in 
paragraph 2.4. 
Duration of ventilation, length of PICU stay and development of nosocomial infection 
in the first week of intensive care stay were secondary outcome measures. 
 
4.8.4 Validation cohort 
A cohort of 1170 Caucasian patients, diagnosed to have coronary artery stenosis by 
angiography (> 50% stenosis in 1 major epicardial coronary artery) recruited in the 
Southampton Atherosclerosis Study, had previously been genotyped for the TLR4 
polymorphism D299G. A subset of patients (n=777) was also genotyped by Taqman 
analysis for both the D299G and T399I polymorphisms. Given substantial time and 
financial constraints associated with recruiting a large equivalent paediatric cohort for 
validation purposes this cohort was a readily available relevant dataset. 
A subset of the Southampton Atherosclerosis Study had a history of recent 
myocardial infarction. This is a severe inflammatory insult to which TLR4 and 
platelets are relevant (Kiechl, Lorenz et al. 2002, Frossard, Fuchs et al. 2004, 
Lundberg and Hansson 2010). 
To validate the observations in paediatric inflammation the hypothesis was tested that 
TLR4 variant carriers, with a history of recent myocardial infarction as a severity 
threshold for inflammation, would show lower platelet counts on admission. 
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This cohort was recruited consecutively from the Wessex Cardiothoracic Unit, 
Southampton General Hospital, as part of the Southampton Atherosclerosis Study. 
The original cohort consisted of 1501 Caucasian subjects admitted for interventional 
or diagnostic coronary angiography. Of these, 1170 had documented coronary 
atherosclerosis of >50% diameter in at least one major coronary artery. The 
demographic data are shown in Table 4-2. 
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Variable  
Age (years) 63.29 (9.96) 
Gender (male/female) 896/274 
Current and ex-smokers 872/298 
Body mass index (kg/m
2
) 27.5 (4.2) 
Plasma cholesterol (mmol/l) 5.1 (1.0) 
Plasma triglyceride (mmol/l) 1.8 (1.2) 
Hyperlipidemia 957/213 
Hypertension 524/646 
Type I Diabetes 37/1133 
Type II Diabetes 119/1051 
Family history of CAD 566/604 
Table 4-2 Demographics adult validation cohort 
 (n=1170) Continuous variables are expressed as mean and (standard deviation) 
Adapted from (Ye, Dunleavey et al. 2003).  
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All members of the cohort had been genotyped already for the TLR4 D299G 
polymorphism, by means of a tetra-primer amplification refractory mutation system 
(ARMS) polymerase chain reaction (PCR) assay to amplify the polymorphic region of 
TLR4. The methods described below are described in (Yang, Holloway et al. 2003). 
“Primers that were used to genotype the polymorphism were: 
Outer upper 5’-CCTGAACCCTATGAACTTTATCC-3’ 
Outer lower 5’-GTTAACTAATTCTAAATGTTGCCATC-3’ 
Inner upper (Asp allele) 5’-GCATACTTAGACTACTACCTCGAaGA-3’ 
 
20 ng of genomic DNA was amplified in a total reaction volume of 10 ml containing 
dNTP 0.2 mM, MgCl2 4 mM, primers (outer upper, 0.1 mM; outer lower, 0.1 mM; 
inner upper, 2 mM; inner lower, 2 mM), AmpliTaq Gold DNA polymerase (0.025 
U/ml) and buffer (Applied Biosystems, Warrington, UK). The PCR cycling 
conditions were 95 8C for 5 min; then 9 cycles of 94 8C for 30 s, X 8C for 30 s 
(where X is initially 72 8C, decreasing 1 8C per cycle to 64 8C), 72 8C for 30 s; then 
31 cycles of 94 8C for 30 s, 64 8C for 30 s and 72 8C for 30 s; and finally 72 8C for 
10 min. A constant PCR product (385 bp) and allele-specific products (Gly 292 bp, 
Asp 147 bp) were resolved by micro-array diagonal gel electrophoresis. Two 
researchers independently scored the genotypes and representative genotypes were 
confirmed by DNA sequencing.” 
 
The TLR4 genotyping results in absolute numbers are shown in Table 4-3. 
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 Original publication Current data 
TLR4 AA (Wildtype) 1256 743 
TLR4 AG or GG 144 84 
TLR4 CC (Wildtype) n/a 755 
TLR4 CT or TT n/a 77 
Table 4-3 TLR4 SNPs genotyping results adult cohort 
The original publication by (Ye, Dunleavey et al. 2003) analysed only TLR4 D299G. 
For the current study both TLR4 D299G as well as T399I genotyping was available. 
These distributions are in HWE and are as expected for Caucasian ethnicity. 
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4.8.5 Statistical analysis  
Hardy Weinberg equilibrium was tested by means of the 2 -test. Univariate analyses 
were performed by 2, Mann-Whitney U, Student’s T test or one-way ANOVA as 
appropriate. A binomial regression analysis incorporated genotype parameters and 
clinically relevant parameters. Statistical significance was set at a two-tailed p value < 
0.05. All statistical analyses were performed using SPSS version 13.0 for Mac (SPSS, 
Chicago, IL, USA). 
 
4.9 Results 
4.9.1 Recruitment 
The total number of children that was recruited amounted to n= 913, (n= 579 from the 
cardiac intensive care at GOSH, n= 299 from the PICU at GOSH and n= 35 from the 
PICU at Southampton). 
4.9.2 Genotyping  
Genotyping was successful for 906 (99.2%) critically ill children.   
All SNPs were in Hardy-Weinberg equilibrium stratified to ethnic background and 
allele frequencies were as previously described (Smirnova, Hamblin et al. 2001).  
TLR4 genotypes varied across ethnicity. The children with an Asian background (n= 
26) showed only wildtype TLR4 genotype, whereas TLR4 D299G was common 
(n=10; 12%) and T399I was observed only once (1.2%) amongst those of African 
descent (n= 78). In the Caucasian group (n= 747) both variant alleles were present 
(D299G n=72 (9.6%); T399I n=74 (9.9%)) and mostly occurred together, i.e. showed 
cosegregation. (Figure 4-2).  
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Figure 4-2 Cosegregation of TLR4 alleles 
P value derived from 2 test  
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4.9.3 Development of SIRS in the first 3 days of intensive care stay 
Overall, SIRS developed in 594/913 (65%) subjects. Significantly more children in 
the Infection group developed SIRS (143/179; 79.8%) than in the Non-infection 
(126/199; 63.3%) or Bypass group (325/535; 60.7%) (Table 4-4).
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Characteristic All (n=913) Non-SIRS (n=319) SIRS (n=594) p value
a 
Precipitating event     < 0.0005 
 Bypass 536 211 325  
 Non-Infection 198 72 126  
 Trauma  104  28  76  
 Cardiac surgery (Non-Bypass)  43  18  25  
 Elective postoperative  36  23  13  
 Other  15  3  12  
 Infection 179  36  143  
     
PIM score expected mortality in % 
b 
2.45 (0.17-98) 2.10 (0.17-88.6) 2.80 (0.24-98) <0.0005 
Observed 28 day mortality % (n) 3.17 (29) 1.56 (5) 4.0 (24) 0.04 
Age in months 17 (0-218) 11 (0-218) 22 (0-207) <0.0005 
Sex ratio (M/F) 1.34 (523/390) 1.35 (183/136) 1.33 (340/254) 0.97 
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Ventilator days 2.0 (0-362) 1.9 (0-106) 2.9 (0-362) 0.002 
Length of stay (days) 3.7 (0.1-362) 2.9 (0.1-106) 3.8 (0.1-362) 0.001 
Nosocomial infection in week 1
 c
 51/688 14/267 37/421 0.08 
Platelet count 1714 1626 1775 0.04 
Ethnicity    0.09 
 Caucasian 747 273 474  
 African 78 18 60  
 Asian 26 7 19  
 Mixed/Unknown 62 21 41  
Table 4-4 Clinical characteristics for the total paediatric cohort stratified according to early development of SIRS 
Continuous values are expressed as medians and range or means  SEM; categorical values as counts and percentages. aComparison between 
SIRS and Non-SIRS. Mann-Whitney U or Student’s t-test (continuous variables); Pearson 2 test (categorical variables) bBased on PIM 
Paediatric index of Mortality(Shann, Pearson et al. 1997) 
c
Not documented in infection group.
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Subjects with wildtype or variant genotypes for either of the TLR4 variant alleles, 
alone or in combination, did not differ in the development of SIRS; 66% (68/103) of 
the subjects with a TLR4 mutation developed SIRS, versus 65% (522/803) with the 
wildtype genotype (Figure 4-3).  
The Bypass and Infection groups (Figure 4-4 and Figure 4-5) showed no difference in 
the rate of SIRS when stratified according to TLR4 genotypes. 
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Figure 4-3 TLR4 wildtype vs. TLR4 variant genotypes PICU 
Univariate analysis for TLR4 polymorphism variant alleles as a risk factor for SIRS in 
the total paediatric cohort. P value derived from 2 test. 
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Figure 4-4 TLR4 genotypes in Bypass group 
Univariate analysis for TLR4 polymorphism variant alleles as a risk factor for SIRS in 
the bypass group. P value derived from 2 test. 
 
 
Figure 4-5 TLR4 genotypes in Infection group 
Univariate analysis for TLR4 polymorphism variant alleles as a risk factor for SIRS in 
the infection group. P value derived from 2 test. 
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In the Non-infection group there was a trend for carriers of the TLR4 variant alleles to 
be at an increased risk for developing SIRS; OR 2.4 (95% CI 0.84-6.6, p = 0.09) 
(Figure 4-6). After multivariate analysis, adjusting for basic demographics, and other 
polymorphisms in the endotoxin recognition complex, CHRNA7, PAI-1, MBL-2 and 
the genes encoding cytokines IL-6, TNF and IL-10 this just reached statistical 
significance (p = 0.03) with an OR 5.4 (95% CI 1.1 - 26.5). 
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Figure 4-6 TLR4 genotypes in non infection group 
Univariate analysis for TLR4 polymorphism variant alleles as a risk factor for SIRS in 
the Non infection group. P value derived from 2 test. 
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4.9.4 Platelet Count 
There was a marked difference in admission platelet count between subjects with 
wildtype and those carrying the 299G and/or 399I TLR4 variant in the total paediatric 
cohort: (mean  SEM: 174  4 vs. 142  7, p = 0.0001) (Figure 4-7). 
The impact of TLR4 genotype on platelet count showed a “dose response” or additive 
pattern. Those children with wildtype genotype had the highest platelet count, 
whereas those with two or more variant alleles had the lowest platelet counts and 
children with 1 variant allele had an intermediate phenotype. (Figure 4-8).  
Consequently, the proportion of children with actual thrombocytopenia (platelet count 
<150 x 109) was significantly higher amongst those carrying one or more variant 
TLR4 alleles compared to wildtype (OR 1.7 (95% CI 1.1-2.7, p = 0.01) (Figure 4-9 
and Table 4-5).  
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Figure 4-7 Platelet count for the total paediatric group stratified by TLR4 
genotype  
P value derived from Student’s t-test. 
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Figure 4-8 One Way ANOVA analysis for platelet count per TLR4 variant allele 
PICU cohort 
One-Way ANOVA analysis for platelet count per TLR4 variant allele (0,1 or 2) for 
the total paediatric cohort. 
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Figure 4-9 Thrombocytopenia by TLR4 genotype PICU cohort 
Thrombocytopenia (platelet count <150x10
9
) stratified by TLR4 genotype for the 
total paediatric cohort (Odds ratio 1.7 (95% C.I. 1.1-2.6, 2 test)). 
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Independent variable Univariate
 a
 Adjusted (logistic regression analysis) 
(Adjusted for: Age (logged), sex, neutrophil count, 
SNPs in CD14, LBP, TNFα, IL6 and IL10; 
CHRNA7, PAI-1 and MBL-2)  
 
Multiple logistic regression analysis 
(Adjusted for: Age (logged), sex, neutrophil count, 
SNPs in CD14, LBP, TNFα, IL6 and IL10; and 
CHRNA7, PAI-1, MBL-2) 
plus risk factors identified on univariate analysis 
i.e: TLR4 SNPs, ethnicity, primary diagnosis, 
severity of illness (PIM), and SIRS) 
TLR4 any variant 1.7 (1.1-2.6)  p =0.01 1.9 (1.2-3.0) p = 0.007 2.2 (1.2-3.9) p = 0.01 
TLR4 variant number
 b
 
 1 
 ≥2 
 
1.1 (0.5-2.2) p = 0.79 
2.2 (1.3-3.7) p = 0.003 
 
1.4 (0.6-3.1) p = 0.39 
2.1 (1.2-3.6) p = 0.01 
 
2.6 (0.9-7.0) p = 0.06 
2.0 (0.99-4.0) p = 0.05 
SIRS 0.79 (0.6-1.03) p = 0.09 0.72 (0.5-0.97) p = 0.03 1.0 (0.7-1.5) p = 0.9 
Primary diagnosis 
c
 
 Cardiac Bypass 
 
7.6 (3.3-17.2) p <0.0005 
 
8.7 (3.5-21) p < 0.0005 
 
9.9 (3.9-25) p < 0.0005 
 227 
Ethnicity 
d
 
 African 
 Asian 
 
0.4 (0.2-0.7) p = 0.001 
0.1 (0.1-0.9) p = 0.03 
 
0.4 (0.2-0.7) p = 0.005 
0.3 (0.1-0.7) p = 0.01 
 
0.4 (0.2-0.7) p = 0.003 
0.6 (0.2-2) p = 0.37 
Table 4-5 Independent variables for thrombocytopenia in the PICU cohort 
Thrombocytopenia (<150*10
9
/l) Results show odds ratios, 95% Confidence Interval and p value. 
a
  Square test. b vs. wildtype TLR4. cvs. 
elective postoperative. 
d
vs. Caucasian
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Interestingly, the effect that TLR4 polymorphisms exerted differed between the 
precipitating event groups. No difference in platelet count could be seen in the Bypass 
group (Figure 4-10).  
In the Non-infection group, children with variant TLR4 alleles had lower admission 
platelet counts than wild type (Figure 4-11). 
A trend in this direction was also evident in the smaller Infection group (Figure 4-12). 
The risk for thrombocytopenia on admission in the whole population associated with 
TLR4 variants remained after multiple regression analysis. It was independent of any 
combination of: primary diagnosis, demographic characteristics, neutrophil count, 
SIRS, PIM score, and other endotoxin complex and PAI-1, MBL-2, CHRNA7, IL-6, 
IL-10 or TNF genotypes (OR 2.2 (95% CI 1.2- 3.9), p = 0.01). 
 
Polymorphisms in LBP or CD14 did not alter the risk for development of SIRS or 
platelet count (Table 4-6).  
The secondary clinical outcome measures, i.e. length of stay, length of ventilation or 
nosocomial infection did not show any stratification according to genotype (Table 
4-7). 
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Figure 4-10 Platelet count per TLR4 genotype in PICU Bypass group 
P value is derived from Student t-test  
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Figure 4-11 Platelet count per TLR4 genotype in Non-infection group 
P value is derived from Student t-test 
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Figure 4-12 Platelet count per TLR4 genotype in Infection group 
P value is derived from Student t-test 
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SNP Non 
SIRS 
SIRS P value
a 
Platelet 
count
b
 
P value
c 
CD14 C-159T 
CC or CT 
TT 
 
232 
62 
 
412 
133 
 
Recessive 0.27 
 
1704.1 
1668.0 
 
Recessive 0.6 
LBP P97P 
TT 
CT 
CC 
 
199 
81 
17 
 
370 
155 
27 
 
Additive 0.85 
Dominant 1.0 
Recessive 0.62 
 
1674.4 
1727.0 
18615.7 
 
Additive 0.46 
Dominant 0.34 
Recessive 0.28 
Table 4-6 Primary outcome measures according to polymorphisms in the 
endotoxin recognition complex 
a
P value derived from 2 test, bMean  SEM cP value derived from Student’s t-test or 
One Way ANOVA.
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SNP
a
 28 day mortality (n) 
no/yes 
Expected mortality in 
%
b
 
Length of stay (days)
c 
Ventilator days
d 
Nosocomial infection 
week 1
e
 (n) no/yes 
TLR4 D299G/T399I 
 WT 
 Variant 
 
 
772/25 
97/4 
 P=0.55 
 
2.4 (0.1-98) 
2.1 (0.6-88) 
 P=0.41 
 
3.6 (0.1-362) 
3.8 (0.2-136) 
 P=0.26 
 
2.0 (0-362) 
2.0 (0-136) 
 P=0.08 
 
561/44 
72/7 
 P=0.64 
CD14 C-159T 
 CC or CT 
 TT 
 
 
622/20 
187/8 
 P=0.5 
 
2.4 (0.1-98) 
2.3 (0.1-75) 
 P=0.75 
 
3.5 (0.1-362) 
3.7 (0.1-83) 
 P=0.08 
 
2.0 (0-362) 
2.0 (0-61) 
 P=0.2 
 
475/33 
131/18 
 P=0.03
f 
LBP P97P 
 TT 
 CT 
 CC 
 
549/18 
230/6 
41/3 
 P=0.33 
 
2.3 (0.1-98) 
2.3 (0.3-75) 
3.1 (0.1-90) 
 P=0.41 
 
3.1 (0.1-135) 
3.8 (0.1-107) 
4.6 (0.8-362) 
 P=0.26 
 
2.0 (0-135) 
2.8 (0-91) 
3.0 (0-362) 
 P=0.08 
 
413/31 
176/16 
27/4 
 P=0.44 
Table 4-7 Clinical outcome measures according to genotype in the endotoxin recognition complex  
Univariate analysis by Mann-Whitney U (continuous variables) or Pearson 2 test (categorical variables).  aSingle Nucleotide Polymorphism, 
b
Based onPaediatric index of Mortality (PIM) score, median and range; 
c, d
Median and range; 
e
Not documented in infection group, 
f
Not 
significant in adjusted logistic regression analysis; P=0.3 (adjusted for clinical co-variates and polymorphisms).
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4.9.5 Validation cohort 
Out of the original 1170 patients, both phenotypic data (age 63.3  0.3 (mean  
SEM), sex ratio (M/F) (888/276) and TLR4 D299G genotype was available for 1065 
patients. Of these patients 573 (54%) had experienced a recent (within 3 months) 
myocardial infarction. In this group those subjects with TLR4 variant genotypes had 
lower platelet counts than those with the wildtype genotype: 217  7.0 vs. 2372.8 
(meanSEM) p = 0.021, Figure 4-13.  
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Figure 4-13 Platelet count per TLR4 genotype in adult validation cohort  
Platelet count for adults with a history of myocardial infarction, stratified by TLR4 
genotype wildtype vs. variant. P value derived from Student’s t-test. 
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Because of the high prevalence of allele cosegregation in this Caucasian cohort, this 
study was not powered to assess a “gene dose effect”. There was no significant 
difference in platelet count in the group that had not suffered a recent myocardial 
infarction, indeed the platelet count in the TLR4 variant group was higher than in the 
wildtype group: variant 244  10 vs. wildtype 229  3.5 (meanSEM), p = 0.14. 
Age and gender are known to influence platelet count.(Miller, Jayachandran et al. 
2007) The current cohort confirmed this; females had higher platelet counts than 
males (254 2.0 vs. 226  5.0 (mean  SEM), p <0.0001) and platelet count was 
inversely correlated with age (p<0.0001). Thrombocytopenia (platelet < 150 x 10
9
/l) 
occurred in 53 cases and there was no difference between TLR4 genotype status. 
 
4.10 Discussion 
This cohort of more than 900 critically ill children shows little impact of common 
functional polymorphisms in the endotoxin receptor on the development of SIRS. 
Conversely, there was a clear and unequivocal effect of TLR4 genotype on platelet 
count.  Polymorphisms associated with reduced TLR4 function exerted a dose-
dependent effect; the lowest platelet counts were seen in the haplotypes associated 
with lowest TLR4 function. The stepwise association between TLR4 polymorphisms 
and lower platelet counts may imply that these two SNPs reduce TLR4 function by 
addition or interaction.  
So-called “common” co-segregation for the D299G and T399I polymorphisms is 
found only in Caucasians. Therefore studies that analyse either SNP in isolation will 
be suboptimal in multiethnic cohorts. (Ferwerda, McCall et al. 2008). This issue may 
underlie some of the variability in the existing literature. 
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The main question to ask in interpreting this data is: 
How can a clinically small (175 vs. 143), but statistically highly significant difference 
in platelet count related to TLR4 haplotype, be reconciled with the lack of effect on 
SIRS?  
The two observations appear to be contradictory, but perhaps they offer some insight 
into acute inflammatory processes and the limitations of the definitions of systemic 
inflammation currently employed for clinical research. 
The apparent conflict arises from the view that platelets are an integral part of the 
acute inflammatory response (Klinger and Jelkmann 2002) with an important 
relationship between thrombocytopenia and severity of illness across all age ranges 
(Vanderschueren, De Weerdt et al. 2000, Peters, Ross-Russell et al. 2001, Akca, Haji-
Michael et al. 2002, Ragazzi, Pierro et al. 2003). Numerous observations suggest that 
platelets actively contribute to the intensity of the acute inflammatory response rather 
than being bystanders that are consumed as a ‘para-phenomenon’.(Davi and Patrono 
2007, Zarbock, Polanowska-Grabowska et al. 2007) Mechanisms include acceleration 
of recruitment of neutrophils and monocytes by formation of heterotypic complexes 
as well as production of inflammatory mediators including CD40 ligand, tissue factor, 
RANTES and matrix metalloproteinases.(Gawaz, Langer et al. 2005)  
 
If platelet activation is inseparable from the acute inflammatory response, why might 
reduced endotoxin responsiveness affect platelet count but have no detectable effect 
on clinical markers of systemic inflammation?   
 
The simplest explanation would be a type II error. SIRS may be an insufficiently 
discriminatory measure and therefore despite the numbers of cases reported here, this 
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study may be inadequately powered.  The limitations of a clinical diagnosis of SIRS 
are well documented.(Vincent 1997) In part this is due to therapy-induced changes on 
the variables temperature, heart rate and respiratory rate that constitute clinical SIRS. 
The label SIRS thus may poorly reflect the underlying state of immune activation. In 
children this is compounded by the normal developmental changes in heart rate, 
respiratory rate and white cell counts. The paediatric criteria for SIRS take into 
account these age-related changes, but these consensus decisions equally have not 
been validated in large cohorts. So, there is no “gold standard” for SIRS.  
Next, the study included only children with a precipitating insult of sufficient severity 
to require admission to intensive care for organ support. Any variability in the 
development of SIRS that may be attributable to TLR4 polymorphisms may be 
swamped by the severity of this level of insult. The patient cohort thus may well be 
too sick to identify what we now know are subtle changes due to common genetic 
polymorphisms. Common genetic polymorphisms in complex disease are expected to 
have but a small influence with odds ratios < 2. (Stranger, Stahl et al. 2011) 
A recent clinical study in stem cell transplant patients demonstrated TLR4 variant 
alleles to be a risk factor for Aspergillosis infection.(Bochud, Chien et al. 2008) 
Unlike the study’s mixed ICU population at risk for SIRS, this was a specific 
complication in a very high-risk population; hence a more favourable ‘signal-to-
noise’ ratio might be expected. In other words, the phenotype description is of utmost 
importance. With a more specific phenotype, the potential increases to ascertain a 
genotype association. 
 
The fact that SIRS is a binary outcome measure compounds these limitations.  In 
contrast, admission platelet count is a near continuous measure that is unlikely to be 
 239 
confounded dramatically by therapy. Dichotomizing data leads to reduction of power 
because of loss of information and reduction in variability.(Altman and Royston 
2006) 
 
Alternatively, it may be that platelet count is just a more sensitive measure of the 
degree of inflammation than the crude indices used to define SIRS. 
More recent evidence to support the hypothesis that platelets are a sensitive (or even 
sentinel) marker of inflammation was found in the observation in mice that a single 
intravenous low dose LPS induced a TLR4-dependent increase in basal P-selectin 
positive platelets 24 hours later and a corresponding increase in reticulated platelets 
two days later, indicating a sustained reactive platelet response. Of note, this 
activation and reduction in life span occurred without measurable changes in serum 
TNFα.(Jayachandran, Miller et al. 2010) 
Then there is the possibility that the effect on platelet count was specific to platelets, 
rather than it being part of systemic inflammation. 
This possibility has credibility, because importantly, no influence of MBL-2 genotype 
on platelet count was demonstrated, while others and we have previously described an 
increased risk of SIRS in children carrying MBL-2 genotypes associated with reduced 
plasma levels of the pattern recognition molecule Mannose Binding Lectin. Therefore, 
another explanation for the discordant results between the impact of TLR4 
polymorphisms on development of SIRS and platelet count requires consideration.  
Rather than these results reflect the degree of complexity and specificity of the two 
end-points themselves, it may be that these results reflect the difference in complexity 
of the inflammatory pathways relevant to the two end-points.  Development of SIRS 
is a complex process with multiple pathways and thus a high level of redundancy. 
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Inherited dysfunction or therapeutic inhibition of single elements are therefore 
unlikely to have a large impact on overall outcome.(Bone 1996, Zeni, Freeman et al. 
1997) Indeed, TLRs intrinsically have different redundancies. Intracellular TLRs are 
less tolerant to reduced function than ligand binding cell surface ones.(Barreiro, Ben-
Ali et al. 2009) 
Specifically, the eukaryotic nucleated intra-cellular signalling response to TLR 
ligation has been described in great detail as an example of a biologically robust 
process.(Oda and Kitano 2006) In contrast to the main effector cells of systemic 
inflammation (monocyte/macrophages and endothelial cells), platelets express a very 
limited range of surface receptors for inflammatory mediators and have a limited 
response repertoire due to the absence of genomic DNA.(Davi and Patrono 2007) 
Thus, it is biologically plausible that endotoxin-TLR4 binding causes a direct, non-
redundant response of platelet activation and consumption that is independent of the 
development of SIRS.  
The demonstration of functional TLR4 expression on platelets (Andonegui, Kerfoot et 
al. 2005, Shashkin, Brown et al. 2008) and the observation that adults with TLR4 
variant genotypes have significant differences in platelet function (Patrignani, Di 
Febbo et al. 2006) provide some support for this concept.  
To validate this concept an independent cohort with a relevant inflammatory insult 
was required. In the absence of a relevant independent paediatric cohort a 
convenience cohort consisting of adults with atherosclerosis and a recent 
inflammatory insult (e.g. myocardial infarction) was identified. Reduced severity of 
atherosclerosis has previously been associated with TLR4 variant genotypes (Kiechl, 
Lorenz et al. 2002, Patrignani, Di Febbo et al. 2006). Indeed, adults with coronary 
artery stenosis and a recent history of myocardial infarction who carried TLR4 variant 
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alleles had platelets counts, which, on average, were 20 x 10
9
/l lower than their 
wildtype counterparts.  
Finally, clinical trial evidence further supports the possibility of the impact of this 
pathway on platelet count.  In a double blind multi-centre randomised study of 393 
children with severe meningococcal disease, the anti-endotoxin molecule recombinant 
bactericidal/permeability increasing protein fragment (rBPI21) had no significant 
effects on mortality (although morbidity was better with less amputations and better 
functional recovery). However, thrombocytopenia was less severe in children 
receiving rBPI21 (control group 36% transfused platelets vs. 25% r-BPI21 group, 
p=0.03).(Levin, Quint et al. 2000) 
Unfortunately, none of the other large anti-endotoxin clinical trials comment 
specifically on the effect of therapy on platelet count or platelet transfusion. 
(McCloskey, Straube et al. 1994, Derkx, Wittes et al. 1999, Vincent, Laterre et al. 
2005) 
The TLR4 antagonist Eritoran study in sepsis was stopped for futility. No data as of 
yet are available on morbidity and haematological parameters such as platelet count 
and transfusions. 
 
4.11 Limitations 
This study has several limitations. The paediatric cohort is heterogeneous. Different 
precipitating events in nature and time course before admission may have led to the 
inability to determine a differentiation in SIRS. Given the inherent non-protocolized 
nature of this observational study, there was no attempt to describe SIRS by way of 
humoral biomarkers of inflammation, such as cytokines. Future strictly protocolized 
 242 
studies may elucidate the temporal pattern of circulating cytokines in relation to 
genetic profile.  
 
The validation cohort differed in age, inflammatory insult and ethnic mix, and thus is 
not perfect.  
Myocardial infarction, however, is an inflammatory process of substantial severity 
with a relevance to platelet count and TLR4. Despite this and also that the observed 
difference on platelet count in this cohort is small (although statistically significant) 
and the counts are in the normal range, this result still corroborates the findings in the 
paediatric cohort. 
 
Polymorphisms in endogenous BPI (Michalek, Svetlikova et al. 2007) and at least two 
components of TLR4 induced intracellular signalling, i.e. Mal (Khor, Chapman et al. 
2007) and IRAK4 (Ku, von Bernuth et al. 2007) may change susceptibility or 
outcome in severe infections. These polymorphisms were not included in this study 
and thus this study might be labelled as incomplete. Given the ever-evolving 
knowledge in this area, however, all similar studies are hampered by this 
phenomenon. 
 
Last, these findings require a mechanistic approach in human ex vivo experiments or 
in vivo knock out mice models to determine the underlying processes. Future studies 
will need to focus on the specific underlying pathophysiological mechanisms.  
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4.12 Conclusion 
In conclusion, TLR4 polymorphisms are associated with lower platelet counts in 
severe inflammation. The reasons for this are unclear but may point to a direct effect 
of the TLR4 pathways on platelets or indicate that platelet counts are a more sensitive 
marker of systemic inflammation than SIRS criteria.  These data support the view that 
variation in TLR4 function influences the early inflammatory response. This 
phenomenon may be one aspect of reduced fitness in the capacity to respond 
appropriately to an insult.  
 
4.13 Future work 
Future strictly protocolized studies may elucidate the temporal pattern of circulating 
cytokines in relation to genetic profile.  
Future studies will need to focus on the specific underlying pathophysiological 
mechanisms.  
Baseline platelet count and percentage reticulated platelets are 20% lower in TLR4 
deficient mice.(Jayachandran, Brunn et al. 2007) An attempt was made to identify 
whether the lower platelet count in the TLR4 variant groups, as observed in both 
cohorts was secondary to the acute phase response or rather a pre-existing state in 
these individuals. Two healthy adult cohorts were identified from the literature where 
platelet counts may have been collected as part of the protocol, the Italian and the UK 
Caerphilly Prospective Study (CaPS). Contact was made by email. One research 
group declined to respond. The other group showed some enthusiasm, but was unable 
to generate the desired data. Thus it remains to be seen whether TLR4 variant 
populations exhibit a baseline loss of redundancy in their capacity to respond to day-
to-day minor insults, such as bacteraemias secondary to brushing teeth. 
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What is the evolutionary meaning of TLR4 polymorphism differences across 
ethnicities. The debate is ongoing whether this is genetic drift or infectious pressure. 
One group states that given the similar frequencies of TLR4 polymorphisms in 
populations with different infectious pressures exerted by malaria, it is likely genetic 
drift that accounts for the prevalence of TLR4 polymorphisms (Greene, Moormann et 
al. 2009) Others however makes the claim that in African populations the prevalence 
of the TLR4 D299G variant is 10-20x higher than in populations from other 
countries.(Ferwerda, McCall et al. 2008)Moreover, TLR4 polymorphsims were 
shown to be protective against malaria with a consistent protective effect in the 
D299G variant in three case control studies with nearly 4500 African children with 
severe malaria. The identification of the malaria parasite GPI anchor molecules as 
ligands for human TLR4 receptors supports the role of TLR4 in malaria. (Hill 2006) 
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Chapter 5 Genetic variability in complement activation  
 
5.1 Complement Activation Cascade 
Complement activation is a key early event in the host response to injury (Fosse, 
Pillgram-Larsen et al. 1998) and infection (Jack, Klein et al. 2001). When 
appropriately activated, this powerful cascade contains, kills and clears pathogens and 
host debris without leading to a detrimental systemic “runaway” response. Three 
major activation pathways exist: the classical, alternative and lectin pathway. (Figure 
5-1) 
 
Classical pathway 
C1q, a complex molecule made up of three different polypeptide chains (A, B and C) 
initiates the classical pathway. The protein is a defence collagen, as are others such as 
Mannose Binding Lectin (MBL), surfactant protein A, surfactant protein D and 
ficolin. They share a collagen-like domain that is in continuity with a noncollagen like 
sequence. This globular carboxyl head recognizes specific pathogen associated 
molecular patterns. It enables the host to mount an immediate response by activating 
the classical (e.g. C1q) or lectin pathway (MBL and ficolin) through auto-activation 
of their associated serine proteases.(Sim and Tsiftsoglou 2004) 
 
Alternative pathway 
The alternative complement pathway is a continuously activated antimicrobial 
defence mechanism that also amplifies the other two pathways (Holers 2008). Strong 
negative feedback mechanisms exist because of the potentially destructive nature of 
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unchecked complement activation. Complement Factor H (CFH) is an important part 
of this regulation. Circulating CFH levels are high and increase during acute 
inflammation, thus preventing potentially dangerous excessive complement 
activation.(Rodriguez de Cordoba, Esparza-Gordillo et al. 2004) Complement Factor 
B (CFB) has the opposite effect; it competes with CFH thereby enhancing the 
alternative pathway. (Lachmann and Hughes-Jones 1984) 
 
Lectin Pathway 
Mannose Binding Lectin (MBL) initiates the lectin pathway. MBL and C1q have 
similar structures and functions; they recognize and bind to pathogen-associated 
membrane patterns and have bactericidal properties. MBL associates with MBL-
associated serine proteases (MASPs) on binding with micro-organisms, which, in 
turn, leads to cleavage of C4 and C2 to form C3 convertase. (Dommett, Klein et al. 
2006) 
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Figure 5-1 Complement activation cascade 
The three pathways that activate the complement cascade are initiated and/or 
modulated by C1qA, MBL, CFH and CFB. These pathways converge at C3, from 
where the downstream complement proteins lead to chemotaxis, opsonization and cell 
wall lysis. 
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5.2 Genetic variation in complement function 
Complement deficiencies are well known to predispose to infection or inflammatory 
disease.(Walport 2001) An ever increasing number of studies report altered risk to 
disease or functional change associated polymorphisms in the genes encoding the 
proteins in all three complement activation pathways (Holers 2008, Heurich, 
Martinez-Barricarte et al. 2011). 
Given the many proteins involved in the complement cascade there are many 
candidate genes. The following polymorphisms were chosen based on the concept of 
final complement activation and known potential disease modifiers: 
MBL-2, lectin pathway activation; 
CFH, alternative pathway inhibition; 
CFB, alternative pathway activation; 
C1qA, classical pathway activation; C1q is the recognition subcomponent of the C1 
complex 
Host genotype determines 63% of the variation observed in CFH levels.(Esparza-
Gordillo, Soria et al. 2004) The CFH Y402H polymorphism results in reduced CFH 
function (Schmidt, Herbert et al. 2008) and is implicated in the aetiology of the 
inflammatory eye disease age-related macular degeneration (Klein, Zeiss et al. 2005) 
and possibly myocardial infarction (Kardys, Klaver et al. 2006), although this is 
questioned (Zee, Diehl et al. 2006). CFB is located on the major histocompatibility 
complex (MHC) class III region on chromosome 6 (Regueiro and Arnaiz-Villena 
1988). Polymorphisms within this gene are also associated with age related macular 
degeneration (Gold, Merriam et al. 2006, Maller, George et al. 2006). A functional 
polymorphism in C1qA have been associated with decreased complement activity in 
relation to dysregulated inflammation in subacute cutaneous lupus erythematosus 
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(SCLE) (Racila, Sontheimer et al. 2003) an increased risk for reduced rate of 
metastases in breast cancer (Racila, Racila et al. 2006) and most recently, an increased 
risk for mortality in breast cancer (Azzato, Lee et al. 2010).  
The most studied component of complement activation in relation to sepsis is 
mannose binding lectin (MBL). Serum MBL levels are predominantly determined by 
genotype in MBL2. Common structural and promoter polymorphisms associated with 
low serum levels are risk factors for infections in vulnerable individuals such as 
young children (Summerfield, Sumiya et al. 1997), neutropenic children (Neth, Hann 
et al. 2001). There exists, however, ongoing debate with regards to MBL2 deficiency 
as a risk factor for severe infection. A recent case control study and meta-analyis did 
not find any association with MBL deficient genotypes and invasive meningococcal 
disease (Bradley, Bourke et al. 2012) and neither did a genome wide association study 
that included rs1800450, which is the most common MBL deficient genotype (B) in 
people of European ancestry (Davila, Wright et al. 2010). 
MBL-2 polymorphisms and reduced serum levels were associated with the 
development of early SIRS/sepsis in a relatively small cohort of critically ill 
children(Fidler, Wilson et al. 2004) and susceptibility to and worse outcome in adults 
with sepsis (Gordon, Waheed et al. 2006). This association of SIRS/sepsis with MBL 
deficiency may reflect the known interactions with pro-inflammatory cytokine 
production. Low dose of MBL enhanced the production of IL1 and IL6 in 
monocytes, whereas high dose MBL profoundly reduced pro-inflammatory cytokine 
production.(Jack, Read et al. 2001) Alternatively, MBL deficiency may exert a direct 
effect on the rate and extent of complement activation. 
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The importance of the three pathways in relation to SIRS is unknown, however it 
seemed plausible that irregularities in the pattern recognition or regulation 
components would influence the magnitude of cascade activation and thus initial host 
response to injury and infection. 
To further determine the importance of the other complement activation pathways in 
the development of SIRS/sepsis in paediatric critically ill patients a larger cohort was 
genotyped for functional polymorphisms in MBL-2, CFH, CFB and C1qA. 
 
5.3 Potential genetic confounders 
Complement activation is only part of the host response to injury and infection.  
Genetic variation in other components of the innate immune system may modify 
outcome in critical illness.(Waterer and Wunderink 2003, Lin and Albertson 2004) To 
determine whether the impact of complement polymorphisms was independent of 
other known genetic variability in the innate immune system the cohort was also 
analysed for functional polymorphisms in TNF, IL6, IL10, and PAI-1. 
Cytokine production is a downstream event relevant to both sepsis and sterile SIRS. 
This process is, in part, under genetic control and this may modify outcome in critical 
illness. (Westendorp, Langermans et al. 1997, Galley, Lowe et al. 2003, Schaaf, 
Boehmke et al. 2003) 
 
5.4 Hypothesis 
Polymorphisms associated with reduced complement activation are associated with an 
increased incidence of SIRS in the first three days of intensive care admission. 
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5.5 Materials and Methods 
5.5.1 Ethical approval and parental consent 
The Great Ormond Street Hospital for Children NHS Trust / Institute of Child Health 
Local Research Ethics Committee approved this prospective observational cohort 
study.  Parental informed consent was obtained according to the Declaration of 
Helsinki guidelines. 
 
5.5.2 Subjects 
Between 2002 and 2006 subjects were recruited consecutively in two recruiting time-
periods from a tertiary paediatric general intensive care unit in London, UK. 
The aim of the selection criteria was to include children who were sick enough to stay 
for longer than an overnight time period but did not have known underlying reasons 
for a more severe illness course. Thus, inclusion criteria were: age up to 18 years and 
the presence of at least one organ system failure for 12 hours or longer (Proulx, Fayon 
et al. 1996) (or death within 12 hours of admission). Excluded were children with 
multiple congenital abnormalities, known immunodeficiency, haematological or 
lymphoid malignancies, systemic immunosuppressive drug therapy other than 
corticosteroids, known central neurological or neuromuscular disease, persistent 
pulmonary hypertension of the newborn, weight less than 2.2 kg, corrected gestational 
age less than 37 weeks, repeat intensive care admission, and non-accidental injury. 
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Ethnicity was coded according to Hapmap classification (2003) on the basis of 
parental described heritage routinely collected on admission in the National Health 
Service (NHS). 
Patients were classified by primary diagnosis as ‘Infection’ and ‘Non-infection’ 
(including elective general surgery, trauma, and other) based on the diagnosis made 
by the responsible admitting physician. Clinical data were collected blinded to the 
genotyping data. 
 
5.5.3 Genotyping 
Blood (2.5 ml) was collected in EDTA bottles and stored at -80C until DNA 
extraction according to the manufacturer’s instructions (QIAamp DNA blood mini or 
midi kit, Qiagen, Crawley, UK). 
The individual CFH, MBL-2, CFB, C1qA, TNF, IL6, IL10 and PAI-1 
polymorphisms were determined by KASPar assay at the commercial genotyping 
facility K-Biosciences (Herts, UK). For quality control purposes duplicates were 
included (5%) as well as three blank wells per 96 well plate. The commercial 
genotyping facility KBiosciences (Herts, UK) has developed a competitive allele 
specific PCR combined with Fluorescence Resonance Energy Transfer (FRET) 
method (KASPar) for single nucleotide polymorphism (SNP) identification. The 
company itself and numerous research groups have validated this method (Weedon, 
McCarthy et al. 2006), including the Wellcome Trust Centre for Human Genetics 
(Zeggini, Scott et al. 2008). 
Results from a subset of the cohort for MBL-2 that had previously been genotyped by 
PCR amplification and heteroduplexing (Fidler, Wilson et al. 2004) served as further 
validation. This showed 100% concordance for the compared genotypes. 
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Genotyping was done blinded to clinical data. 
 
5.5.4 CFH Genotypes analysis 
The non-synonymous SNP Y402H occurs due to substitution of the wildtype T allele 
with the variant C allele at nucleotide position 1277. This results in an amino-acid 
change from tyrosine (Y) to histidine (H) at amino acid position 402. The 
mechanisms underlying reduced CFH functionality of the 402H variant was recently 
reviewed. Although not completely elucidated, the current understanding of reduced 
functionality centres around the CFH binding affinity. (Schmidt, Herbert et al. 2008) 
This loss of function translates to the clinical field: A meta-analysis showed that 
homozygote variant carriers (CC) were at highest risk for the inflammatory eye 
disease age related macular degeneration (AMD) (Thakkinstian, Han et al. 2006). A 
recessive model, i.e. CC vs. CT/TT genotypes, seems to be the most appropriate. 
 
5.5.5 MBL-2 Genotypes 
The MBL-2 gene has 6 common polymorphisms: 3 structural gene variants in exon 1 
at positions 52, 54 and 57 (known as variants C, B and D respectively) and 3 
promoter SNPs at positions -221, -550 and +4 (denoted as X/Y, L/H and P/Q, 
respectively). By convention, wildtype genes are denoted “A” and variant genes “O”. 
Strong linkage disequilibrium causes there to be just seven common haplotypes. 
(Madsen, Garred et al. 1995, Madsen, Satz et al. 1998) 
Full MBL-2 haplotypes were inferred from the raw genotyping data based on these 
seven known haplotypes. These haplotypes then combine into 28 possible genotypes. 
Based on previously reported associations between plasma MBL levels and MBL-2 
 254 
genotypes (Fidler, Wilson et al. 2004, Gordon, Waheed et al. 2006) (Madsen, Garred 
et al. 1995) (Madsen, Satz et al. 1998) the genotypes HYPA/HYPA, HYPA/LYQA, 
LYQA/LYQA, HYPA/LYPA, HYPA/LXPA, LYQA/LYPA and LYQA/ LXPA 
qualified as wildtype and all other genotypes as variant. Both the structural gene and 
the promoter variants influence plasma MBL levels. Homozygous wildtype carriers 
for HYPA have the highest MBL plasma levels and lowest plasma levels are found in 
individuals who are homozygous or compound heterozygous for gene variants LYPB 
and LYQC. In between these two extremes are combinations of haplotypes that result 
in intermediate phenotypes. The structural gene polymorphism haplotype HYPD is 
associated with higher plasma levels than found for the other variants, but clinically 
behaves as other gene-variants. The X promoter and L promoter have both been 
associated with lower plasma MBL levels, such that LXPA, and to a lesser extent the 
LYPA genotypes are associated with lower plasma MBL levels (Madsen, Satz et al. 
1998). Thus homozygotes and compound heterozygotes for these haplotypes were 
assigned variant status. Due to sample size restrictions a detailed analysis on the basis 
of the 28 possible genotypes is not feasible. The genotypes were therefore categorized 
into two groups: wildtype and variant based on the above classification. 
 
5.5.6 Complement activation potential 
To semi-quantify complement activation potential the MBL-2 and CFH haplotypes 
combined to “Very high”: MBL-2 HYPA/HYPA plus CFH CC; “High” MBL-2 
HYPA/LYQA or LYQA/LYQA or HYPA/LXPA or HYPA/LYPA or LYQA/LYPA 
or LYQA/LXPA plus CFH CC; “Very low” MBL-2 double structural gene variants 
(O/O) plus CFH TT; “Intermediate” all other combinations of MBL-2 and CFH. 
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5.5.7 CFB Genotypes 
Two SNPs in the CFB gene were found to be associated with reduced risk of the 
complement mediated inflammatory eye disease AMD: L9H in exon 1 and R32Q in 
exon 2.(Gold, Merriam et al. 2006) The L9H SNP is caused by a T to A allele change, 
leading to a leucine (L) to histidine (H) amino acid change at amino acid position 9. 
The R32Q polymorphism is caused by a change from G to A (antisense C to T) 
leading to the arginine (R) to glutamine (Q) change at amino acid position 32. Both 
SNPs are associated with loss of function, thus reducing the capacity to form 
complement C3b.(Gold, Merriam et al. 2006, Montes, Tortajada et al. 2009) They 
conferred a protective effect for AMD independently of each other in a co-dominant 
model. (Maller, George et al. 2006) The analysis done here followed this principle. 
 
5.5.8  C1qA Genotypes 
The SNP C1qA-Gly70GGA at nucleotide position 276 in exon 2 of the C1qA gene 
consists of a change from G to A in the codon for Gly70 (GGG to GGA). 
Homozygosity for the A allele was associated with significantly reduced serum C1q 
levels both in healthy individuals and a non-familial form of subacute cutaneous lupus 
erythematosus (SCLE) patients and an increased risk for SCLE (Racila, Sontheimer et 
al. 2003). The data was thus analyzed in recessive inheritance mode (alleles GG and 
GA vs. AA). 
 
5.5.9 Possible confounding polymorphisms 
Known functional SNPs in genes possibly associated with modification of critical 
illness were analysed. The following SNPs were chosen as potential confounding 
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factors: the promoter polymorphisms in the cytokines TNF -308 G/A, IL6 -174 G/C, 
IL10 -1082 G/A and the insertion deletion SNP PAI-1 4G/5G.  
Table 5-1 lists the descriptive details for the analysed SNPs. Many more genetic 
polymorphisms may influence outcome in critical illness. The host response to injury 
and infection is a complex phenomenon that encompasses thousands of genes 
(Calvano, Xiao et al. 2005) and thus potential polymorphisms. These SNPs were 
chosen as possible confounders for the following three reasons: 1) Common 
prevalence of the SNP (>1%); 2) Change in function associated with the SNP and 3) 
Direct relevance to downstream effects of complement activation (Jack, Read et al. 
2001, Wojta, Kaun et al. 2002, Nauta, Castellano et al. 2004, Sprong, Jack et al. 2004, 
Kastl, Speidl et al. 2006). 
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rs 
number
a 
Gene Locus Region Nucleotide 
change 
Effect of 
SNP 
Key references 
5030737 MBL-2 10q11.2-q21 Exon 1 “D” 52C>T 
Arg>Cys 
“D” reduced (Madsen, Garred et al. 1995, 
Madsen, Satz et al. 1998, 
Fidler, Wilson et al. 2004, 
Gordon, Waheed et al. 2006) 
1800450 MBL-2  Exon 1 “B”  
54G>A 
Gly>Asp 
“B” reduced  
1800451 MBL-2  Exon 1 “C” 57G>A 
Gly>Glu 
“C” reduced  
7096206 MBL-2  Promoter -221 G/C 
X/Y 
“X” reduced  
11003125 MBL-2  Promoter -550 C>G 
L/H 
“L” reduced  
7095891 
 
MBL-2  Promoter +4 C>T 
P/Q 
“P” depends 
on genotype 
 
1061170 CFH 1q32 Exon 9 1277T>C 
Tyr402His; 
Y402H 
CC reduced (Klein, Zeiss et al. 2005, 
Kardys, Klaver et al. 2006, 
Schmidt, Herbert et al. 2008) 
172378 C1qA 1p36.12 Exon 2 276G>A; 
Gly70GGA 
AA reduced (Racila, Sontheimer et al. 
2003) 
4151667 CFB 6p21.3 Exon 1 T>A 
L9H; 
Leu9His 
AA (Gold, Merriam et al. 2006, 
Maller, George et al. 2006) 
641153 CFB  Exon 2 95 G>A; 
R32Q; 
AA reduced   
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Arg32Gln 
1800795 IL6 7p21 Promoter -174G>C CC reduced (Terry, Loukaci et al. 2000, 
Rivera-Chavez, Peters-Hybki 
et al. 2003) 
1800896 IL10 1q31-q32 Promoter -1082G>A AA reduced 
 
(Turner, Williams et al. 1997, 
Westendorp, Langermans et al. 
1997) 
1800629 TNF  6p21.3 Promoter -308 G>A AA increased (Kroeger, Carville et al. 1997, 
Westendorp, Langermans et al. 
1997) 
1799889 PAI-1 7q21.3-q22 Promoter -765 4G/5G 4G/4G 
increased 
(Dawson, Wiman et al. 1993, 
Festa, D'Agostino et al. 2003, 
Hermans and Hazelzet 2005) 
Table 5-1 Gene and polymorphism characteristics in the complement activation cascade and potential confounders 
a
NCBI dbSNP number
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5.6 Outcome measure 
The outcome measure was occurrence of SIRS within the first three days of 
admission. SIRS was defined according to the 1992 ACCP-SCCM consensus 
guidelines (1992), modified for age as described previously (Fidler, Wilson et al. 
2004). Briefly, a diagnosis of SIRS was made if 2 or more of the following were 
present: white cell count >12x10
9
/l or < 4x10
9
/l, heart rate (beats per minute, bpm) 
outside age specific ranges (newborn to 3 months:  95-145 bpm, 3-12 months 110-175 
bpm, 1-<3 years 105-170 bpm, >3-<7 years, 80-140 bpm, >7-<10 years 70-120 bpm, 
>10 years 60-100 bpm), central temperature >38.0
o
C or < 36.0
o
C. The respiratory 
score was not included in the measure as most children were expected to be 
ventilated. Temperature was scored only when not controlled artificially. 
 
5.7 Statistical analysis  
Hardy Weinberg equilibrium was calculated by 2 -test. 
Univariate analysis was performed by Fisher exact, 2 or Mann-Whitney U tests as 
appropriate. Binary logistic regression analysis was used to determine the independent 
contribution to risk of the genetic and demographic covariates. In the final regression 
analysis a two-tailed P value < 0.01 was considered to be statistically significant. This 
incorporates a stringent Bonferroni correction for 5 independent candidate gene 
variants. All statistical analyses were performed using SPSS version 13.0 for Mac 
(SPSS, Chicago, IL, USA). 
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5.8 Results 
Three hundred children were recruited into the study. Blood for genotyping was 
available for 299 patients. Patient clinical details are summarized in Table 5-2. Most 
children were ventilated (275/299; 92%) or on cardiovascular support (152/299; 51%) 
at admission. SIRS occurred in 223/299 (74%) subjects.  Mortality was in the 
expected range: 21/299 (7%). All children who died were ventilated and more likely 
to have been on inotropes, diagnosed with SIRS and thrombocytopenia on admission. 
No differences were found for sex, ethnicity, entry criterium, acute lung injury or 
genetic polymorphism in relation to mortality. 
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Characteristic All (n=299) Non-SIRS (n=76) SIRS (n=223) P value
a 
Age in months  40 (0-218) 35 (0-218) 43 (0-199) 0.83 
Sex (M/F) 183/116 49/27 134/89 0.49 
Ethnicity (n) 
 Caucasian 
 African 
 Asian 
 Mixed/Unknown 
 
216 
36 
18 
29 
 
58 
7 
5 
6 
 
158 
29 
13 
23 
0.72 
Primary diagnosis  
 Non Infection  
  Elective postop 
 Trauma 
 Other 
 Infection 
  Septic shock 
  Lower respiratory tract infection 
  Meningitis/encephalitis 
  Other 
 
141 
 35 
 99 
 7 
158 
 62 
 56 
 20 
 20 
 
51 
 23 
 28 
 0 
25 
 2 
 13 
 8 
 2 
 
90 
 12 
 71 
 7 
133 
 60 
 43 
 12 
 18 
0.00005
b 
PELOD on admission
c 
11 (0-61) 2 (0-31) 11 (0-61) 0.001 
Risk of mortality
d 
0.06 (0.007-0.98) 0.038 (0.007-0.37) 0.068 (0.008-0.98) < 0.0005 
28 day mortality n (%) 21 (7.0) 1 (1.3) 20 (8.96) 0.024 
Ventilator days 4.0 (0-362) 3.0 (0-20) 4.0 (0-362) 0.007 
Length of stay days 4.6 (0.1-362) 3.6 (0.4-20.3) 4.8 (0.1-362)
e 
0.020 
Continuous values are expressed as medians and range. Descriptive statistics are expressed as counts and percentages for categorical values. 
a
Comparison between the groups with and without SIRS by the Mann-Whitney U test (continuous variables); Pearson chi-square or Fishers 
exact (categorical variables). 
b
Non-Infection vs. Infection.  
c
PELOD Pediatric Logistic Organ Dysfunction (Leteurtre, Martinot et al. 2003).  
d
Based on PIM Paediatric index of Mortality (Shann, Pearson et al. 1997). 
e
One child remained ventilated until transfer to a chronic care facility. 
Table 5-2 Description of PICU cohort and comparison of SIRS and non-SIRS patients
 262 
5.9 Genetic variation in complement activation and SIRS 
5.9.1 Genotyping overall results 
Genotyping for CFH Y402H, CFB L9H, CFB R32Q and C1qA-Gly70GGA was 
successful in 280, 293, 290 and 292 children respectively. A full MBL-2 genotype 
analysis was completed for 294 children. All genotypes were in Hardy Weinberg 
equilibrium when stratified according to ethnicity and allele frequencies were in 
accordance with those previously described in the literature. (see Table 5-3 and Table 
5-4). 
  
 263 
Genotype Total Caucasian African Asian Other/Unknown 
Total (n) 299 216 36 18 29 
CFH Y402H 
 TT  
 CT 
 CC 
 
112 
126 
42 
73 
102 
29 
16 
12 
6 
12 
4 
1 
11 
8 
6 
CFB L9H 
 TT  
 TA 
 AA 
 
273 
19 
1 
197 
14 
1 
36 
0 
0 
16 
1 
0 
24 
4 
0 
CFB R32Q 
 CC  
 CT 
 TT 
 
234 
42 
10 
173 
29 
9 
22 
9 
0 
13 
3 
1 
26 
1 
0 
C1qA 
 GG 
 GA 
 AA  
 
73 
135 
84 
34 
104 
74 
21 
12 
3 
9 
5 
2 
9 
14 
5 
MBL-2 
HYPA/HYPA  
HYPA/LYQA 
LYQA/LYQA 
HYPA/LYPA  
HYPA/LXPA  
LYQA/LYPA 
LYQA/ LXPA 
LYPA/LYPA  
LYPA/LXPA  
LXPA/LXPA  
HYPD/HYPA 
HYPD/LYQA  
HYPD/LYPA  
HYPD/LXPA  
LYPB/HYPA  
LYPB/LYQA  
LYPB/LYPA  
LYPB/LXPA  
LYQC/HYPA  
LYQC/LYQA 
LYQC/LYPA  
LYQC/LXPA 
HYPD/HYPD  
LYPB/HYPD  
LYQC/HYPD  
LYPB/LYPB  
 
20 
48 
14 
11 
34 
12 
26 
2 
8 
16 
8 
7 
4 
12 
20 
11 
6 
9 
4 
10 
2 
2 
1 
2 
2 
3 
12 
44 
4 
7 
25 
9 
18 
1 
7 
10 
6 
7 
3 
10 
15 
11 
5 
7 
3 
2 
1 
0 
1 
1 
2 
2 
0 
1 
10 
3 
3 
3 
1 
1 
0 
0 
0 
0 
0 
2 
1 
0 
0 
0 
1 
8 
1 
1 
0 
0 
0 
0 
1 
1 
0 
1 
3 
0 
4 
0 
0 
2 
1 
0 
0 
0 
3 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
1 
7 
2 
0 
0 
3 
0 
3 
0 
1 
4 
1 
0 
1 
0 
1 
0 
1 
2 
0 
0 
0 
1 
0 
1 
0 
0 
Table 5-3 Complement genotype distribution according to ethnicity 
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Genotype All Caucasian African Asian Other/Unknown 
Total (n) 299 216 36 18 29 
 
IL6 -174G>C      
 GG  161 95 36 13 17 
 GC 104 91 0 3 10 
 CC 26 24 0 1 1 
 
IL10 -1082G>A      
 GG 62 51 3 1 7 
 GA 128 100 15 6 7 
 AA 103 61 18 10 14 
 
TNF -308 G>A      
 GG 221 153 29 17 22 
 GA 67 55 6 0 6 
 AA 6 5 1 0 28 
 
PAI-1-765 4G/5G      
 5G/5G 80 52 22 1 5 
 5G/4G 139 102 12 7 18 
 4G/4G 72 57 1 9 5 
Table 5-4 Distribution of possible confounding polymorphisms according to 
ethnicity
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5.9.2 Complement activation components as a risk factor for SIRS 
Table 5-5 shows the univariate analysis for the different complement activation 
candidate genes in relation to early SIRS. Given the cohort size, prevalence of SIRS 
and minor allele frequencies, this study was powered  >80% at an  of 0.05 to detect 
an Odds Ratio ≥ 2 at allele level in all but the CFB candidate gene and at the 
dichotomy variant/wildtype for the MBL genotypes. 
The CFH Y402H polymorphism was associated with a significant lower incidence of 
SIRS. Figure 5-2shows the analysis in recessive mode (CC vs. CT/TT genotypes): OR 
0.4 (95% CI 0.2 -0.8, P = 0.006. 
After binary logistic regression analysis this was shown to be independent of other 
covariates (demographic characteristics, severity of illness, diagnosis group and 
polymorphisms in both the complement pathway and other components of the innate 
immune system): adjusted OR 0.3, 95% CI 0.1-0.7, P = 0.005 (Table 5-6). 
Structural variant haplotypes in MBL-2 were seen in 34% (103/299) of children. 
LYPB and HYPD were the most common variant haplotypes in patients of Caucasian 
and Asian descent. Children of African descent carrying structural MBL-2 gene 
defects showed a preponderance of LYQC carriers. Low MBL promoter variants X 
and/or L were less common; 8.7% (26/299) individuals carried combinations with 
both LXPA and/or LYPA. 
Children who carried variant MBL-2 haplotypes showed an increased risk for 
developing early SIRS (Figure 5-3): Unadjusted Odds Ratio 2.0, 95% Confidence 
Interval 1.1-3.4; P = 0.016). 
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Table 5-5 Univariate analysis for the complement candidate genes in relation to 
SIRS 
a
Pearson chi square; 
b
recessive; 
c
dominant 
  
Gene Name Genotype Non-SIRS SIRS OR (95% CI) P value
a 
CFH Y402H TT 23 89 0.4 (0.2-0.8) 0.006
b 
  TC 31 95   
  CC 18 24   
 
MBL-2  Wildtype 51 114 2.0 (1.1-3.4) 0.016c 
  Variant 24 105   
 
CFB L9H TT 69 204 0.8 (0.3-2.1) 0.6
c 
  TA 6 13   
  AA 0 1   
 
CFB R32Q CC 60 174 2.1 (0.5-9.5) 0.3
b 
  CT 11 31 1.1 (0.6-2.3) 0.7
c 
  TT 2 12   
 
C1qA Gly70GGA GG 18 55 1.1 (0.6-1.9) 0.9
b 
  GA 36 99   
  AA 21 63   
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Figure 5-2 Risk for SIRS according to CFH Y402H genotype 
The percentage of children developing SIRS according to Complement Factor H 
genotype. Univariate analysis in recessive heritability mode, P value is derived from 
2 test. 
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Risk factor Univariate analysis Binary logistic regression 
analysis
a 
CFH CC variant 0.4 (0.2-0.8) P=0.006 0.3 (0.1 - 0.7) P= 0.005 
MBL-2 variant 2.0 (1.1-3.4) P=0.016 2.5 (1.3 - 5.0) P= 0.008 
Infection
b 
 8.3 (3.0 - 24) P< 0.0005 
Table 5-6 Risk factor analysis for the development of early SIRS/sepsis  
a
Adjusted for sex, age (logged), ethnicity, risk of mortality (PIM), primary diagnosis 
(elective postoperative, infection, trauma, other), MBL-2, CFH, C1qA, CFB, IL6, 
IL10, TNF and PAI-1 polymorphisms. bVersus elective postoperative. Results are 
shown as Odds Ratios with 95% confidence interval and P value. Only the covariates 
with a P value < 0.01 in the final analysis are shown. (cohort n=299) 
  
 269 
  
Figure 5-3 Risk factor for SIRS according to MBL2 genotype 
Comparison of early SIRS development between the two MBL-2 genotype categories. 
Variant genotypes include both structural gene variants as well as promoter variants. 
Univariate analysis, P value is derived from 2 test. 
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This risk increased and was significant after correction for demographic 
characteristics, severity of illness, diagnosis group and polymorphisms in both the 
complement pathway and other components of the innate immune system (adjusted 
OR 2.5, 95% CI 1.3-5.0, P = 0.008, Table 5-6). 
 
In this cohort of critically ill children the odds for developing systemic inflammation 
were, at least in part, dependent on CFH and MBL-2 genotype.  
This association remained after controlling for admission reason (infectious or non-
infectious). In other words, children admitted with an infectious insult were more 
likely to develop sepsis if they carried genotypes that are associated with reduced 
Complement activation potential and children admitted with a non-infectious insult 
were more likely to develop SIRS if they carried genotypes associated with reduced 
complement activation potential. 
 
5.9.3 Sepsis and sterile SIRS may be differentially modulated 
A priori the sample size prohibits quantifying effect size in the sub groups “Non-
infection” and “Infection” separately with adequate statistical power. Nonetheless, to 
better understand the underlying pathophysiology this analysis was performed. The 
results suggest that the effect size for the two genotypes is larger for those children 
admitted with infection (Table 5-7). 
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 Non-infection Infection 
 OR (95% CI) P value OR (95% CI) P value 
MBL-2 variants 
 Univariate 
 Adjusted
a
 
 
1.8 (0.9-3.6) 
1.9 (0.7-5.1) 
 
0.11 
0.18 
 
2.4 (0.9-6.1) 
3.3 (0.9-12) 
 
0.07 
0.06 
CFH CC variant 
 Univariate 
 Adjusted
a
 
 
0.7 (0.2-1.4) 
0.3 (0.1-1.2) 
 
0.23 
0.11 
 
0.2 (0.1-0.7) 
0.12 (0.02-0.6) 
 
0.004 
0.01 
Table 5-7 Risk factor analysis for the development of early SIRS/sepsis 
according to admitting diagnosis 
Non-infection n=141 Infection n=158. OR= Odds Ratios for SIRS with 95% CI. P 
values derived from Pearson 2 analysis or logistic regression analysis. aAdjusted for 
sex, age (logged), ethnicity, risk of mortality (PIM), MBL-2, CFH, C1qA, CFB, IL6, 
IL10, TNF and PAI-1 polymorphisms. 
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5.9.4 Overall complement activation capacity and risk of SIRS 
When CFH and MBL-2 genotypes were combined to provide a crude measure of 
complement activation potential, a stepwise increase became apparent in the risk of 
SIRS in those genotypes with increasingly lower complement activation potential 
(Figure 5-4). 
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Figure 5-4 Risk for SIRS according to complement activation potential 
Combination of MBL-2 and CFH genotypes show an increase in the risk of SIRS 
according to potential of complement activation. “Very high”: MBL-2 HYPA/HYPA 
and CFH CC, “high” MBL-2 HYPA/LYQA or LYQA/LYQA or HYPA/LXPA or 
HYPA/LYPA or LYQA/LYPA or LYQA/LXPA plus CFH CC, “very low” MBL-2 
homozygous or compound heterozygous variant (O/O) and CFH TT, “interm” 
(intermediate) all other genotypes. P value is derived from 2 test. 
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5.9.5 CFB, C1qA and potential confounding polymorphisms 
Neither CFB nor C1qA SNPs showed any influence on the occurrence of SIRS (Table 
5-5). Although TNF and PAI-1 variant carriers trended toward less SIRS in 
univariate analysis, in the final binary logistic analysis there was no influence of the 
potentially confounding polymorphisms in TNF, IL6, IL10 and PAI-1 on the 
occurrence of SIRS (see Table 5-8).
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Gene Promoter 
SNP 
Genotype Non-SIRS SIRS OR (95%CI) P value
a 
Adjusted 
OR (95% CI)
b 
Adjusted P value 
TNF  -308G>A GG 50 171 0.6 (0.3-1.0)
c 
0.05 0.5 (0.2-1.0)
c
 0.06 
  GA 23 44     
  AA 2 4     
         
IL6  -174G>C GG  37 124  0.5   
  GC 30 74   0.7 (0.3-1.5)
d
 0.4 
  CC 6 20   0.9 (0.3-3.3)
d
 0.9 
         
IL10  -1082G>A GG 18 44  0.7 1.3 (0.5-2.9)d 0.6 
  GA 31 97   0.9 (0.4-2.1)
d
 0.7 
  AA 25 78     
         
PAI-1 -765 4G/5G 5G/5G 17 63 0.6 (0.3-1.0)
e 
0.05 1.0 (0.5-2.1)
e
 0.9 
  5G/4G 33 106 0.9 (0.4-1.7)
d
 0.7 1.1 (0.5-2.6)
d
 0.8 
  4G/4G 25 47 0.5 (0.2-1.0)
d
 0.07 1.1 (0.4-2.9)
d
 0.8 
Table 5-8 Analysis possible confounding polymorphisms in relation to SIRS 
a
Pearson 2 test; bBinary logistic regression analysis; Adjusted for sex, age (logged), ethnicity, risk of mortality (PIM), primary diagnosis, 
(elective postoperative, infection, trauma, other), MBL-2, CFH, C1qA, CFB, IL6, IL10, TNF and PAI-1 polymorphisms. cDominant mode;. dvs. 
wildtype;
 e
Recessive mode
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Binary logistic analysis showed that the final model, incorporating sex, age (logged), 
ethnicity, risk of mortality (PIM), primary diagnosis (elective postoperative, infection, 
trauma, other), MBL-2, CFH, C1qA, CFB, IL6, IL10, TNF and PAI-1 
polymorphisms explained 29% of the variance in SIRS/sepsis (r
2 
Nagelkerke = 0.29), 
whereas the clinical characteristics alone explained only 22% (r
2 
Nagelkerke = 0.22). 
This implies that some of the inherited variability in critical illness phenotype may be 
explained by genetic variability in complement activation. It also implies that further 
elucidating in the understanding of paediatric SIRS remains. 
 
5.10 Discussion  
These data show that polymorphisms in genes involved in the complement cascade 
are associated with the likelihood of developing early SIRS/sepsis in children 
admitted to intensive care. Homozygous CFH Y402H variant allele carriers were 3 
times less likely to develop early SIRS compared with wildtype, whereas MBL-2 
variant genotypes conferred a two-fold increased risk of developing early SIRS. 
Importantly, this remained so after correcting for severity and type of illness, 
demographical characteristics and other polymorphisms in the innate immune system. 
Thus, it seems that genotypes that predispose to less complement activation are 
associated with an increased risk of SIRS/sepsis in the early part of intensive care 
stay. 
This study did not address causality, in that no mechanistic experiments were 
performed. Nonetheless, the premise that the polymorphisms that were studied here 
indeed have altered function is supported by work that others have performed. In vivo 
data in septic patients showed that MBL deficient patients indeed had lower plasma 
MBL levels than did wildtype (Dean, Minchinton et al. 2005) and CFH polymorphic 
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patients showed higher complement activation than did wildtype (Scholl, Charbel Issa 
et al. 2008), which may have contributed to an altered likelihood to develop 
SIRS/sepsis. Interestingly, the Y402H CFH polymorphism has recently been 
identified as protective in group A streptococcal infections. This was postulated to be 
due to reduced binding affinity of group A streptococcus to CFH, thus precluding 
optimal intravascular bacterial growth. (Haapasalo, Jarva et al. 2008, Haapasalo, 
Vuopio et al. 2012) 
The alternative pathway maintains a continuous low level of complement activation. 
This “ticking over process” is attenuated by CFH. Therefore, a polymorphism in this 
protein that leads to less inhibition of this pathway, could allow for the complement 
cascade to respond more vigorously when provoked. The finding that the CFH 
Y402H variant genotype CC exerts a strongly protective influence on the occurrence 
of early SIRS/sepsis is biologically interesting. The resultant amino acid change is 
thought to lead to a change in ligand binding properties and hence a reduced 
functionality in homozygous (CC) individuals especially (Schmidt, Herbert et al. 
2008). Presumably, the reduced complement inhibitory properties would then lead to 
increased complement activation. This can be detrimental as seen in the chronic 
inflammatory eye disease AMD (Klein, Zeiss et al. 2005), where the tissue is 
chronically exposed to high complement activity. High complement activity, i.e. a 
vigorous containing and killing capacity could however be beneficial in the acute 
phase of critical illness. Early neutralisation of the offending agent might prevent 
downstream signaling and resultant SIRS/sepsis. Indeed, the promoter polymorphism 
CFH C-496T CC genotype, which is associated with increased CFH levels (and hence 
reduced complement activation potential) has been associated with a predisposition to 
meningococcal disease in children.(Haralambous, Dolly et al. 2006) 
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Similarly, low MBL levels are associated with less complement activation. This study 
confirms the previous observations of increased risk for SIRS/sepsis with 
polymorphisms associated with reduced MBL levels (Fidler, Wilson et al. 2004). The 
current study expanded the MBL genotyping to the full haplotype in a larger cohort.  
 
Classification of MBL-2 variants on the basis of the full promoter genotype can be 
problematic. The homozygous and heterozygous structural gene MBL-2 
polymorphisms D, B and C (denoted OO for compound heterozygotes/homozygotes 
and AO for heterozygotes) are invariably designated variant. However, other 
genotypes are also associated with low resting MBL levels, at least in healthy adults. 
These include the LXPA/LXPA, LYPA/LYPA and LXPA/LYPA. Median serum 
MBL levels associated with the LYPA/LYPA and LYPA/LYQA genotypes have been 
reported to be low compared with the LYQA/LYQA genotype. (Madsen, Satz et al. 
1998) Subjects with the LXPA/LXPA genotype had even lower serum 
levels.(Madsen, Garred et al. 1995) Thus MBL deficiency is a complex defined by 
absolute levels, type of exon 1 variant and promoter capacity to increase levels.  
This study shows an increased risk for SIRS/sepsis with MBL-2  genotypes associated 
with a reduced capacity to respond, either due to constitutively low MBL levels or the 
reduced ability to increase levels. Arguably, in the context of an infectious or 
inflammatory challenge, it is not merely the resting MBL levels that are important but 
the capacity to increase levels when needed. This may explain the high levels of MBL 
seen in adults (but not children) with Cystic Fibrosis and high producing MBL-2 
genotypes (Davies, Turner et al. 2004). It was postulated then that this could be 
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related to patients with these genotypes being able to respond to the infectious and 
inflammatory stimuli seen in patients with advanced disease. 
 
The precise interplay between these polymorphic genes is unknown, let alone how 
this affects patients with combinations of polymorphisms in the complement cascade. 
A crude categorization of complement activation potential by combining of the CFH 
and MBL-2 polymorphisms showed a direct relationship between high complement 
activation potential and the development of SIRS/sepsis in the early phase of critical 
illness. This would be consistent with the view that many cases of SIRS/sepsis result 
from the host failing to contain an infectious or inflammatory challenge at the earliest 
possible opportunity.  Vigorous and early mobilisation of the complement system 
could help to control the infectious or inflammatory insult before initiating or 
propagating harmful downstream events manifested clinically as SIRS/sepsis.  As 
such, SIRS/sepsis as a sequela of genetic polymorphism in the complement activation 
system may be an example of extreme sensitivity to initial conditions, a central 
property of complex systems such as the systemic inflammatory response (Seely and 
Christou 2000). Specifically, the physiological correlate for sepsis in this scenario 
might be that complement activity determines if an inoculum of bacteria are rapidly 
killed or whether some escape to enter a phase of logarithmic growth necessitating a 
more widespread inflammatory response. 
 
5.11 Limitations 
There are several limitations to this study. 
A consequence of the open cohort study design is that data from a subset of this 
cohort has been analysed previously when investigating related questions (Fidler, 
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Wilson et al. 2004) (Stephens, Fidler et al. 2006, Plunkett, Agbeko et al. 2008) 
(Agbeko, Holloway et al. 2010). This limitation is compounded by the absence of an 
independent validation cohort. For these results to be robust the current findings need 
to be corroborated in an independent well-powered cohort.  
The study was underpowered to assess the influence of one candidate gene in 
recessive analysis (CFB) and one possible confounder (TNFA). Thus it may not have 
been able to detect a CFB R32Q modifying effect due to the small number of children 
who were homozygous for the variant allele (Richardson, Islam et al. 2009). Also, 
new data on AMD shows that the CFB L9H polymorphism may not modify risk after 
all.(McKay, Silvestri et al. 2009, Richardson, Islam et al. 2009) 
Thus false negative results may have occured. In contrast, it is less likely to have 
generated false positive results because of the observed tight confidence intervals and 
stringent adjustment for multiple testing. 
Further, bias due to an ethnically mixed cohort and therefore different prevalence 
rates of polymorphisms may have influenced the study. From a purist point of view 
genetic association studies require an ethnically homogeneous population. This was 
not possible given the geographical location of the investigation (a large urban 
quaternary centre) Therefore ethnicity was part of the final regression analysis.   
Last, SIRS as an outcome measure to assess the acute inflammatory response is an 
imprecise metric; clinical parameters are age dependent and sensitive to external 
manipulation. Other, more precise, surrogate markers would be useful, but are 
currently not available. 
GOSH admitted 2611 children to the units in May 05-Dec 06.(PICANet, 2007) Most 
did not meet the inclusion criteria, some were missed or refused consent, which might 
elicit concern re generalizability. Currently there is no means to quantify this. 
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5.12 Conclusions 
Despite these limitations this study shows that polymorphisms in the CFH gene may 
modulate the acute inflammatory response and corroborated the previously reported 
finding that MBL-2 variant genotypes are a risk factor for the early occurrence of 
SIRS/sepsis in a large cohort of paediatric critical care patients independent of other 
potentially important functional polymorphisms in the complement and innate 
immunity system. A better understanding of how these polymorphisms operate at the 
pathophysiological level is needed before these findings can be translated to clinically 
useful therapeutic modalities. 
In summary, this study demonstrates that genetic polymorphisms associated with 
reduced complement activation may be associated with early SIRS/sepsis. This is 
consistent with a view that appropriate complement activation occurring early 
following an infectious or inflammatory insult protects children from early 
SIRS/sepsis. 
 
5.13 Future work 
Rather than concentrate on blocking what is thought to be a harmful excessive 
inflammatory response the focus needs to shift to increasing early activation. 
This flies in the face of current paradigms and thus requires data for the paradigm 
shift to happen. Corroboration for this position is found not only in the many 
disappointing interventional clinical trials in sepsis, but also from recent evidence that 
showed an inverse relationship between severity of illness and c5a levels at 
presentation to the emergency department with severe sepsis.(Younger, Bracho et al. 
2010) 
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The same principle was demonstrated on a more global level in a study evaluating 
fever in the early stages of sepsis.(Young, Saxena et al. 2012) 
Potential avenues are: 
Observational cohort studies in paediatric sepsis/SIRS analysing CFH and MBL2 
genotype and early plasma complement activation levels. 
Ex vivo models to elucidate the underlying mechanisms of CFH in paediatric sepsis. 
Interventional trial to inhibit CFH or increase c5a at an early stage of injury/infection. 
Interventional trial in paediatric sepsis to withhold anti-inflammatory agents vs. usual 
practice. 
  
 283 
Chapter 6 Mannose binding lectin in health and critical 
illness 
6.1 Introduction 
Mannose binding lectin (MBL) is a circulating serum protein, synthesized in the liver 
with a key role in innate immunity. 
The protein is phylogenetically old, estimated to have been around for five hundred 
and fifty million years, when innate immunity was developing in early 
invertebrates.(Flajnik 1998) It is found in mammals and birds alike. Two different 
MBL proteins, i.e. MBL A and MBL C, are found in many mammals, but only one 
type is found in humans. (Holmskov, Malhotra et al. 1994) MBL1 is a pseudogene, 
assumed to have become defunct during evolution. MBL2 encodes for the human 
equivalent of MBL C. 
Mannose binding lectin belongs to the collectin family of proteins. This 
categorization is based on the underlying structure of collagenous and C-type 
carbohydrate recognizing domains (CRD) lectin subunits. Other collectins are 
Surfactant Protein A and Surfactant Protein D. All three proteins are engaged in the 
first line of host defence. 
Collectins bind to highly conserved carbohydrate patterns on many microbes: viruses, 
bacteria, fungi and protozoa and prepare these organisms for phagocytosis 
(opsonization).(Turner and Hamvas 2000) Additionally, they activate complement 
pathways. The ficolins, L-ficolin, M-ficolin, H-ficolin are similar to collectins but 
they have different structures with a fibrinogen-like domain. Both MBL and the 
ficolins initiate the lectin pathway of complement activation via associated serine 
proteases (MASPs).(Holmskov, Thiel et al. 2003) On electron microscopy the MBL 
structure has a bouquet like  structure, similar to complement factor c1q.(Lu 1997)  
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MBL is central to many innate immune function processes, including complement 
activation (Ohta, Okada et al. 1990), enhancing complement-independent 
opsophagocytosis (Tenner, Robinson et al. 1995), modulation of cytokine production 
(Jack, Read et al. 2001, Fraser, Bohlson et al. 2006), recognition and clearance of 
apoptosed or altered host cells (Stuart, Henson et al. 2006). 
The liver is the main organ that synthesises MBL, although extra-hepatic derived 
MBL production might be relevant to local host response in the small 
intestine.(Seyfarth, Garred et al. 2006) MBL is configured as oligomers of two or 
more subunits, each of which consists of three polypeptides coiled around each other.  
(Holmskov, Thiel et al. 2003) Serum contains MBL multimeres up to octamers, but 
mostly trimers and tetramers.(Lipscombe, Sumiya et al. 1995) 
MBL serum levels in humans are modulated by genetic factors (Madsen, Garred et al. 
1995) and inflammatory state (Ezekowitz, Day et al. 1988). Upstream from exon 1 
there are two transcription start sites, both of which have IL6 and glucocorticoid 
responsive elements.(Heitzeneder, Seidel et al. 2012) 
There exist polymorphisms in exon 1 that change the collagen like structure of MBL 
such that they preclude higher order oligomerisation (polymorphisms B and C) or 
change the number of cysteines in the collagen like structure, such that 
oligomerisation is not needed to attain a stable molecule (polymorphism D). (Jensen, 
Weilguny et al. 2005) This reduced oligomerisation, in turn, reduces serum MBL 
levels. (Lipscombe, Sumiya et al. 1995) Individuals homozygous for MBL structural 
defects have near absent MBL serum levels.(Lipscombe, Sumiya et al. 
1992)Heterozygosity is characterized by protein levels which, on average, are 
approximately 1/8 normal.  This may be explained by the fact that heterozygous 
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individuals have only a 1 in 8 probability of assembling three normal peptide chains 
during MBL biosynthesis.(Turner 1998) 
In addition to polymorphisms that lead to structural defects, promoter polymorphisms 
modulate the capacity to increase serum levels on provocation.(Madsen, Garred et al. 
1995) 
However, these polymorphisms do not explain all variation in MBL levels. 
MBL deficiency is common, dependent on the population studied, MBL deficiency 
occurs in 20% to 80% of the population.(Garred, Larsen et al. 2006) The clinical 
importance of MBL deficiency has been established in young children who show an 
increased susceptibility to infections.(Super, Thiel et al. 1989) Other associations 
remain more disputed, but many report that vulnerable populations, such as infants or 
immuno-compromised children and adults are at greater risk of developing 
infections.(Eisen and Minchinton 2003) 
Conversely, one might ask the question: “why does such a high prevalence of MBL 
deficiency exist?” Two not necessarily mutually exclusive propositions are i) a 
protective effect on collateral damage from complement activation to the host in 
inflammatory processes(Lipscombe, Sumiya et al. 1992) and ii) a protective effect 
against parasites that infect the host by means of C3 mediated opsonisation and 
intracellular uptake (e.g. Leishmania and mycobacteria) (Garred, Harboe et al. 1994).   
6.2 Modulation of serum MBL levels 
6.2.1 MBL2 genotype  
 
The relationship between serum MBL levels and MBL-2 genotype is complex and 
depends in part on exon 1 polymorphisms and promoter polymorphisms. 
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6.2.1.1 Structure of MBL2 
The MBL2 gene structure is given in Figure 1-9. 
MBL2 is located on the long arm of chromosome 10 (10q11.2-q21). (Sastry, Herman 
et al. 1989) The protein encoding area is made up of four exons. (Taylor, Brickell et 
al. 1989) Exon 1 encodes the signal peptide, a cysteine rich domain, as well as part of 
the glycine-rich collagenous region (seven Gly-Xaa-Yaa repeats). Exon 2 encodes the 
rest of the glycine-rich collagenous region (twelve Gly-Xaa-Yaa repeats), which 
conforms to a triple helix structure. Exon 3 encodes the so-called neck region, and 
exon 4 encodes the carbohydrate-binding domain, that configures into a globular 
arrangement. (Sastry, Herman et al. 1989, Taylor, Brickell et al. 1989) 
The carbohydrate-binding domain is the pattern recognition area of the protein. It 
recognizes microbial as well as endogenous ligands. Upstream from the protein 
encoding exons lies the promoter part of the gene, which affects transcription of the 
protein.(Madsen, Garred et al. 1995) 
6.2.1.2 Polymorphisms in the MBL2 gene and promoter region 
 
The first identified polymorphism in exon 1 that underlies MBL deficiency is located 
at codon 54. The wildtype nucleotide GGC sequence is changed to GAC, which then 
results in a change in translation from Glycine to Aspartic acid.(Sumiya, Super et al. 
1991) This is the most prevalent defect in people of European and Asian descent and 
is denoted “B”, (rs1800450). 
The next polymorphism to be identified was the Glycine to Glutamic acid change at 
codon 57 because of a nucleotide change GGA to GAA. This defect is most 
prominent in populations of Sub-Saharan African descent and is denoted “C” 
(rs1800451). 
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Finally, a change in nucleotide at codon 52, changing the sequence from CGT to TGT 
results in an amino acid change Arginine to Cysteine.(Madsen, Garred et al. 1994) 
This variant is named “D” (rs5030737). Collectively the variant types are denoted 
“O” in differentiation to wildtype “A”. 
The functional change in variants B and C are thought to be due to impaired 
oligomerisation. The B variant causes a disruption of the fifth Gly-Xaa-Yaa repeat in 
the collagen like domain, which may prevent formation of the triple helix (Sumiya, 
Super et al. 1991) and stable higher order oligomers (Garred, Larsen et al. 2003). The 
variant lower order oligomers show reduced binding capacity (Garred, Larsen et al. 
2003) and impaired complement activation (Super, Gillies et al. 1992). The functional 
effect of the C variant is analogous to that of the B variant. (Lipscombe, Sumiya et al. 
1992) 
The D variant is somewhat different in that plasma levels are found to be higher than 
B and C deficient genotypes. This is mainly thought to be due to D variant protein to 
form stable, if dysfunctional, higher oligomers with wildtype protein.(Garred, Larsen 
et al. 2003) 
In addition to these structural variants, there are three promoter variants that 
independently influence circulating MBL levels. They are located at positions -550 
(H/L) with a G to C nucleotide substitution (rs11003125); -221 (X/Y) with a C to G 
nucleotide substitution, (rs7096206) and at  +4 from the start of transcription the 
(P/Q) C to T nucleotide substitution, (rs7095891). The X/Y polymorphism exerts the 
greatest influence on plasma MBL levels. 
Due to strong linkage disequilibrium only eight common haplotypes are found in the 
population. These haplotypes are associated with varying amount of circulating 
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MBL.(Madsen, Garred et al. 1995) Concentrations of MBL vary 1000 fold between 
the lowest deficient O/O and highest HYPA/HYPA genotypes. 
Although these genetic variants explain much of MBL serum levels, they do not 
explain all. Notably, within wildtype genotype groups there still are log differences in 
MBL serum level.(Madsen, Garred et al. 1995) 
6.2.2 Non genetic modulation of MBL serum levels 
 
In addition to genetic effects, age (Thiel, Bjerke et al. 1995), inflammatory state 
(Ezekowitz, Day et al. 1988, Thiel, Holmskov et al. 1992) and hormonal regulation 
(Sorensen, Hansen et al. 2006) are known to influence MBL serum level. 
6.2.2.1 MBL may be an acute phase protein 
 
The capacity of the host to respond to MBL associated ligands is thus determined by 
the structure of the molecule but also by the capacity of the liver to increase levels in 
response to gene activation. The promoter polymorphisms (H/L, P/Q and X/Y) may 
thus be of additional importance in the host response to inflammatory threat, over and 
above constituent MBL serum levels as defined by the structural genotypes A, B, C or 
D. 
The literature gives conflicting results regarding the extent to which MBL functions 
as an acute phase protein. Initial studies showed elements in the transcription region 
that classically would be regarded as acute phase reactants, such as IL6 and 
glucocorticoid responsive regions. (Ezekowitz, Day et al. 1988) Later studies in 
critically ill adults are less convincing. In a cohort of adults undergoing major 
abdominal surgery there was a robust early response in IL6 and CRP, but not in MBL. 
MBL levels actually reduced significantly, albeit modestly (17%) in the first 48 hours, 
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and then increased back to baseline between day 8 and 30 postoperatively (Ytting, 
Christensen et al. 2006) Patients undergoing major orthopaedic surgery did show a 
1.5-3 fold increase in MBL serum levels between day 1 and 3 postoperatively.(Thiel, 
Holmskov et al. 1992) This contrasts with another preoperative study in adults 
undergoing oesophageal adenocarcinoma resection. This study showed that MBL rose 
4 fold compared to baseline between day 5 and day 10 postoperatively.(Van Till, 
Boermeester et al. 2006) 
In a more recent description of MBL levels in acute pancreatitis, a disease that 
induces severe SIRS, the authors showed only a slight increase in MBL serum levels 
by day 2 but no association with severity of illness or multi organ dysfunction. 
(Novovic, Andersen et al. 2011) 
The data on the acute phase response to severe infection are similar. For instance, in a 
Spanish cohort of adults with community acquired pneumococcal pneumonia there 
was no difference in MBL levels in the acute phase (within 48 hours of admission) 
compared to recovery (at least 4 weeks after resolution). (Perez-Castellano, Penaranda 
et al. 2006) 
These studies adjusted MBL levels for the structural but not the promoter 
polymorphisms. This may underestimate the true variability in MBL concentration in 
terms of both baseline and capacity to change MBL concentration. 
The two studies that did take into account promoter polymorphisms actually did show 
a modified acute phase response of MBL in exon 1 wildtype genotypes. These were 
the X/Y polymorphism in adult community acquired pneumonia (Herpers, Endeman 
et al. 2009) and the HY polymorphisms in febrile neutropenia in children (Frakking, 
van de Wetering et al. 2006). (Herpers, Endeman et al. 2009) defined acute phase 
response as a change of 25% in serum value on day 1 of illness. Interestingly, only the 
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haplotype YA/YA showed a significant correlation with CRP levels, suggesting this 
to be the most responsive MBL haplotype in the early phase of acute pneumonia. 
 
6.2.2.2 MBL serum levels differ in age groups 
 
At birth, MBL serum levels are on average 37% of MBL serum levels at 3 months of 
age, which reflects that of the adult population.(Thiel, Bjerke et al. 1995) These lower 
levels of MBL in newborns were replicated in several larger studies (Kilpatrick, 
Liston et al. 1996), including one cohort of 1800 newborns (Swierzko, Szala et al. 
2009). Several studies report even further reduced MBL serum levels in premature 
infants in comparison to term babies(Lau, Chan et al. 1995, Sallenbach, Thiel et al. 
2011) although this is not universal (Swierzko, Szala et al. 2009). These lower levels 
may contribute to some of the vulnerability to infections in this age group. MBL 
deficiency as defined by means of MBL levels has been shown to be a risk factor for 
sepsis in newborns, but MBL2 polymorphisms were not found to be a risk factor in a 
recent systematic analysis.(Israels, Frakking et al. 2010) 
 
6.2.2.3 Hormonal regulation of MBL levels 
 
Hepatocytes exposed to thyroid hormone and growth hormone increased MBL 
secretion at least three fold. Thyroid hormone was more potent than growth hormone. 
Interestingly, IL6 caused very little increase in MBL production.(Sorensen, Hansen et 
al. 2006)In critically ill adults MBL serum levels were weakly correlated with serum 
T3 levels but not with outcome.(Koenig, Potlukova et al. 2012) 
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6.2.2.4 Measurement of serum MBL 
 
Last, the method by which MBL serum levels are measured is of importance. The 
amount of measured deficient MBL protein varies dependent on method. However, 
when applying a cut off of 500 ng/ml for MBL deficiency, these differences are of no 
consequence. (Frederiksen, Thiel et al. 2006) 
 
6.3 MBL2 genotype, MBL serum levels and systemic inflammation 
 
There are few data on the genetic and serum level interplay in paediatric sepsis/SIRS. 
Most studies on susceptibility to, or severity of, inflammatory disease have focussed 
on either MBL levels or MBL2 genotype rather than both.  
MBL levels and MBL2 polymorphisms in paediatric sepsis and SIRS are not 
interchangeable. Children with MBL2 polymorphisms were at higher risk of 
developing systemic inflammation in the presence or absence of infection. However, 
these children did not consistently show MBL deficiency as defined by MBL serum 
levels. (Fidler, Wilson et al. 2004) The study was limited to the structural gene and 
XY promoter polymorphism, thus precluding more detailed analysis on the 
association of promoter polymorphisms, the acute phase response and MBL levels.  
Thus, it is unknown whether the nuances in full haplotype are of relevance in 
assessing the host capacity to respond, or whether it suffices to assess the partial 
genotype based on exon 1 polymorphisms and the (X/Y) promoter polymorphism. 
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6.4 Role of MBL in paediatric critical illness 
The Systemic Inflammatory Response Syndrome (SIRS) is integral to much of 
paediatric critical care related morbidity and mortality. (Tantalean, Leon et al. 2003, 
Proulx, Joyal et al. 2009) Host factors have been implicated in the variability of 
individual responses to insults of similar severity. MBL2 genotype and MBL serum 
levels may contribute to this variability. MBL2 deficient genotypes in adults 
predisposed to severe sepsis and septic shock and low serum MBL levels were 
associated with worse outcome.(Gordon, Waheed et al. 2006) This chapter examines 
the contribution of MBL variability to the host response after a severe insult and the 
susceptibility of children to be admitted to PICU with severe infection. MBL serum 
levels in critically ill children may be determined by genetically defined factors and 
by the capacity to counteract presumed consumption. 
The three exonal and three promoter polymorphisms as well as serum MBL levels 
were determined in a cohort of healthy children and a cohort of children admitted to 
PICU. 
6.5 Aims 
 
1. To establish if full genotyping for MBL2 is superior to partial genotyping in 
predicting low serum MBL levels in children admitted to the paediatric intensive care 
unit. 
 
2. To determine if MBL levels in the acute phase response are higher than in health. 
 
3. To ascertain if MBL genotypes associated with MBL deficiency predispose to 
PICU admission with infection. 
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4. To establish if MBL serum levels are higher in children admitted to PICU without 
SIRS than those developing SIRS. 
 
6.6 Methods 
6.6.1 Summary of sample handling in the PICU cohort 
 
Serum levels were taken within a 48-hour time frame from admission, immediately 
spun and frozen -80C until analysis. Samples 1-147 had been freeze-thawed twice 
before the current analysis. All other samples had not been freeze-thawed. 
Two samples were taken as control for validation of high and low levels as well as 
process consistency. All measurements were performed in duplicate. 
6.6.2 MBL ELISA process 
 
MBL levels in subject sera were determined by a symmetrical sandwich ELISA kit 
(Bioporto Diagnostics, Denmark) according to the manufacturer’s instructions.  The 
MBL ELISA works according to the following principle: A monoclonal antibody 
against the carbohydrate recognition domain of MBL is coated on microwell plates. 
Serum is added to the microwell. Biotin labelled antibody detects bound MBL, 
incubation with added horseradish peroxidase (HRP) conjugated to streptavidin 
induces a colour change.  Serum was defrosted and diluted 1:10, 1:100 or 1:200 
dependent on the expected value from the known genotype. Samples were 
immediately processed and read within 5 minutes after the stop solution had been 
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added.  This kit was chosen because of its widespread use in clinical cohort studies, 
thus allowing for reliable inter research group comparisons of MBL levels. 
6.6.3 ELISA validation 
 
The kit supplies MBL standards for each ELISA plate. A calibration curve was fitted 
by plotting the mean of the duplicate optical densities (OD) values for each MBL 
standard on the y axis and the corresponding MBL concentrations in ng/ml on the x 
axis. All samples were assayed in duplicate. 
The MBL concentration in the specimen was then calculated by multiplying the 
obtained mean OD by the dilution factor and referencing to the calibration curve. 
Results were taken to be valid if all of the following occurred: 
1. a calibration curve within the specifications of the manufacturer 
2. coefficient of variation between duplicate samples of <10% (standard 
deviation of the replicate response X 100/mean of the response) 
3. adequate interplate variation, i.e. if the high, medium and low standard 
samples were within 10% of their expected value 
6.6.4 MBL genotypes and serum levels in healthy control subjects 
 
MBL full genotypes and serum concentrations were available from a large cohort of 
healthy British Caucasian children previously studied. (Johnson 2007) 
This cohort of children was recruited from the Avon Longitudinal Study of Parents 
and Children (ALSPAC).  
Serum MBL levels in the PICU cohort had been analysed for n=137 patients in 2006 
(Fidler 2007).  The same ELISA method as described above was used in both 
historical cohorts.  
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6.7 Results 
6.7.1 General Results 
 
A total of 531 full genotype and MBL levels were available from the ALSPAC 
cohort. The original ALSPAC cohort was 661 samples. The assay failed in n=3 and 
genotype was not fully measured in 127 [personal communication M Johnson]. 
Genotype distribution was in Hardy Weinberg Equilibrium and in keeping with 
previously described European cohorts (Madsen, Garred et al. 1995) This cohort had, 
in part, been genotyped for MBL2 before.(Mead, Jack et al. 1997) 
 
The total PICU cohort comprised of 299 patients. Serum samples were not available 
for 24, samples were not attempted in 32, the assay failed in 28, and full genotype 
data was not available for 6.  Thus in the PICU cohort 233 samples were available for 
analysis with full genotype and MBL levels. 
 
The two cohorts did not differ in proportion of deficient genotypes 129/294 vs. 
235/531 (2, p = 0.9). 
 
The two control samples were comparable in measured level at the two dates (2006 
and 2009) and both were representative for a low and high level (Table 6-1). 
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Sample Value 2006 Value 1 2009  Value 2 2009 Mean 2009 
High 3176 3255 2689 2972 
Low 17 34 34 34 
Table 6-1 MBL control samples 
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6.7.2 MBL serum levels are defined by both gene and promoter genotype in the 
acute phase response 
 
MBL serum levels for the PICU cohort are shown in Figure 6-1. AA denotes 
wildtype, AO denotes heterozygote deficient (either B, C or D) and OO denotes 
homozygous or compound heterozygous deficient genotypes. There is an additive, 
significant difference between structural gene polymorphisms AA/AO/OO, (p <.0001, 
Kruskall-Wallis).  
The AA genotype group was further analysed by adding in the XY promoter 
polymorphism. When adding in the main promoter polymorphism X/Y to the 
homozygous AA group there is again a differentiation in MBL serum levels for 
YAYA , XAYA and XAXA genotypes (p <.0001, Kruskall-Wallis) (Figure 6-2). 
The last step was to fully classify MBL2 genotype YAYA with all three promoter 
polymorphisms (Figure 6-3). This does not differentiate any further (p =.38, Kruskall-
Wallis) except maybe for the homozygous LYPA/LYPA genotype that may be 
expected to have intermediate values. However, there are only two patients with this 
genotype, thus warranting cautious interpretation. 
It would have been of interest to be able to attribute some of the variability of MBL 
serum levels to timing between the insult and blood sampling, given that there was a 
potential for this to be between 0 and 48 hours. Unfortunately this information was 
not available. 
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Figure 6-1 MBL serum level split in AO genotype only in the PICU cohort 
 (n=236), Kruskal-Wallis test. 
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Figure 6-2 PICU cohort MBL serum levels divided according to AO and 
promoter XY  
P value derived from Kruskal-Wallis test. 
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Figure 6-3 Full sub division of YAYA genotype by promoter polymorphism 
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The influence of the X/Y polymorphism was also observed in the heterozygote 
population, with the XAO sub group showing half of the YAO subgroup serum levels 
(Figure 6-4) (Mann Whitney, p =.007). 
Further characterisation of the YAO genotypes revealed that the HYPD genotypes 
had significantly higher MBL serum levels than other genotypes (p=.008, Kruskal-
Wallis (Figure 6-5).  This observation is in keeping with previous studies. 
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Figure 6-4 MBL serum levels for AO heterozygotes divided according to XY 
polymorphism 
P value derived from Kruskall-Wallis 
 
 
Figure 6-5 MBL serum levels in YAO genotypes subdivided according to L/H 
and P/Q polymorphisms 
P Value derived from Kruskall-Wallis 
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6.7.3 MBL serum levels in the acute phase response compared with health in 
children 
 
The median MBL serum level in the PICU cohort was 1753 ng/ml (IQR 3152) and 
3155 ng/ml (IQR 3213) in the ALSPAC cohort. Levels in the PICU cohort were 
approximately half that of levels in healthy children. This difference was statistically 
significant (p < .0001, Mann-Whitney test). Levels stratified according to genotypes 
are shown in Table 6-2.  
The intermediate genotypes XAYA, XAXA and YAO show the most difference in 
MBL serum levels between the PICU and ALSPAC cohorts.  
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Genotype PICU ALSPAC P value Absolute 
difference 
Percentage 
difference 
All 1753 3155 <.0001 -1402 -44 
YAYA 3866 4197 0.02 -331 -7.9 
XAYA 2230 3653 <.0001 -1423 -39 
XAXA 1030 2589 .001 -1559 -60 
YAO 498 935 <.0001 -437 -47 
XAO 220 295 NS -75 -25 
OO 64 36 .03 +28 +56 
Table 6-2 MBL median values by genotype for PICU and ALSPAC cohorts 
P values derived from Mann-Whitney test 
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6.7.4 Do MBL genotypes associated with MBL deficiency predispose to a PICU 
admission with infection? 
 
The occurrence of MBL deficient genotypes was not higher in the group that was 
admitted with infection compared with the cohort of healthy children 69/154 (44%) 
vs. 235/531 (44%) (2, p = 0.9). However, overall, MBL serum levels were 
significantly lower in those children admitted to PICU with infection than healthy 
children (median 1384 vs. 3155, p <.0001 Mann Whitney test) Figure 6-6. 
Of note, serum MBL levels were lower in the whole PICU group vs. healthy children 
(Table 6-2). 
This suggests that MBL deficiency is not a risk factor for severe infections in 
children, but MBL consumption might be higher in the infection group. 
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Figure 6-6 MBL levels ALSPAC vs. PICU infection 
P value derived from Mann-Whitney test  
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Children admitted to PICU with non infectious diagnoses had lower MBL levels than 
healthy children, and children admitted to PICU with infection had even lower MBL 
levels (p <.0001, Kruskall Wallis test), Figure 6-7. 
The difference in MBL levels admitted to PICU with infection vs. non-infection 
showed a trend to lower MBL levels in the infection group (p = .09, Mann Whitney), 
Figure 6-8. 
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Figure 6-7 MBL levels in health, infection and sterile insults 
Median MBL levels in ng/ml: ALSPAC 3155 (IQR 885, 4098), PICU non-infection 
2069 (IQR 554, 3896), PICU infection 1384 (IQR 551, 3208). 
 
 
Figure 6-8 MBL levels in infection and non-infection 
P value derived from Mann-Whitney test 
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6.8 MBL serum levels are higher in children admitted to PICU without SIRS 
than those developing SIRS 
The PICU cohort did show lower MBL serum levels for those children who 
developed SIRS compared to those who did not  (median 1480 vs. 2230 ng/ml, p < 
.05, Mann Whitney, Figure 6-9). 
This is mirrored by the increased risk that MBL defient genotypes pose to developing 
early SIRS in PICU. (Table 6-3) 
MBL deficient genotypes predispose to SIRS and those children who developed SIRS 
had lower MBL serum levels. 
Within the infection group there was a trend towards MBL levels being higher in the 
group that did not develop SIRS vs. those who did develop SIRS (sepsis) (Figure 
6-10). 
Children with sepsis had lower serum levels of MBL (median 1250 ng/ml) when 
compared with children with sterile SIRS  (2058 ng/ml), but this did not reach 
significance (Figure 6-11). 
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Figure 6-9 MBL levels SIRS vs. no SIRS 
P value derived from Mann-Whitney test  
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Risk factor Univariate analysis Binary logistic regression analysis
a 
CFH CC variant 0.4 (0.2-0.8) P=0.006 0.3 (0.1 - 0.7) P= 0.005 
MBL-2 variant 2.0 (1.1-3.4) P=0.016 2.5 (1.3 - 5.0) P= 0.008 
Infection
b 
 8.3 (3.0 - 24) P< 0.0005 
Table 6-3 in the PICU cohort Risk factors for early SIRS/sepsis  
a
Adjusted for sex, age (logged), ethnicity, risk of mortality (PIM), primary diagnosis 
(elective postoperative, infection, trauma, other), MBL-2, CFH, C1qA, CFB, IL6, 
IL10, TNF and PAI-1 polymorphisms. bVersus elective postoperative. Results are 
shown as Odds Ratios with 95% confidence interval and P value. Only the covariates 
with a P value < 0.01 in the final analysis are shown. (cohort n=299) 
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Figure 6-10 MBL levels in the infection group SIRS vs. non SIRS 
P value derived from Mann Whitney test 
 
 
 
Figure 6-11 MBL levels sepsis vs. SIRS 
P value derived from Mann Whitney test 
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In univariate analyses the association with MBL serum levels depends on MBL2 
genotype, PICU admission, and development of SIRS.  In a linear regression model 
incorporating clinical relevant parameters, e.g. age, sex, severity of illness (PIM2 
score), development of SIRS, and admission diagnosis with MBL2 genotype showed 
that only MBL2 genotype (standardized coefficient  -0.6; p <0.0001) and infection 
(standardized coefficient  -0.15; p =0.015) were independently associated with MBL 
serum level. 
 
6.9 Summary of results 
This study showed that: 
Extending genotyping beyond the exonal and XY polymorphisms did not yield any 
further discriminatory capacity in terms of MBL serum levels in critically ill children. 
MBL2 genotype distribution in a general PICU cohort was comparable to a cohort of 
healthy children. 
MBL serum levels were lower in critical illness than in the healthy population.  
Children with intermediate MBL2 genotypes showed the greatest difference in serum 
MBL levels in critical illness when compared with healthy children. 
MBL2 deficient genotypes predisposed to SIRS in critically ill children. 
Children admitted to PICU with infection had a similar genotype distribution 
compared to healthy children. 
MBL serum levels in children who developed early SIRS were lower than those who 
did not. 
MBL serum levels were lowest in children admitted to PICU with infection, 
compared to children admitted to PICU for other reasons and highest in healthy 
children. 
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Children with sepsis had lower MBL serum levels than children with localized 
infection. 
Children with sepsis showed similar MBL serum levels compared to children with 
sterile SIRS. 
In multivariate analysis MBL serum levels were independently associated with 
infection and MBL2 genotype. 
 
6.10 Discussion 
The results of this study suggest that MBL is integral to the acute phase response in 
children. Lower serum MBL levels were each associated with critical illness and 
SIRS. Less clear is how MBL levels and MBL2 genotype each define predisposition 
and outcome. 
One way to interpret the current results is that MBL serum levels are a resultant of 
constitutive, genetically defined factors compounded by presumed consumption. 
Insults large enough to warrant PICU admission would induce MBL consumption, 
regardless of baseline levels. Those genotypes, however, least capable of replenishing 
MBL back to baseline would show the highest difference when compared to health. 
Both constituently low as well as an inability to replenish MBL genotypes produce 
MBL levels that predispose to SIRS because the host is incapable to quickly contain 
the insult. 
It may be that containing infection requires more MBL than does scavenging 
endogenous debris resulting from a sterile insult. This might explain why infection 
induces lower MBL levels than do sterile insults. 
Alternatively, in this cohort, the time period between the onset of sterile insult to 
PICU admission and the onset of infection to PICU admission may have been 
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sufficiently different to explain the MBL serum level difference in terms of duration 
of time for MBL to be consumed, rather than type or severity of insult. 
To be able to better understand MBL levels in the context of genotype and insult, 
further studies would require consecutive serum levels from admission to hospital 
until discharge and convalescence. Both infectious as well as sterile insults would 
need to be included, as well as timing of onset of illness. 
One explanation for the differences between the two cohorts in the intermediate 
genotypes is different laboratory processing. However, given that three other 
genotype groups do not show this difference, that is not likely. Another explanation is 
that these intermediate genotypes are less able to maintain MBL serum levels in 
critical illness.  
MBL is consumed in the acute phase response and this consumption may be seen 
more clearly in those genotypes that have intermediate levels to start with. At the very 
high end of the spectrum (YAYA) there is a surplus of MBL combined with a high 
capacity to replenish MBL, serum levels do not drop as much.  
At the lower end of the spectrum (XAO and OO) levels are so low that MBL 
consumption in critical illness does not make much of a difference. 
To more realibly answer this question serum MBL levels in the PICU cohort would 
need to be measured while they were well. 
The current study fits within a “capacity to respond” hypothesis. The host prevents 
downstream effects to insults such as SIRS by being capable of inducing a robust, 
vigorous first response. 
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6.11 Limitations 
The comparison of the ALSPAC cohort with the PICU cohort poses the following 
methodological issues: 
The ALSPAC cohort is of Caucasian descent only, while the PICU cohort is 
ethnically mixed. 
Although the same ELISA kit was used, there may be systematic differences due to 
different time points of sample processing. 
Freeze thawing twice may have induced flaws in measurement of PICU MBL serum 
levels, although the two control samples do not suggest this. 
Given the many potential modifiers of serum MBL levels this study falls short in 
evaluating potential influencers such as hormonal influences. Thyroid hormone levels 
do vary in critical illness, and is known as sick euthyroid syndrome.  
 
6.12 Conclusions 
MBL2 genotyping does not render more information with regards to MBL serum level 
when all promoter and structural polymorphisms are identified over and above 
structural polymorphisms and the XY promoter polymorphism. 
MBL serum levels in SIRS or sepsis were lower as compared with critically ill 
children without systemic inflammation.  
The children admitted with infection did not have a surplus of MBL deficient 
genotypes as compared with healthy children. This suggests that MBL deficient 
genotypes do not predispose to severe infection. 
MBL levels are most reduced in the acute phase response in those genotypes that have 
intermediate serum levels, which may reflect a consumption of MBL in critical illness 
and an inability to maintain pre-insult MBL serum levels. 
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Chapter 7 Defining the Systemic Inflammatory Response 
Syndrome (SIRS) by means of physiological signal 
analysis 
 
7.1 Introduction 
Inflammation due to severe injury and infection is a complex physiological response 
that ultimately leads to healing and resolution. The synthesis and interplay between 
the inflammatory cascade, neuro-endocrine and autonomic nervous systems defines 
the course of systemic illness.(Sharshar, Hopkinson et al. 2005) A suboptimal or 
detrimental trajectory may occur at any stage in the time-period between initiation 
and resolution. Ultimately, the most detrimental outcome is terminal organ failure and 
death.  
 
The previous chapters have focussed on how differences in initial conditions, such as 
polymorphisms in genotype may influence outcome in acute inflammatory processes. 
The occurrence of SIRS, regardless of initiating insult, is in part dependent on genetic 
variability in the innate immune system. (Agbeko, Fidler et al. 2010) However, these 
techniques are expensive, time consuming, and not point of care. At best they might 
identify those patients at higher risk for SIRS or sepsis, but not whether they are 
actually on the trajectory for developing systemic inflammation. 
The current clinical definition of the systemic inflammatory response syndrome is a 
very unrefined reflection of the complex physiological response to injury and 
infection. This chapter examines whether SIRS can be characterized more specifically 
in terms of initiating insult. 
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The definition of SIRS is based on respiratory rate, heart rate, temperature and white 
cell count, regardless of aetiology. (1992) It is a convenient, but crude score that does 
not do justice to the complex underlying interactions in immune response, autonomic 
function and neuro-endocrine activation (Vincent 1997). 
Increasingly, there is an understanding that infectious SIRS (i.e. sepsis) and sterile 
SIRS do not share the same clinical trajectory or molecular pathophysiology. 
A large adult cohort multi-centre observational study (n= 35430) showed that 
although mortality did not differ between severe sepsis and sterile SIRS patients, there 
were significant differences in aetiology of death (mortality in adults with sepsis was 
more often due to severe organ dysfunction compared to the more prevalent 
neurological aetiology in sterile SIRS), length of ICU stay and time to peak organ 
dysfunction. (Dulhunty, Lipman et al. 2008) Thus, although the host response to a 
severe insult or infection may look the same (abnormal heart rate, respiratory status, 
temperature and white cell count) and end the same (death) there may be patho-
physiological differences between SIRS and sepsis. These differences may then lead 
to different required interventions in preventing adverse outcome. 
 
7.2 Diagnosing and differentiating SIRS and sepsis 
Attempts to define SIRS more specifically include the use of inflammatory 
biomarkers. Acute response proteins CRP and procalcitonin were elevated and 
correlated with severity of organ dysfunction in both states, but levels were higher in 
sepsis.(Castelli, Pognani et al. 2004) A more detailed probe into the molecular basis 
for SIRS by means of gene array analysis showed communal but also differentiating 
patterns after three different types of insult (burn injury, trauma/haemorrhage and 
intraperitoneal LPS) leading to systemic inflammation in a mouse model. Out of 1461 
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probes that were differentially up- or down regulated in blood compared with sham 
mice, only 13 were shared between the 3 models.(Brownstein, Logvinenko et al. 
2006) Similarly, gene expression profiling and liquid chromatography show that an 
immunological distinction can be made between sterile and infectious SIRS: up to 48 
hours before developing sepsis, patients with SIRS showed differential regulation in 
inflammatory pathways related to innate immunity (including TLR4, TLR2, MD2), 
cytokine receptors, T-cell differentiation and protein synthesis)(Johnson, Lissauer et 
al. 2007). 
Plasma levels of complement and coagulation activation factors were significantly 
differentiated in sepsis and sterile SIRS patients (Lissauer, Johnson et al. 2007). 
A prospective multicentre observational study showed that a panel of 42 gene 
expression markers in the dynamics of immune function could differentiate sepsis 
from sterile SIRS and normal controls. This study required RNA analysis platforms 
and sophisticated bioinformatics and statistical analysis.(Sutherland, Thomas et al. 
2011) 
Uncovering the molecular fingerprint of sepsis and SIRS is of interest, but also a time 
consuming and costly avenue before it is translated to the bedside. 
Given that the autonomic nervous system plays an integral part in SIRS (Borovikova, 
Ivanova et al. 2000, Elenkov, Wilder et al. 2000), measuring cardiac autonomic 
function is a potential alternative route. Physiological signal analysis provides a real-
time and cost-effective way of assessing ICU patients for overall changes in 
physiology (Goldstein 2006). Physiological signal analysis has been most used in 
neonatology (Griffin, Lake et al. 2005), cardiology (Stein, Domitrovich et al. 
2005)and intensive care (Goldstein, Kempski et al. 1996, Tibby, Frndova et al. 
2003)to predict outcome, usually mortality. 
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Whether physiological systems analysis may be of use in the early diagnosis of sepsis 
has only recently been studied in neonates (Moorman, Carlo et al. 2011) and adults 
(Bravi, Green et al. 2012). These preliminary results suggest that sepsis may be 
diagnosed earlier than currently possible with conventional tools. 
 
7.3 Heart rate variability  
Heart rate variability (HRV) is a dynamic measure of beat-to-beat differences in heart 
rate. This normal variability reflects cardiovascular, central nervous and autonomic 
system interactions. Thus, HRV may be a surrogate marker for physiological state. 
Decreased HRV has been noted in many chronic disease states such as diabetes 
mellitus (Chessa, Butera et al. 2002) but also as a prognosticator for mortality after 
myocardial infarction (Stein, Domitrovich et al. 2005), trauma (Norris, Ozdas et al. 
2006), stroke (Makikallio, Makikallio et al. 2004) and neonatal sepsis (Griffin, Lake 
et al. 2005). 
Reduced heart rate variability has long been recognized as a sign of disease. As early 
as 300 AD Dr. Wang Su Ho wrote in The Pulse Classic that “‘If the pattern of the 
heart beat becomes as regular as the tapping of a woodpecker or the dripping of rain 
from the roof, the patient will be dead in four days.” (Cowan 1995). 
In more modern times Goldberger reintroduced this concept of HRV as a mirror of 
health and aging (Goldberger 1996) (Figure 7-1) 
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Figure 7-1 Tachogram 
Legend: A and C sinus rhythm in congestive heart failure, B normal healthy adult, D 
atrial fibrillation. (Goldberger, Amaral et al. 2002) 
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Studies in critical care have repeatedly shown that loss of HRV is associated with 
more severe disease and mortality. (Bigger, Fleiss et al. 1993) 
At the most severe end of the health spectrum markedly reduced HRV was seen in 
brainstem death (Goldstein, DeKing et al. 1993) (Su, Kuo et al. 2005) and multiple 
organ dysfunction syndrome (MODS)(Schmidt, Muller-Werdan et al. 2005). 
Incremental decrease in HRV in relation to severity of illness was observed cross-
sectional in brain injury (Su, Kuo et al. 2005), critically ill adults (Schmidt, Muller-
Werdan et al. 2005) and critically ill children (Tibby, Frndova et al. 2003). 
Longitudinal studies showed a correlation with severity of illness over time in 
critically ill children (Ellenby, McNames et al. 2001), in patients progressing to brain 
stem death (Rapenne, Moreau et al. 2000) and inflammatory complications after 
traumatic brain injury (Norris, Ozdas et al. 2006). Thus, HRV was able to predict and 
reflect severity of disease. A more specific application of HRV was attempting to 
predict onset of sepsis in neonates(Griffin, Lake et al. 2005, Moorman, Lake et al. 
2006) and adults(Ahmad, Ramsay et al. 2009). 
 
7.3.1 Quantification of heart rate variability 
Many measures exist to quantify HRV. The debate is still ongoing which metrics to 
use and what they signify.(Bravi, Longtin et al. 2011) One view is that HRV does not 
differentiate well between pathophysiological states and its usefulness lies primarily 
in individual longitudinal changes in severity of illness (Goldstein 2006). A different 
view is that HRV metrics are specific to certain pathophysiological states. For 
instance, HRV metrics in septic adult patients were different from those with a 
neurological insult (Korach, Sharshar et al. 2001). Another study showed that HRV 
indices changed in trauma patients when sepsis developed.(Norris, Ozdas et al. 2006) 
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This could be explained either way: a different process developed as well as a clinical 
deterioration. 
Techniques used for HRV analysis can be roughly divided into three areas: time 
domain, frequency domain and regularity/complexity domain. They have different 
limitations and may complement each other in interpretation. (Bravi, Longtin et al. 
2011) For the purpose of this thesis I will limit myself to frequency domain analysis 
as this is the most used metric in critical care populations, which allows for relation to 
the existing body of knowledge. 
 
7.3.2 Fast Fourier Transform Spectral Analysis 
Time series, such as heart rate, may be transformed to their frequency components. 
Heart rate is thus a composite of sinusoidal oscillations that can be broken down to 
frequencies. One widely used method in heart rate variability analysis is Fast Fourier 
Spectral Analysis (Seely and Macklem 2004). Each sine and cosine wave has an 
amplitude. This amplitude determines the contribution of the waves to the signal. 
Thus frequency domain analysis shows the level of contribution to the signal as a 
function of frequency. The square of the amplitude of each frequency in the signal is 
called the power of that frequency. The sum of all power related to their respective 
frequencies or area under the curve is the total power in a signal. 
Fast Fourier Transform analysis presumes the signal to be periodic, i.e. not random, 
and stationary. Stationary is the requirement that the signal’s statistical properties 
such as mean and standard deviation are stable over the measured time 
period.(Electrophysiology 1996) Given that physiological systems are not stationary 
over a prolonged period of time, FFT analysis is done over short time windows of 5-
15 minutes. 
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Defined bandwidths for adults are low frequency (LF) at 0.04-0.15 Hz and high 
frequency (HF) at 0.15-0.4 Hz. These spectra relate to physiology albeit that the exact 
mechanisms are currently still unknown. It is generally thought that LF and HF 
predominantly reflect cardiac autonomic function. LF is influenced by both 
sympathetic and parasympathetic influences related to the baroreflex. HF is 
characterised by parasympathetic modulation. The HF portion of the power spectrum 
is associated with respiratory sinus arrhythmia (RSA).  These fluctuations in heart rate 
are a resultant of parasympathetic functions such as central vagal outflow to the heart, 
baseline cardiac vagal tone, the baroreflex and respiratory modulation of vagus 
activity. (Berntson, Bigger et al. 1997) 
Ultra low frequency (ULF) at  0.003 Hz (>5 h our cycles) and very low frequency 
(VLF) 0.0003-0.04 Hz (> 25 second cycle length) waves are identified as well if 
recordings are made over 24 hour time periods. These bandwidths are not well 
understood, but may reflect circadian rhythms (ULF), temperature and humoral 
influences (Braga, da Silva Lemos et al. 2002).(Electrophysiology 1996)Sympathetic 
nerve discharges induce a strong circadian rhythmicity. (Barrett, Navakatikyan et al. 
2001) 
A typical frequency domain analysis is shown in Figure 7-2. 
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Figure 7-2 Frequency domains in heart rate variability analysis 
VLF Very Low Frequency; LF Low Frequency; HF High Frequency. Power is 
expressed on the Y axis as spectral density in ms
2 
/Hz. This ensures that the spectral 
amplitude is not dependent on the record length. The integration of the spectral area, 
i.e. the area under the curve is equal to the variance (ms
2
). 
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One summary statistic is to compare LF and HF components of the observed 
frequency analysis. The normal LF/HF ratio in adults is 1.5-2 (Electrophysiology 
1996). In children normal values change with age. LF, HF and total power increase 
between 0-6 yrs, followed by a decrease. Infants show higher indices than children 
and they tend to have much greater LF power. (Mehta, Super et al. 2002) 
Although myocytes and hearts have an intrinsic beat, there is no variability to this 
rhythm. A non-rejecting denervated transplanted heart shows virtually no variability 
in heart rate and it’s power spectrum has no peaks. The inflammatory state of graft 
rejection corresponded with reappearance of heart rate variability. However the 
appearance was not of distinct peaks of LF and HF, but rather a random “broad band” 
pattern. This was not a universal phenomenon, as other patients in acute rejection did 
not show an increase in spectral power.(Sands, Appel et al. 1989) 
LF and HF power spectra change with time of day (Yamasaki, Kodama et al. 1996), 
gender and age (Kuo, Lin et al. 1999), behavioural state (Pagani, Furlan et al. 1989) 
and fitness (Cornolo, Brugniaux et al. 2005).  
 
7.3.3 Heart rate variability and inflammation 
Clinical data suggest an association between decreased HRV and systemic 
inflammation. A review of the literature on inflammation and HRV in cardiac patients 
showed that serum inflammatory markers were negatively correlated with LF HRV. 
(Haensel, Mills et al. 2008). 
A relationship between increased plasma levels of pro-inflammatory cytokines TNF 
and IL6 and reduced HRV has been shown in chronic and acute illness (Malave, 
Taylor et al. 2003, Gonzalez-Clemente, Vilardell et al. 2007, Sloan, McCreath et al. 
2007, Tateishi, Oda et al. 2007). Administration of endotoxin to human adult 
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volunteers induces self-resolving clinical systemic inflammation, a concomitant 
cytokine response and reduced HRV (Alvarez, Katsamanis Karavidas et al. 2007). A 
mild form of sterile stress, such as exercise induces systemic inflammation 
(Bruunsgaard 2005) and reduced HRV (Yamamoto, Hughson et al. 1991). 
Overall, HRV is expected to decrease with systemic inflammation. 
 
7.3.4 Heart rate variability after trauma 
Extremely low or even absent HRV was observed in those children that were brain 
dead (Goldstein, DeKing et al. 1993). LF was preserved in relation to HF in all but 
brain dead patients (Su, Kuo et al. 2005). In neurotrauma low LF/HF ratio was 
observed in those children with high (>30 mm Hg) ICP (Biswas, Scott et al. 2000). 
Marked sympathetic activation is a hallmark for traumatic brain injury and was 
associated with immunoparalysis (low monocyte HLA-DR expression) and 
nosocomial infection (Woiciechowsky, Asadullah et al. 1998). Long-term 
sympathetic dysautonomia in traumatic brain injury patients is associated with 
increased LF (Katz-Leurer, Rotem et al.)((Baguley, Heriseanu et al. 2006). 
 
7.3.5 Heart rate variability in sepsis, SIRS and MODS 
Several investigators have shown that HRV in septic shock is lower than in sepsis. 
One group showed that sepsis patients (including septic shock) showed lower HRV 
than sterile SIRS in adults (Korach, Sharshar et al. 2001). That group also observed 
greater LF in those patients with a neurological insult. 
Schmidt showed that all HRV indices were significantly reduced in MODS, but VLF 
was most predictive of 28 day mortality (Schmidt, Hoyer et al. 2008). 
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More recently, a prospective study in ambulatory post bone marrow transplant 
patients a panel of HRV indices, including LF/HF were early markers of sepsis. A 
drop of 25% in HRV was seen 24-120 hours prior to clinical diagnosis of 
sepsis.(Ahmad, Ramsay et al. 2009)  
A similar result was found in premature neonates. A change in heart rate 
characteristics preceded the onset of sepsis by 12 to 24 hours. (Griffin, O'Shea et al. 
2003)This group performed a trial in 3003 premature infants, randomising the cohort 
to presence or absence of heart rate characteristics on the monitor display. The group 
that was randomised to having their heart rate characteristics displayed had 
significantly lower sepsis associated mortality, with an absolute risk reduction of 
6.1%. This group was subjected to more blood cultures (1.8/month vs. 1.6/month), but 
did not receive antibiotics for a longer time period.(Moorman, Carlo et al. 2011) 
 
7.3.6 Pathophysiology of HRV changes in systemic inflammation 
The underlying mechanics of systemic inflammation induced reduction of HRV are 
not well understood. Reduction of vagal activity (Huston and Tracey 2011) and 
increase in sympathetic activity (Pagani, Montano et al. 1997) (Annane, Trabold et al. 
1999) are both directly as well as indirectly implicated. The innate immune response 
and neuro-hormonal activity are both, in part, under autonomic control. 
HRV changes may be due to a mechanistic effect of cytokines. An LPS mouse model 
showed a temporal effect of cytokines and HRV indices of both parasympathetic and 
sympathetic parameters (Fairchild, Saucerman et al. 2009). However, others found 
that adrenergic attenuation of the immune response to LPS as measured by plasma 
TNF did not modulate autonomic changes (Jan, Coyle et al. 2009), suggesting that 
cytokines may not be the predominant pathophysiological substrate for altered HRV. 
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Instead, corticosteroids may explain part of the changes in systemic inflammation 
associated reduced HRV. Decreased HRV was associated with relative adrenal 
insufficiency (Morris Jr, Norris et al. 2007) and in a mouse model HRV increased 
after steroids (Fairchild, Saucerman et al. 2009). Notably, a placebo controlled human 
study on the effects of low dose glucocorticoids on endotoxin induced physiological 
changes showed that cytokines TNF and IL6 were significantly reduced, but 
decreases in HRV remained.(Alvarez, Katsamanis Karavidas et al. 2007)  
 
7.3.7 Factors attributed to modulating HRV 
There are possible confounding factors when attributing differences in HRV to 
systemic inflammation. Their effect size in relation to systemic inflammation has 
however not been quantified. Some of these may be too subtle to be of interest with 
this magnitude of insult. 
Respiratory Sinus Arrhythmia (RSA) originates from both peripheral as well as 
central mediated processes. RSA has been observed during apnoea and pulmonary 
denervation, which implies the existence of a central oscillator. Thoracic stretch 
receptors inhibit vagal motor outflow during inspiration, which causes an increase in 
heart rate. Therefore mechanical ventilation may in itself contribute to HF 
power.(Berntson, Bigger et al. 1997) This interaction in itself is poorly understood in 
critically ill patients. For instance it was shown that both LF and HF decreased in 
patients when ventilation strategy was changed from mandatory assisted ventilation to 
spontaneous breathing.(Shen, Lin et al. 2003)Mechanically ventilated premature 
infants showed HF power amplitudes that corresponded to the ventilator rate.(van 
Ravenswaaij-Arts, Hopman et al. 1995)  Drugs that block and augment adrenergic 
and cholinergic function (Ahmed, Kadish et al. 1994) (Martinmaki, Rusko et al. 2005) 
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or sedative medications (Win, Fukayama et al. 2005) may influence HRV. 
Conversely, in patients with MODS, catecholamines did not appear to influence 
HRV.(Schmidt, Muller-Werdan et al. 2005)Unfortunately, there are no metrics to 
quantify the effect size of these potential modulators.  
In healthy children, HRV indices are influenced by age. However, “normal” HRV 
changes with age depend, in part, on type of HRV metric, definition of HRV metric, 
age cut off points, sleep state, circadian rhythm (Massin, Maeyns et al. 2000), and 
gender. Table 7-1 shows a summary of variation HRV power spectrum values for 
healthy neonates, infants and children and effect of interventions/illness. 
 333 
 
Author Year Age Diagnosis LF HF Observations 
(Electrophysiology 
1996) 
1996 Adults Standard 
Adults 
0.04-0.15 0.15-0.4 n/a 
(Fracasso, Porges et 
al. 1994) 
1994 5-13m Healthy n/a 0.24-1.04 No change 
(Finley and Nugent 
1995) 
1995 1m-24 y Healthy 0.03-0.15 0.15-0.6 LF, HF and TP increase 
between 0-6 years followed 
by a decrease 
(Massin and von 
Bernuth 1997) 
1997 3 d-14 y Healthy 0.04-0.15 0.15-0.4 LF/HF decreases with age 
(Rosenstock, 
Cassuto et al. 1999) 
1999 Neonates 
and 
infants 
Healthy 
Review 
0.04-0.2 0.2-1.5 HRV increases with age in 
first 6 months 
(Villa, Calcagnini 
et al. 2000) 
2000 9.42.3m 
and 
8.930.65 
y 
Healthy 0.04-0.15 0.15-0.4 HF higher in children; 
LF/HF lower in children 
(Acharya, 2004 10  5 y Healthy 0.04-0.15 0.15-0.4 LF/HF = 1.4251.05 
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Kannathal et al. 
2004) 
(Andriessen, 
Oetomo et al. 2005) 
2005 Preterm 
32.13.7 
wk 
Healthy 0.04-0.15 0.4-1.5 HF and LF increase with age 
(Annane, Trabold 
et al. 1999) 
1999 Adults Septic 
shock 
0.06-0.14 .2-.35 LF, HF and LF/HF lower in 
septic shock vs. sepsis 
(Goldstein, Fiser et 
al. 1998) 
1998 1 d- 22 y 
6.86.2 y 
Mixed 
PICU 
0.01-0.15 0.15-2.0 Lower LF worse outcome 
(Toweill, 
Sonnenthal et al. 
2000) 
2000 1m-18y 
8.35.7y 
Sepsis 
Septic 
shock 
0.01-0.15 0.15-1.0 LF lower in septic shock 
(Ellenby, McNames 
et al. 2001) 
2001 6m-21 y Septic 
shock 
0.04-0.15 0.15-1.0 LFn and LF/HF increase with 
recovery 
(Lin, Wang et al. 
2006) 
2006 1-9 y Enterovirus 
infection 
0.04-0.15 0.15-0.4 LF and HF lower with worse 
disease LF/HF higher with 
worse disease 
(Polson, McCallion 
et al. 2006) 
2006 Term 
infants 
Co-
arctation 
0.04-0.15 0.15-1.1 LF and HF decreased 
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(Pruvost, Zaaimi et 
al. 2006) 
2006 7-18 y 
mean 
11.7y 
Epilepsy 
VNS 
0.04-0.15 0.15-0.6 HF decreased 
Table 7-1 HRV power spectrum values in infants and children 
LF Low Frequency, HF High Frequency, LFn Normalised LF, VNS Vagus Nerve Stimulator
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Other known influences on HRV include circadian rhythm (Bilan, Witczak et al. 
2005) and ethnicity (Urbina, Bao et al. 1998). Heritability of HRV was shown to be 
high (up to 70%) (Kupper, Willemsen et al. 2004, Newton-Cheh, Guo et al. 2007). In 
one study African American youth had higher HRV indices than did European 
Americans (Wang, Thayer et al. 2005).  
Candidate genes to narrow this heritability down to specific genetic variability are 
GNAS1 (Yasuda, Matsunaga et al. 2004), eNOS (Binkley, Nunziatta et al. 2005) and 
ACE I/D. The ACE I/D studies give conflicting evidence: DD homozygotes have 
higher HF (Busjahn, Voss et al. 1998), lower HF (Thayer, Merritt et al. 2003) or the 
same HF (Steeds, Fletcher et al. 2002) compared with the II genotypes. In another 
study, ADRB2 polymorphisms and HRV complexity metrics were independently 
associated with mortality after trauma, but not with each other (Norris, Canter et al. 
2009). 
No HRV study in children has focussed on the differentiation of infective (sepsis) vs. 
sterile SIRS. This differentiation is relevant to early source control and antibiotic 
stewardship as well as therapeutic potential for anti-inflammatory or autonomic 
nervous system modulation. 
To explore the potential of HRV to differentiate between SIRS and sepsis we studied 
HRV in a cohort of critically ill children. 
 
 
Hypotheses: 
1. Clinical SIRS can be differentiated from sterile and infectious SIRS on the basis of 
heart rate variability metrics. Specifically, the sepsis group is expected to have 
reduced LF power and LF/HF ratio compared with the sterile SIRS group. 
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2.Admission LF and LF/HF in the SIRS group that go on to develop nosocomial 
infection are higher than those who did not go on to develop nosocomial infection. 
7.4 Methods 
Prospective observational matched pairs study. 
The total cohort consisted of n=176 consecutive paediatric patients admitted to PICU 
with > 1 organ failure and an expected stay > 24 hrs or death < 12 hours. From this 
dataset the study set was chosen based on the following criteria: 
First ECG recording within 24hrs of admission; 
Diagnosis of SIRS/sepsis in the first 24 hrs of admission; 
Matching for age and severity of illness. 
A control group was assembled with the same inclusion criteria but without SIRS. 
HRV metrics analysis was done blinded to SIRS and admission diagnosis. 
These data were collected as part of the genetic study outlined in paragraph 2.1.1. 
 
7.4.1 Definitions 
SIRS and sepsis were defined according to the modified criteria as described in 
paragraph 2.4. 
Nosocomial infection was defined as initiation of antibiotics for a new onset 
presumed infection at the treating physician’s discretion. 
 
7.4.2 Physiological Data Acquisition System (PDAS) hardware and software 
The PDAS hardware consists of a laptop computer, a standard PCMCIA serial card 
(Socket Communications, Inc. Newark, CA), RS232 serial interface cables (Oregon 
Electronics, Portland, OR) and a RS232 card fitted to the ICU monitoring devices. 
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A dual high-speed serial I/O PCMCIA card provided serial ports on the laptop. This 
card connected to a RS232 communication port on the medical devices with a 
custom-built T25-pin serial interface cable. The RS232 communication card provides 
an interface to export data from a medical device, i.e Philips Component Monitoring 
System (CMS) (Philips Medical Systems, Guildford Surrey, UK) patient monitor to a 
laptop.(Figure 7-3) 
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Figure 7-3 PDAS hardware setup 
Back of the Merlin/CMS monitor with cable inserted in RS232 board connected to 
laptop. 
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The PDAS software is custom-made.(Vinecore, Aboy et al. 2007) It was developed at 
Oregon Health & Science University (OHSU) in collaboration with Portland State 
University. The software acquires and stores physiological signals from ICU 
monitoring devices and coordinates the incoming data flow from each of the 
physiological signals. All recorded data are transferred to text files in patient specific 
files and folders. These files were then imported offline for post hoc signal 
processing, waveform analysis and statistical analysis into Excel (Microsoft, 
Redmond WA) or MATLAB (The MathWorks, Natick, MA). 
Physiological data from the Philips patient monitors were downloaded at sampling 
rates of 500 Hz for ECG waveforms, 125 Hz for other waveforms and parametric data 
at 60 Hz. Both waveform signals and parametric data were displayed real time on the 
laptop screen. (Figure 7-4) 
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Figure 7-4 Screenshot of real time data capture with PDAS 
Screenshot of data capture. Four waves are depicted. From top to bottom: ECG 
(Electrocardiogram), ABP (Arterial Blood pressure), SpO2 (Oxygen saturation) and 
AWP (airway pressure).  
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The CMS patient monitor’s data transmission rate of 38400 bits per second (bps) 
limited data capture for each RS232 connection to a maximum of one 500 Hz ECG 
signal and three additional 125 Hz signals with their numerical values. 
The software creates a hierarchical structure for data storage on the laptop’s hard 
drive based on the specific research study, the study specific patient identification 
number, the recording session number and the type of signal. The data files are stored 
in ASCII text format files with one data point per line.  
Each session generated a single information text file with meta data such as scaling 
values, units, and study start and stop times for each of the signals recorded, (Figure 
7-5). 
Clinical or study annotations and comments were entered as free-form and stored in a 
separate ACSII text file. The file was time-stamped and indexed to both the 125 Hz 
and 500 Hz data files allowing for clinical events to be associated with the 
physiological data. 
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Figure 7-5 Hierarchical structure and meta data PDAS signals 
A. Patient identified recording session number and type of signals 
B. Timed recording sessions with identified signals and values 
C. Individual signal labels with bandwidth of values  
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7.4.3 Metrics definitions 
Frequency domain band spectra were defined as follows: 
Low frequency (LF) 0.04-0.15 Hz; 
High Frequency (HF) 0.15-1 Hz; 
Total HRV power 0.04-1 Hz; 
Normalised LF (LFn) LF/(LF+HF)*100; 
Normalised HF (HFn) HF/(LF+HF)*100; 
LF /HF ratio 
The Low Frequency component was defined according to the taskforce definition of 
0.04-.15 Hz.(Electrophysiology 1996) The High Frequency component of the spectral 
analysis was defined in the frequency spectrum between 0.15 and 1 Hz. The taskforce 
specified a frequency bandwidth between 0.15 and 0.4 Hz for adults. This takes into 
account the normal respiratory rate and hence RSA for adults, but not for children. 
Given the higher respiratory rates for children in general and infants in particular, 
especially when they are ill, the HF bandwidth was set between 0.15 and 1 Hz.  
7.4.4 Clinical circumstances 
Patients were nursed supine in bed. Routine practice has the head of the bed at 0 
except in the case of traumatic brain injury, when the head of the bed is kept at 30. 
Recordings took 15 minutes, during which no clinical interventions took place. 
Diagnosis, medications and ventilator settings were annotated bedside. 
Recordings were done in the morning as much as possible. 
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7.4.5 Data processing 
The 15 minute raw ECG files were uploaded to a custom made software programme  
Sympatho-Analysis 2.0. This software program was kindly shared by Ir. C.H.L. 
Peters, Departement of Clinical Physics, Máxima Medical Centre, Veldhoven, The 
Netherlands. Sympatho-Analysis was developed using LabVIEW 7.0, National 
Instruments, Woerden, The Netherlands. 
The programme allows visual inspection of the ECG signal over the full measurement 
time period. Gross artefacts, disconnections and/or trends were identified. Two usable 
5 minute epochs had to be available. These recordings were then transferred to the 
Biomedical Signal Processing Laboratory, Electrical and Computer Engineering, 
Portland State University, Portland, USA. 
RR intervals were identified with an automated R wave peak detection tool (Mr 
Timothy Ellis, Biomedical Signal Processing Laboratory, Electrical and Computer 
Engineering, Portland State University, Portland, USA). After identification of RR 
intervals they were plotted to identify unexpected jumps. The power spectral density 
was estimated from RR intervals as described in (McNames and Aboy 2006). The 
programme is Matlab based, MathWorks, Natick, MA, USA. 
7.4.6 Statistical analysis 
Paired Student t-test or paired non-parametric Wilcoxon signed ranked test was 
performed for the measures LFn and LF/HF ratio between the sepsis and SIRS groups.  
Independent Student t-test was performed for the measures LFn and LF/HF ratio 
between SIRS and secondary infected SIRS groups. 
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7.5 Results 
7.5.1 General Results 
Based on the selection criteria the following number of patients was identified: 
n=20 patients age and severity of illness matched with SIRS (n=10 sepsis and n=10 
sterile SIRS) and n=4 patients with no SIRS as a control sample. 
The admission session for one sepsis patient showed many artefacts, thus this patient 
was removed together with their age equivalent in the SIRS group. In the non SIRS 
group data for one patient failed analysis and one patient was mistakenly identified. 
This left only 2 patients in the non-SIRS group. 
 
Table 7-2 shows the demographics according to diagnosis group. 
All ECG waves were manually inspected for artefacts. (Figure 7-6) 
  
 349 
 SIRS (n=9) Sepsis (n=9) P value Non SIRS 
(n=2) 
Age meansda  10658 10756 0.9 9494 
Gender M:F 7:2 7:2  1:1 
PIM2 0.080.10 0.120.11 0.35 0.220.21 
Ethnicity 7 Caucasian; 
1 Asian;  
1 Unknown/other 
6 Caucasian; 
1 Black; 
2 Unknown/other 
 2 
Caucasian 
28d mortality (n) 1 0  0 
Ventilated 9 9  2 
Inotropic support 3 5  0 
Sedation 9 9  2 
Nosocomial 
infection 
5 n/a  0 
Table 7-2 Demographic according to diagnosis group HRV study 
a
Age in months
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Figure 7-6 ECG tracings from waveform patient 204 
The heart rate (in Hz) is superimposed on top of a spectrogram of the ECG signal.  
The ECG signal spectrogram is depicted in the centre. Colours indicate the relative 
power of the signal as it varies over time. The strongest (i.e., darkest red) band flows 
from left-to-right and represents the fundamental cardiac frequency. 
The lighter coloured bands below the dark red band correspond to the power of the 
patient's breathing cycle. 
A light-grey line (outlined in dark grey) is superimposed on the central image. It 
should more-or-less follow the dark red band on the spectrogram. This is the heart 
rate as identified from the RR interval data. 
A randomly-selected four-second time-domain example of the ECG signal is plotted 
at the bottom of the image. Red dots correspond to the times of R peak detection. A 
vertical thick medium grey line represents the four-second corresponding portion on 
the central spectrogram image. 
The thin vertical colour bar to the left of the central image represents how the colours 
on the spectrogram correspond with the relative power of the signal in frequency and 
time: colours near the top indicate more power, those near the bottom indicate less 
power.  
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The far-left box is a vertically-oriented plot of the power spectral density (PSD) of the 
signal over its entire duration. It represents the power at each frequency averaged over 
the length of the signal. The blue line represents the average heart rate frequency 
computed from the detected R-to-R intervals. This blue line should correspond with 
the peak of the red (PSD) line. (personal communication Mr Timothy Ellis) 
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Figure 7-7 Overview five minute heart rate recording session in first 24 hours of 
admission sterile SIRS 
Plots identified by patient number  
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Figure 7-8 Overview five minute heart rate recording session in first 24 hours of 
admission sepsis 
Plots identified by patient number   
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204 205 
 
Ventilator rate and sedation n/a Ventilator rate and sedation n/a 
266 270 
 
Ventilator rate 13 (0.21 Hz); midazolam/morphine Ventilator rate 30 (0.5 Hz); muscle relaxed 
 
271 275 
 
Ventilator rate 14 (0.23 Hz); muscle relaxed Ventilator rate 16 (0.27 Hz); muscle relaxed 
 
285 301 
 
Ventilator rate 17 (0.28 Hz); midazolam/morphine Ventilator rate 24 (0.4 Hz); muscle relaxed 
 
317 
 
Ventilator rate 20 (0.33 Hz); muscle relaxed 
 
Figure 7-9 Power spectrum derived from five minute RR interval measurement 
sterile SIRS group 
Plots identified by patient number 
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238 245 
 
HFO; midazolam/morphine Ventilator rate 10 (0.16 Hz); midazolam/morphine 
 
261 272 
 
Ventilator rate 12 (0.2 Hz); midazolam/morphine Ventilator rate 16 (0.26 Hz); midazolam morphine 
 
282 284 
 
Ventilator rate 16 (0.26 Hz); midazolam morphine Ventilator rate and sedation n/a 
 
297 298 
 
Volume support; chloralhydrate Ventilator rate 20 (0.33 Hz); midazolam/morphine 
 
327 
 
Ventilator rate 7 (0.11 Hz); midazolam/morphine 
Figure 7-10 Power spectrum derived from five minute RR interval measurement 
sepsis group 
Plots identified by patient number 
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 SIRS (n=9) Sepsis (n=9) W value P value 
LF median; IQR 12.9; 48.2 15.7; 65.2 -1 NS 
LF Range 0.9-275.9 0.1-172.9   
HF median IQR 16.4; 57.1 10.7; 22.7 9 NS 
HF range 2-801.2 2.6-117.8   
TP median 64.7; 177.4 73.6; 245.7 3 NS 
TP range 9.1-1581.7 6.7-428.8   
 
LFn 0.28 0.38  0.31 
HFn 0.51 0.32  0.029 
LHR 0.62 1.55  0.11 
Table 7-3 HRV characteristics between sterile SIRS and sepsis groups 
LF low frequency; HF high frequency; TP total power; LFn normalised LF; HFn 
normalised HF; LHR low frequency/high frequency ratio.  
P value derived from paired Wilcoxon signed ranked test and for LFn, HFn and LHR 
from paired Student t-test. 
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A. 
 
B. 
Figure 7-11 LF analysis between sterile SIRS and sepsis groups A. LF power B. 
LF power normalized 
LF Low Frequency. No difference between the two groups (paired Wilcoxon signed 
ranked test)   
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Figure 7-12 HF (normalized) power analysis between sterile SIRS and sepsis 
groups  
HF High Frequency, SIRS Systemic Inflammatory Response Syndrome 
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The distribution of values for LF and HF violated the Kolmogorov-Smirnov test for 
normality. Thus, the paired non-parametric Wilcoxon signed ranked test was used. 
For this to be significant at P=0.05 on 9 pairs the W value would have to be at least 
29. For LFn, HFn and HF/LF the distribution was normal, thus paired Student t-test 
was used. No significant difference was found between the sterile SIRS and sepsis in 
absolute LF power  (Figure 7-11 A. and Table 7-3). 
Given the large interindividual differences in absolute power, the data were also 
normalized. This way LFn (LF/(LF+HF)) was also assessed. This metric too did not 
show a significant difference between groups. If anything, the LFn was lower in the 
sterile SIRS group (Figure 7-11 B.). 
Surprisingly, a difference was found in the HFn spectrum. The sterile SIRS groups 
showed higher HFn than the sepsis group (Table 7-3 and Figure 7-12).  
 
7.5.2 Nosocomial infection 
Nosocomial infection occurred in 5/10 patients admitted with sterile SIRS. Those that 
developed infection tended to be older, 137 vs.74 (p 0.08), but had no difference in 
severity of illness. All HRV metrics were lower in the group that developed infection, 
except for HF, but these were not significant (Table 7-4). 
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Group Statistics 
 any infection in 
first week N Mean 
Std. 
Deviation 
Std. Error 
Mean 
LF power none 5 75.680 114.4581 51.1872 
yes 5 21.120 26.2107 11.7218 
HF power none 5 1.725E2 351.5559 157.2206 
yes 5 29.520 39.1301 17.4995 
Total power none 5 3.842E2 670.9763 300.0697 
yes 5 1.007E2 96.7211 43.2550 
LF power 
normalized 
none 5 .39960 .226299 .101204 
yes 5 .26500 .171991 .076917 
HF power 
normalized 
none 5 .44500 .176688 .079017 
yes 5 .51820 .176753 .079046 
LHR none 5 1.3560 1.60435 .71749 
yes 5 .6840 .75132 .33600 
Table 7-4 HRV metrics for nosocomial infection 
LF low frequency; HF High Frequency; LHR low high frequency ratio  
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7.6 Discussion 
As previously noted by other groups there is a striking loss of HRV in paediatric 
critical illness. In this paired sample no differences were seen in LF metrics to 
differentiate sterile SIRS from sepsis. Neither was there a difference in LF metrics 
between those children who went on to develop a nosocomial infection and those who 
did not. 
The strength of this study is the matching of severity of illness and age to reduce 
confounding. However, there still remain the small number of children, the different 
ventilatory requirements, sedation and inotropic medication that may have caused this 
study to be underpowered. 
Given the new data on the importance of vagal mediated dampening of systemic 
inflammation in sepsis, the significantly higher normalised HF in sterile SIRS vs. 
sepsis was not expected. One reason might be that the HF component is a 
combination of patient driven and ventilator modulation. Different ventilatory 
requirements in the groups may have caused this difference. This is compounded by 
the occurrence of first order and sometimes second order harmonics in the HF 
spectrum in some patients. 
The data were analysed with conventional frequency domain methods. This metric 
was chosen to allow for comparison with work that had previously been done in 
critical care. Also, the small sample size would not allow for multiple testing had 
different types of analysis been added without an a priori hypothesis to test against. 
Finally, rather than comparison between groups, it may be more valuable to follow 
individual patients longitudinally in order to capture HRV changes that correlate with 
the development of sepsis. The data compiled from the sterile SIRS group showed 
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that all HRV metrics were lower in the group who developed infection. The group 
was small (n=5 in each group), therefore a larger cohort might be able to answer this 
question. 
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Chapter 8  Final discussion and future work 
8.1 Introduction 
This work originated from the following queries: 
1) why do children differ in their response to similar infectious and inflammatory 
insults? 
2) is genetic predisposition a factor underlying individual responses in critical 
illness? 
3) might be possible to better define the complex inflammatory state known as 
the Systemic Inflammatory Response Syndrome (SIRS). 
It has been long recognized that individuals (James, Nicol et al. 1932) and populations 
(Modiano, Petrarca et al. 1996) vary in their susceptibility to severe infectious 
disease. Part of this variation was found to be highly hereditable (Sorensen, Nielsen et 
al. 1988). The challenge remained to pinpoint the specific genetic differences that 
underlie this heritability. When the currently reported work started several genetic 
association studies had been published in the domain of innate immunity and 
sepsis/SIRS. These studies were typically small and at risk for being underpowered. 
None of these studies had addressed paediatric systemic inflammation. Most studies 
had only assessed a single gene or single polymorphism in a very complex disease. 
This study was therefore conceived to reduce errors in study design and produce data 
that were pertinent to paediatric practice. Technology was only now available to 
achieve this because of simplification of the genotyping process. This permitted us to 
assess several polymorphisms simultaneously, within less time and at an affordable 
price. 
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This study also focussed on key pathways, rather than isolated genes. The thinking 
behind this approach was that given the complexity of systemic inflammation, it was 
unlikely that a single gene would modify outcome in critical illness in a way that we 
could measure. Chapter 5 illustrates the concept of the additive effect of multiple 
genes. Here, polymorphisms in two genes in the complement pathway incrementally 
increased the risk for SIRS. Conversely, as described in Chapter 4, the multi gene 
endotoxin recognition transmembrane complex did not modify risk for SIRS, but 
polymorphisms in the single gene TLR4 were associated with admission platelet 
count. Assessing the risk that small changes may confer in a complex system very 
much depends on the relationship between those seemingly small differences and the 
outcome of interest. The complement genes seemed to confer a linear risk to SIRS, 
whereas the TLR4 polymorphisms may have identified a weak point in terms of 
redundancy. Platelets in themselves, or as part of the larger systemic inflammatory 
response, may not be able to maintain responsiveness, other than at the cost of 
reduced numbers. 
Suggested future work includes specific mechanisms for TLR4 mediated platelet 
activation and their role in systemic inflammation (Smith and Weyrich 2011), and 
containment of microbes such as NETs (Clark, Ma et al. 2007). 
  
8.2 Probing the genetics of the host response to infection and injury 
Many studies have tried to identify specific genes and variation in gene function to try 
to answer what the genetic variation actually is that underlies hereditary differences in 
response to microbes. The candidate gene approach, based on either locus 
identification from family studies or based on known roles of certain genes in the 
disease process has proven to be disappointing. 
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Very few, if any, polymorphic genes have been identified confidently as contributors 
to sepsis and SIRS. The reasons for this are many fold, not least because of 
methodological concerns. (Little, Higgins et al. 2009) We were able to limit the 
impact of some of these issues in the current study, but a number remain. 
The population we studied was heterogeneous in terms of demographics (ethnicity, 
age, gender), but also in type of insult (injury, infection, causative organism) and pre-
morbid condition (deprivation). Nonetheless, the cohort may have been large enough 
to be able to stratify for most of these potential confounders and still be able to 
identify genetic risk. The genetic risk factor however would have to have exerted a 
sufficiently large effect and prevalence.  
Genome Wide Association Studies (GWAS) are a method to overcome some of the 
above-mentioned concerns. There is no burden of a priori (and potentially wrong) 
mechanistic hypotheses. The approach allows for many hundreds of thousands to 
millions of SNPs to be investigated at the same time. Conversely, statistical methods 
need to be robust to safeguard against false positive results. When the current study 
was conducted, this approach was still in its infancy. There is now more evidence that 
GWAS may aid understanding susceptibility to infectious disease. A GWAS in n = 
7522 individuals found that two SNPs in the CFH and CFHR3 were protective against 
meningococcal disease. (Davila, Wright et al. 2010) The two SNPs were in complete 
LD with each other, but not with the functional CFH polymorphism previously 
associated with age related macular degeneration and in this study (Chapter 5) shown 
to be protective for SIRS. 
Studying individual and families who have rare monogenic defects may be yet 
another way of better understanding of infectious and inflammatory processes. Whole 
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exome sequencing is currently used to identify the molecular basis for hitherto 
unexplained primary immune deficiencies. (Hambleton, Salem et al. 2011)  
Primary immune deficiency has traditionally been defined as highly penetrant single 
gene mutations leading to severe and diverse childhood infections. This concept is 
changing to a broader understanding, in part due to identification of polymorphisms in 
immune-related genes that lead to susceptibility or protection against a very narrow 
range of pathogens in otherwise healthy individuals.(Casanova and Abel 2007) 
One such example is the TLR–nuclear factor-κB (NF-κB) signalling pathway.  
Genetic defects downstream in this pathway include interleukin-1 receptor-associated 
kinase-4 (IRAK4) deficiency, myeloid differentiation primary response gene 88 
(MYD88), NF-κB essential modulator (NEMO; also known as IKBKG, which 
encodes the I‑ κB kinase regulatory subunit IKKγ) and NFKBIA (which encodes the 
IκBα inhibitor of NF-κB). Children with IRAK4 and MYD88 defiency are very 
vulnerable to invasive pneumococcal infections, but with time there is improvement. 
(Picard, von Bernuth et al. 2010) The NEMO and NFKBIA deficiencies have a more 
severe phenotype, presumably because of an interruption of multiple innate and 
adaptive pathways. The hosts are more susceptible to not only encapsulated bacteria, 
but also atypical mycobacteria, fungi and viruses. Reviewed in (Chapman and Hill 
2012). 
These mutations are very rare, but gene association studies have identified common 
polymorphisms in this pathway that were associated with a modified susceptibility to 
infectious diseases. People with the Mal polymorphism were protected from invasive 
pneumococcal disease, malaria, bacteraemia and tuberculosis.(Khor, Chapman et al. 
2007) 
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Subsequently to this study it was found that heterozygote carriers for the 180L allele 
were at lower risk of septic shock and showed an intermediate pro inflammatory 
cytokine response.(Ferwerda, Alonso et al. 2009)  
These insights into modulation of susceptibility and response to pathogens may lead 
to more specific treatment of individuals with sepsis. Risk stratification based on 
innate capacity to clear pathogens might inform antibacterial strategy, for instance in 
treatment and prevention of nosocomial infection. Large sepsis trials may be stratified 
according to innate inflammatory response capacity, thus preventing harm by 
enrolling a mixed population by not including those that would be potentially harmed 
by an intervention. The challenge remains to not only identify these key pathways and 
genes, but also the appropriate timing and population.(Grau and Maennel 1997) 
Both rare and common polymorphisms in key pathways and genes have been shown 
to modify susceptibility to invasive pneumococcal disease (TLR–NF-κB pathway) 
and meningococcal disease (CFH gene). 
In contrast this has not been found for another pillar of innate immunity, TLR4. This 
gene harbours both rare and common polymorphisms. Rare polymorphisms were 
identified as a risk factor for susceptibility to severe meningococcal disease, whereas 
common polymorphisms were not.(Smirnova, Mann et al. 2003) 
Performing whole exome sequencing in individuals with extreme phenotypes is one 
way of identifying these key genes and pathways. These extreme phenotypes may 
well be found in the intensive care unit. Therefore a large programme that will collect 
DNA samples as well as a detailed phenotype and environmental description would 
inform targeted interventions in what is currently ineptly named sepsis or SIRS. 
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8.2.1 Whole genome sequencing 
The most recent advances in whole genome analysis have shown that variation 
between humans depends not only on common single nucleotide polymorphisms, but 
also on copy number variation, rare variants (0.1% present in a population), 
epigenetic regulation, variability in transcription sites, and distance regulation. 
(Genomes Project, Abecasis et al. 2010, Mills, Walter et al. 2011, Consortium, 
Dunham et al. 2012, Djebali, Davis et al. 2012, Genomes Project, Abecasis et al. 
2012, Sanyal, Lajoie et al. 2012). On average, each person might harbour 
approximately 250 to 300 loss-of-function variants and 50 to 100 variants that have 
been associated with inherited disorders. (Genomes Project, Abecasis et al. 2010) In 
addition, genes may overlap and have multiple beginnings and ends. Such is the 
variation of regulation in transcription, that the term gene may have to be 
redefined.(Djebali, Davis et al. 2012) 
 
8.3 Signal to Noise ratio 
8.3.1 Replication in genetic studies 
This study has shown associations between biological plausible candidate genes and 
conventional outcome measures. There remains, however, the issue of replication. 
The replication cohort for the TLR4 study described in Chapter 4 was unconventional 
since both age and type of insult were different. The complement study in Chapter 5 
had no replication cohort at all. False positive results, therefore, cannot be excluded. 
Nonetheless, corroborative evidence that complement may be a key variant in host 
response in acute severe infection has emerged since this study was 
performed.(Davila, Wright et al. 2010) 
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8.3.2 Environmental variation 
All clinical studies suffer from heterogeneity introduced by treatment and logistics. 
This is especially so in diseases in which there is no stringent treatment protocol. 
In this study this was compounded by the issue that children were admitted with a 
variety of diagnoses, time-lines to admission to PICU and from a multitude of 
healthcare areas. This alone may have introduced elements into the study that have 
nothing to do with the host per se or their disease, but with access to healthcare, 
logistics, and quality of health care provision. This may have induced such a 
heterogeneity in case mix that a weak signal in genetic predisposition may have been 
lost. 
The phenotypic description was extensive, but lacked details on pre-admission data 
regarding duration of illness prior to admission, and timing and appropriateness of 
interventions such as fluid resuscitation, inotropic support, oxygenation and timely 
appropriate antibiotics. That these issues matter has been shown clinically (Rivers, 
Nguyen et al. 2001) (de Oliveira, de Oliveira et al. 2008) (Maitland, Babiker et al. 
2012) (Kumar, Roberts et al. 2006) as well as influencing the immunological profile 
(Rivers, Kruse et al. 2007). The differences in outcome may not have been entirely 
because of the intervention per se, but because of different circumstances that arose 
from the intervention. This risk of attribution error (Ross 1977) occurs in all clinical 
studies, because of an inherent change in circumstance. Maybe the reduction in 
mortality in the first early goal directed therapy trial in the emergency department 
(Rivers, Nguyen et al. 2001) was not the algorithm that was used, but the expert 
bedside-attending who administered it. This may explain why his results were not 
clearly replicated in subsequent independent studies, although we are still awaiting 
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data from Australasian Resuscitation In Sepsis Evaluation Randomised controlled 
Trial (ARISE), ClinicalTrials.gov Identifier NCT00975793, the North American 
Protocolized Care for Early Septic Shock (ProCESS) ClinicalTrials.gov Identifier 
NCT00510835 and the UK Protocolised Management in Sepsis (ProMISe), UKCRN 
ID 9820.  
  
We collected detailed clinical phenotype data from the time of intensive care 
admission. These data were collected to a high level standard. Data pertaining to the 
pre-admission period would not have been as accurate. Collecting detailed pre-PICU 
admission data would have required a complex multiple centre set-up. This was 
beyond the scope of the current study. 
Regionalisation of retrieval services and an increasing number of dedicated paediatric 
emergency departments lead to data gathering for clinical research becoming more 
feasible. 
This is due to the changing nature of organising research. There is a trend towards a 
more collaborative approach across departmental boundaries via such collaborations 
as the Paediatric Intensive Care Society Study Group (PICS-SG). In addition, the 
increasing acceptance of approaches such as deferred consent mean that it is possible 
to perform clinical research in time critical acute situations. This now applies not only 
in adult interventional trials (Investigators, Finfer et al. 2009), but also in English 
paediatric intensive care, e.g. the Catheter Infections in Children (CATCH) trial, 
ClinicalTrials.gov Identifier NCT01029717. 
 
8.3.3 Description and Definition 
A fundamental flaw in this study is the lack of discrete diagnoses, definitions and 
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scoring methods when studying sepsis and systemic inflammation. This is important 
because it is nigh on impossible to count reproducibly what one cannot define with 
discrimination. Case in point: recently it was demonstrated that the increase in sepsis-
associated hospitalizations was offset by the concurrent decrease in hospital 
admissions with pneumonia. Coding differences over the years had introduced a false 
understanding.(Lindenauer, Lagu et al. 2012) Obviously both entities share 
communalities that might have led to spurious results in counting. 
The current definitions of systemic inflammation and sepsis are derived from a 
consensus meeting held in 1991 by North American experts in adult critical 
care.(Bone, Sibbald et al. 1992) They aimed to describe sepsis to be better able to risk 
stratify and treat this phenomenon. The driver behind this initiative was the high 
incidence of failing organs and death. Ten years after the SCCM conference a second 
conference was held, this time it also included European researchers. The conclusion 
was that there was no additional evidence to change the 1992 definitions (Levy, Fink 
et al. 2003). 
Boiling down this highly complex process to four markers of dysfunction is attractive 
because it allows a common language and understanding. The downside of lumping 
together these generic common features is the risk of ignoring important differences. 
Ignoring the route the patient took to end up in a classification group termed “sepsis” 
or “SIRS” ignores fundamental differences in pathophysiology. (Soni 2010) Many 
interventions in sepsis have failed. In part, this is a problem of definition. 
Since 1992 we have a better understanding of the molecular basis of systemic 
inflammation and sepsis but we are no further in our capacity to differentiate the two 
at the bedside. We are still describing sepsis and SIRS rather than defining them. 
Rather than continue to “lump” we must also “split”.(Baue 2004) 
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Future work requires identifying specific causes for infection and specific host 
responses, not only cross sectional but also longitudinal. The success of interventions 
not only depends on the type of intervention, but also of timing and the state the 
patient is at that particular moment. Sepsis and systemic inflammation are dynamic 
processes. One example is fluid resuscitation. Early larger bolus fluid resuscitation 
allowed for less total volume and better outcome compared to smaller boluses over 
longer period of time.(Carcillo, Davis et al. 1991)  
It is unhelpful to our patients to define rigidly systemic inflammation and sepsis in 
terms of dichotomous notions such as clotting/immunity, innate/adaptive; 
self/nonself; danger/nondanger; pro-inflammatory/anti-inflammatory. False 
dichotomies hinder creative thinking and potential new avenues in helping our 
patients. (Suffredini and Munford 2011) 
The attempt to define sterile SIRS and sepsis by means of HRV was not successful. 
Future studies might focus on longitudinal studies to observe changes in variability 
that then can be correlated with infection and/or deterioration/recovery. 
A critically ill patient may be seen as an entity with many dimensions and it should 
therefore be possible to assess their extent of similarity via multiple ways. The 
principle of purpose dependent ontology takes into account clarity of definition as 
well as purpose of definition.(Greenspan 2004) 
The concepts of sepsis, SIRS, severe sepsis and septic shock require revisiting. 
Although convenient, it is now time to question and challenge this scheme. Twenty 
years have passed without this schema bringing discernible benefit to our patients. 
A more useful way of classifying this group of patients might by their capacity to 
respond. Longitudinal studies have been instrumental in identifying a temporal 
change in inflammatory status. Profound immune depression is common in the course 
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of sepsis or injury. Immunoparalysis of monocytes (Docke, Randow et al. 1997) 
(Allen, Peters et al. 2002) and prolonged lymphopenia (Felmet, Hall et al. 2005) 
predict adverse outcome in critically ill children. Apoptosis of B and T cells (Tinsley, 
Grayson et al. 2003) is thought to be a key driver in the concept of the Compensatory 
Anti-inflammatory Response Syndrome (CARS) (Bone 1996). 
Dichotomisation loses the complexity of critical illness. Rather than asking the 
question whether this patient is in SIRS, sepsis, severe sepsis, septic shock, or CARS 
maybe a more useful question is whether a patient is still robust enough to respond. 
 
8.4 Complex systems, redundancy and resilience 
The human body is continuously responding to stressors. In health, there is enough 
redundancy in the complex system to allow for these attacks. The capacity to maintain 
responsiveness is a core attribute of resilience. However, when overload has occurred 
with the consequence of critical illness, there is less capacity to deal with ongoing or 
new threats.(McEwen and Wingfield 2003)  This may manifest itself as multiple 
organ dysfunction. Differences in initial response capacity may influence subsequent 
outcomes. People who have an initial vigorous capacity to respond may benefit in 
infection because they eliminate the pathogen swiftly, e.g. complement activation 
capacity (Chapter 5 and Chapter 6) Conversely, people who respond vigorously to 
injury may induce exaggerated longer term sequelae in immunosuppresion. 
(Woiciechowsky, Asadullah et al. 1998)The disappointments in trying to block “pro-
inflammatory” compounds have lead to trials intervening by immunostimulation. 
Glutamine supplement(Ong, Eaton et al. 2012) was successful in neonates to reduce 
sepsis, GM-CSF (Hall, Knatz et al. 2011) reversed immunoparalysis as measured by 
HLA-DR but the combination of zinc, selenium, glutamine, and metoclopramide did 
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not reduce nosocomial infections in a paediatric critical cohort (Carcillo, Dean et al. 
2012). 
Although these trials focus on immunomodulation by increasing response capacity the 
paradigm of pro- and anti-inflammatory is not touched upon. 
Small difference in initial state may have profound impact on outcome. This is a key 
understanding in the behaviour of complex systems.(Lorenz 1963) This non-linear 
behaviour might underpin the large effect some polymorphisms exert in the acute 
phase response, especially if they reside in an area without redundancy to overcome 
the disadvantage. The TLR4 study in Chapter 4 may have illustrated the concept of 
redundancy. There is evidence that TLR4 is directly involved in platelet activation. 
(Berthet, Damien et al. 2010) This, in combination with platelets’ reduced capacity to 
maintain counts during severe acute inflammatory disease (Peters, Ross-Russell et al. 
2001) may have led to identification of a fragile part in the acute host response. 
Methods to capture resilience in critical care have not been developed yet. Loss of 
complexity may manifest itself in rhythms that are more monotonous. In critical 
illness monotony and decomplexification associated with worse outcome has been 
measured in T cell repertoire, serum glucose levels and most extensively in heart rate. 
Reduced heart rate variability measures were associated with worse organ failure and 
mortality in critically ill adults (Schmidt, Werdan et al. 2001) and children (Tibby, 
Frndova et al. 2003), and susceptibility to sepsis in immunocompromised adults 
(Bravi, Green et al. 2012). The concept of complexity and allostasis has only recently 
been introduced to the intensive care literature. (Cuesta and Singer 2012) 
Future work might encompass assessing resilience using an HRV metric. The dataset 
used in this study might be used to that end by ways of complexity metrics rather than 
frequency analysis. More ambitious goals include performing interventional studies to 
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restore health by targeting regularity such as adding noise to mechanical ventilation 
(Graham, Gulati et al. 2011) and cardio pulmonary bypass (Graham, Warrian et al. 
2002). 
 
8.5 Conclusion 
This thesis has added to the understanding of the acute phase response in critically ill 
children. 
Genetic predisposition to systemic inflammation was identified in the complement 
activation cascade. This may lead to interventions increasing an individual’s capacity 
for complement activation. 
The role of TLR4 in platelet participation in the acute phase response was identified, 
which may allow for avenues to harness TLR4 mediated platelet activation in the 
acute phase response. 
A better definition of systemic inflammation in the presence or absence of infection is 
still required. Physiological systems analysis did not generate definitive answers, but 
may have identified an area worth pursuing: that of longitudinal intra patient change 
in heart rate variability as a measure of robustness. 
This thesis supports the concept that in children control of an inflammatory threat is 
aided by a vigorous capacity to respond. 
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